Compositions and methods for immunotherapy
The problem of cell depletion and long preparation time in existing therapies is solved by using immune cells expressing chimeric antigen receptors and engineered T cell receptors in adoptive T cell therapy, rapid ex vivo amplification and infusion, Improves anti-tumor activity and therapeutic effect.
Patent Information
- Application Number
- CN202410984775.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-26
- Filing Date
- 2019-12-06
- Publication Date
- 2024-11-12
AI Technical Summary
Existing adoptive T cell therapies have problems such as cell depletion, long preparation time and ineffective engineering cell composition when treating cancer, and it is difficult to effectively target tumors.
Using engineered immune cells that express chimeric antigen receptors (CAR) and/or engineered T cell receptors (TCRs), enhance the memory and cytotoxicity of immune cells through rapid ex vivo expansion and infusion, reducing the memory and cytotoxicity of immune cells. Cell depletion improves the recognition and killing ability of targets.
It significantly improves the anti-tumor activity of immune cells, reduces cell depletion, shortens preparation time, enhances the recognition and killing ability of cancer cells, and improves the therapeutic effect.
Smart Images

Figure CN118931967A_ABST
Abstract
Description
[0001] This application is a divisional application of an application with an application date of December 6, 2019, application number 201980091527.0, and invention name “Compositions and methods for immunotherapy”.
[0002] Cross-references
[0003] This application claims priority to Chinese Patent Application No. 201811501797.8, filed on December 7, 2018; PCT Application No. PCT / CN2019 / 073252, filed on January 25, 2019; Chinese Patent Application No. 201910297171.8, filed on April 12, 2019; and PCT Application No. PCT / CN2019 / 097996, filed on July 26, 2019, each of which is incorporated herein by reference in its entirety. Background Art
[0004] As an example of immunotherapy, adoptive T cell therapy involves the isolation and ex vivo expansion of tumor-specific T cells to obtain a greater number of T cells than could be obtained with vaccination alone. The tumor-specific T cells are then infused into cancer patients, allowing their immune system to overwhelm the remaining tumor with T cells that can attack and kill the cancer. While there are multiple forms of adoptive T cell therapy for cancer, they generally suffer from various drawbacks. These include cell exhaustion, long preparation times, and ineffective engineered cell composition. Summary of the invention
[0005] In view of the above, there is a great need for alternative compositions and methods for immunotherapy. The compositions and methods of the present disclosure address this need and also provide additional advantages. In particular, various aspects of the present disclosure provide systems for immune cell modulation.
[0006] On the one hand, the present disclosure provides a method of administering a cell therapy comprising engineered immune cells expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), comprising: infusing an immune cell population comprising the engineered immune cells into a subject in need, wherein the engineered immune cells have not undergone ex vivo expansion for no more than 2 weeks or 1 week, and wherein the population is further characterized in that the central memory T cells (TCM) in the population are more abundant than effector memory T cells (TEM). In some embodiments, the engineered immune cells have undergone ex vivo expansion of less than 13, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, the engineered immune cells have undergone ex vivo expansion of less than 6, 5, 4, 3, 2, or 1 day. In some embodiments, the engineered immune cells have undergone ex vivo expansion of less than 5 days. In some embodiments, the engineered immune cells have undergone ex vivo expansion of less than 72, 48, 36, 32, or 24 hours. In some embodiments, TCM is CD45RO + CD62L + In some embodiments, TEM is CD45RO + CD62L-. In some embodiments, the population is further characterized by its lower abundance in PD1 and LAG3. In some embodiments, reduced depletion of cells in the population is observed compared to depletion of cells in a comparable population that has undergone ex vivo expansion for no more than 2 weeks, or 1 week, or 10 or 9 days.
[0007] In some aspects, the reduced depletion of a population is characterized in that the population comprises fewer cells expressing PD1 and LAG3.
[0008] In some embodiments, the engineered immune cell is a T cell, a NK cell and / or a NKT cell. In some embodiments, the TCR comprises (i) a ligand binding domain specific for a ligand and (ii) a transmembrane domain. In some embodiments, the CAR comprises: (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some embodiments, the ligand of the TCR or CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD4 4V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, RANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRα, TCRβ, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79, Notch-1-4 and / or Claudin18.2. In some embodiments, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. In some embodiments, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS). In some embodiments, CAR comprises at least 2 intracellular signaling domains. In some embodiments, CAR comprises at least 3 intracellular signaling domains. In some embodiments, CAR further comprises a hinge. In some embodiments, the hinge is from CD28, IgG1 and / or CD8α. In some embodiments, CAR further comprises a signal peptide, and wherein the signal peptide is derived from IgG1, GM-CSF and / or CD8α.In some embodiments, engineered immune cells are from peripheral blood, cord blood, bone marrow and / or induced pluripotent stem cells. In some embodiments, engineered immune cells are from peripheral blood, and wherein the peripheral blood cells are T cells. In some embodiments, compared with comparable populations that experience ex vivo expansion no more than 2 weeks or 1 week, greater memory and / or dryness are observed in the population. In some embodiments, compared with TEM, TCM is 2 times more. In some embodiments, compared with TEM, TCM is 4 times more. In some embodiments, infusion is intravenous. In some embodiments, administration includes infusion of about 1x10. 4 / kg body weight of engineered immune cells. In some embodiments, administration comprises infusing about 3x10 5 / kg body weight of engineered immune cells. In some embodiments, at least 10% of immune cells express CAR and / or TCR. In some embodiments, at least 20% of immune cells express CAR and / or TCR. In some embodiments, at least 40% of immune cells express CAR and / or TCR. In some embodiments, the method further includes administering a second agent to a subject in need. In some embodiments, the second agent is a therapeutically effective amount of an immunostimulant, an immunosuppressant, an antifungal agent, an antibiotic, an antiangiogenic agent, a chemotherapeutic agent, a radioactive agent and / or an antiviral agent. In some aspects, the immunostimulant is IL-2. In some aspects, the method further includes obtaining peripheral blood from the subject in need after the administration. In some aspects, the engineered immune cells in the subject are quantified from the peripheral blood. In some embodiments, the growth factor level in the subject is quantified. In some embodiments, the growth factor is selected from IL-10, IL-6, tumor necrosis factor α (TNF-α), IL-1β, IL-2, IL-4, IL-8, IL-12 and / or IFN-γ. In some aspects, the method includes repeated infusions. In some embodiments, the immune cell colony is allogeneic for the subject in need. In some aspects, the immune cell colony is autologous for the subject in need. In some aspects, the subject suffers from cancer. In some embodiments, the cancer is hematological. In some aspects, the blood cancer is leukemia, myeloma, lymphoma and / or a combination thereof. In some embodiments, the leukemia is chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), T cell acute lymphocytic leukemia (T-ALL), B cell acute lymphocytic leukemia (B-ALL) and / or acute lymphocytic leukemia (ALL). In some embodiments, the lymphoma is mantle cell lymphoma (MCL), T cell lymphoma, Hodgkin lymphoma and / or non-Hodgkin lymphoma. In some embodiments, cancer is solid. In some embodiments, the solid cancer is selected from: Wilms tumor, Ewing's sarcoma, neuroendocrine tumor, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, biliary tract cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma or bladder cancer. In some embodiments, the subject in need has a BCR-ABL mutation, and the mutation is in the BCR-ABL kinase domain. In some embodiments, the subject in need has T315I and / or V299L mutations in the BCR-ABL kinase domain. In some aspects, the subject shows resistance to tyrosine kinase inhibitors. In some aspects, the subject suffers from a tumor or is susceptible to a tumor after chemotherapy.In some aspects, chemotherapy is used to pre-treat the subject prior to the administration. In some aspects, the chemotherapy includes administration of fludarabine, cyclophosphamide and / or cytarabine. In some embodiments, the subject has minimal residual disease (MRD), and the MRD is acute lymphoblastic leukemia.
[0009] In some embodiments, the immune cell colony of the subject is further characterized in that, compared with the proliferation, cytotoxicity and / or bone marrow migration of a comparable population (e.g., C-CART) that undergoes ex vivo expansion for no more than 2 weeks or 1 week, greater proliferation, cytotoxicity and / or bone marrow migration are observed in the population. In some embodiments, the following levels of determination can be used to evaluate the subject's cell population (such as F-CART): migration, proliferation, cytotoxicity and effector activity. Chemotaxis can be used to determine the level of migration. On the one hand, migration can refer to migration into the bone marrow. On the one hand, migration can refer to migration out of the bone marrow. On the one hand, migration can also be directed to the movement of targets such as chemokines or cancer cells. On the one hand, the chemokine system includes more than 40 chemokines and more than 18 chemokine receptors. The definition of chemokine receptors is that they can induce cells (such as engineered immune cells) to migrate in the gradient direction of chemotactic cytokines (chemotaxis). Chemokine receptors are a family of 7 transmembrane domain, G protein-coupled cell surface receptors, which are designated as CXCR1 to CXCR5, CCR1 to CCR11, XCR1 and CX3CR1 according to their specific preference for certain chemokines. Chemokines are small secreted proteins that can be divided into two major subfamilies, CXC or CC chemokines, depending on whether the two conserved cysteine residues present in all chemokines are separated by intermediate amino acids. In some embodiments, migration or chemotaxis can be quantified in engineered immune cell populations. On the one hand, migration or chemotaxis to cancer can be assessed in vitro using the CXCR4 and ligand SDF-1 (CXCL12) axis. On the one hand, the percentage of CD3, CD4 and / or CD8 F-CART expressing CXCR4 is higher than that of CD3, CD4 and / or CD8 C-CART expressing CXCR4. On the one hand, compared with CXCR4 on CD3, CD4 and / or CD8 positive C-CART, a greater mean fluorescence intensity (MFI) of CXCR4 is observed in CD3, CD4 and / or CD8 positive F-CART. The expression of CXCR4 can indicate that the migration potential of immune cell colonies to the target expressing CXCR4 ligands and CXCL12 increases. On the one hand, the MFI of receptors such as CXCR4 can be quantified in engineered immune cell colonies to determine the density of CXCR4 receptors on cells. The MFI or CXCR4 density on engineered immune cells (such as F-CART) increases, which can indicate that the migration potential of cells increases. In some cases, the migration in F-CART and C-CART colonies can be measured by determining the number of cells that migrate to a target (e.g., stromal cell derived factor 1 (SDF1), also referred to as CXC motif chemokine 12 (CXCL12)). In one embodiment, a gradient of SDF-1 (human or murine) can be established in vitro or in vivo and used to determine the migration or chemotaxis of engineered immune cells (such as F-CART) toward a target.On the one hand, compared with the percentage or MFI of CXCR4 of C-CART, the percentage or MFI of CXCR4 of F-CART may be about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or up to about 100% or more. On the one hand, compared with the comparable populations comprising engineered immune cells that undergo ex vivo expansion no more than 2 weeks or 1 week when the populations comprising engineered immune cells and comparable populations contact the target, the cytotoxicity in the population comprising engineered immune cells is at least 0.1 times, 0.2 times, 0.3 times, 0.4 times, 0.5 times, 0.6 times, 0.7 times, 0.8 times, 0.9 times, 1.0 times, 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 2.5 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times higher.
[0010] On the one hand, compared with the comparable population that experiences ex vivo expansion no more than 2 weeks or 1 week when the population and comparable population contact target, the proliferation of the cell population comprising engineered immune cells in vivo is enhanced, and the proliferation in the population comprising engineered immune cells is at least 0.5 times, 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 50 times, 100 times, 500 times, 1000 times, 5000 times or 10000 times higher. On the one hand, the proliferation can be quantified in vitro using carboxyfluorescein succinimidyl ester (CFSE) assay. On the one hand, the proliferation can be quantified in vitro using a cell counter, such as using a cell counter. The variables that can be measured by cell counting methods include, for example: cell size, cell count, cell morphology (shape and structure), cell cycle stage, DNA content, and the presence or absence of specific proteins in cell surface or cytoplasm. The cell counter can assess the cell mass observable in the cell proliferation process. The cell mass can be used as a factor for assessing the enhanced proliferation, such as in an engineered cell population. On the other hand, a cell counter can be used to count cells. On the one hand, a cell counter (such as a flow cytometer) can be used to quantify multiple cells in a sample (e.g., blood, cell culture, bone marrow, tumor, and any combination thereof). A flow cytometer can quantify cells using cell surface proteins, such as engineered immune cells. Available cell markers can be: CD45, CD2, beacon, CAR, TCR, CD3, CD4, CD8, CD62, and any combination thereof.
[0011] On the one hand, the proliferation and / or persistence of engineered immune cells can be determined in vivo by quantifying the copy number of engineered immune cells in a subject using quantitative PCR (qPCR). On the one hand, the copy number of engineered immune cells is calculated as the number of blood cells per microliter. On the one hand, the copy number of engineered immune cells is calculated as the number of DNA copies per microgram. On the one hand, persistence can also be calculated in vivo.
[0012] In one aspect, bone marrow migration is at least 0.1-fold, 0.2-fold, 0.3-fold, 0.4-fold, 0.5-fold, 0.6-fold, 0.7-fold, 0.8-fold, 0.9-fold, 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater in a population comprising engineered immune cells compared to a comparable population that has undergone ex vivo expansion for no more than 2 weeks or 1 week when the population and comparable population are contacted with a target.
[0013] On the one hand, target can be cancer cell or chemokine.In some cases, chemokine is stromal cell derived factor-1 (SDF-1).In some cases, SDF-1 is expressed in the bone marrow of the subject of the cell therapy comprising engineered immune cells.On the one hand, compared with the comparable colonies no more than 2 weeks or 1 week of experience ex vivo expansion, the colonies comprising engineered immune cells have a larger percentage of CXCR4 positive cells.On the one hand, compared with the median percentage of CXCR4 positive cells expressed by comparable colonies no more than 2 weeks or 1 week of experience ex vivo expansion, the colonies comprising engineered immune cells have a larger median percentage of CXCR4 positive cells, and the median percentage is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90% or 100%. On the one hand, compared with the median percentage of CXCR4 positive cells expressed by comparable populations that experience ex vivo expansion no more than 2 weeks or 1 week, the colony comprising engineered immune cells has a larger median percentage of CXCR4 positive cells, and the median percentage is at least 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times larger. On the one hand, compared with the CXCR4 density on the cell surface of comparable populations that experience ex vivo expansion no more than 2 weeks or 1 week, the colony comprising engineered immune cells has a larger CXCR4 density on the cell surface of CXCR4 positive cells. On the one hand, density is measured by the mean fluorescence intensity (MFI) of CXCR4 on the cell surface of assessment CXCR4 positive cells. CXCR4 positive cells can be CD3+, CD4+, CD8+ and any combination thereof. In some embodiments, cytotoxicity can be measured using in vivo assays. On the one hand, compared with the cancer burden observed in comparable subjects of comparable populations that experience ex vivo expansion no more than 2 weeks or 1 week, when the subject applies a colony comprising engineered immune cells, cancer burden reduction is observed in the subject. In one aspect, cancer burden is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% in subjects treated with a population comprising engineered immune cells compared to comparable subjects administered a comparable population that underwent ex vivo expansion for no more than 2 weeks or 1 week.
[0014] On the one hand, in mammalian tumors expressing CAR on F-CART and C-CART to which specific targets are displayed, F-CART has more number relative to C-CART. On the one hand, in mammalian femurs expressing CAR on F-CART and C-CART to which specific targets are displayed, F-CART has more number relative to C-CART. F-CART and C-CART can be quantified in tumors and / or femurs of mammals by the expression of CD45, CD2 and / or CAR. On the one hand, compared with C-CART, F-CART in mammalian tumors and / or femurs is about 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times or up to about 20 times.
[0015] On the one hand, the cytotoxicity of engineered immune cells such as F-CART is measured in an in vitro assay and compared with the cytotoxicity of C-CART. In some aspects, cytotoxicity is measured in an in vivo assay. On the one hand, cytotoxicity can be measured by quantifying the IFNγ levels secreted by cells such as CAR-T+ cell engineered immune cells. On the one hand, compared with C-CART or when contacting with CAR to a target that shows specificity to it, F-CART can secrete and / or express higher levels of IFNγ and / or IL-2. On the one hand, when contacting cells expressing CAR to which specific targets are shown, compared with C-CART, F-CART secretes and / or expresses an increase of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or up to about 100% of IFNγ and / or IL-2. On the one hand, greater cytotoxicity is observed in vivo. On the one hand, cytotoxicity can be measured by quantifying the tumor reduction level of a mammal with cancer, and the mammal with cancer is treated with engineered immune cells such as F-CART with a CAR receptor specific for cancer. The reduction of cancer in mammals can be measured by quantifying the fluorescence level of mammals with tumor cells containing fluorescent proteins. Lower fluorescence in mammals with tumor cells containing fluorescent proteins can indicate the cytotoxicity of engineered immune cells to cancer. In some cases, compared with mammals treated with C-CART cells, the cancer reduction of mammals treated with F-CART can increase by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or up to about 100%. On the one hand, the level of cell proliferation can be quantified. Cell proliferation can refer to cell counts, cell clumps in culture and / or cell division. Cell proliferation can be quantified using in vivo or in vitro assays. In some cases, cell proliferation can be measured by quantifying many cells using a cell counter and / or by in vitro assays such as carboxyfluorescein succinimidyl ester (CFSE). On the one hand, when contacted with a target to which CAR shows specificity, F-CART can proliferate more than C-CART. On the one hand, when contacted with cells expressing a target to which CAR shows specificity, greater proliferation is observed in the F-CART population compared to comparable populations of C-CART, and the proliferation can increase by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or up to about 100%.On the other hand, the present disclosure provides a method of administering a cell therapy comprising an engineered immune cell expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), comprising infusing an immune cell population comprising the engineered immune cell into a subject in need, wherein the engineered immune cell has not undergone ex vivo expansion for no more than 2 weeks or 1 week, or less than 13, 12, 10, 9, 8, 7 or 6 days, and wherein at least 2% of the population is a stem cell-like memory T cell (TSCM). In some embodiments, at least 5% of the population is TSCM. In some embodiments, at least 10% of the population is TSCM. In some embodiments, at least 15% of the population is TSCM. In some embodiments, at least 20% of the population is TSCM. In some embodiments, at least 40% of the population is TSCM. In some embodiments, at least 50% of the population is TSCM. In some embodiments, at least 2%, 5%, 10%, 20%, 40%, 50% or at least 60% of the population is TSCM. In some embodiments, the TSCM is CD45RO. - CD62L +. In some embodiments, the engineered immune cells have undergone less than 1 week of ex vivo expansion. In some embodiments, the engineered immune cells have undergone less than 72, 48, 36, 32, or 24 hours of ex vivo expansion. In some embodiments, the TCR comprises (i) a ligand binding domain specific for a ligand and (ii) a transmembrane domain. In some embodiments, the CAR comprises: (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some embodiments, the ligand of the TCR or CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD4 4V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, RANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRα, TCRβ, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79, Notch-1-4 and / or Claudin18.2. In some embodiments, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. In some embodiments, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS). In some embodiments, CAR comprises at least two intracellular signaling domains. In some embodiments, CAR comprises at least 3 intracellular signaling domains. In some embodiments, CAR further comprises a hinge. In some embodiments, the hinge is from CD28, IgG1 and / or CD8α.In some embodiments, CAR further comprises a signal peptide, and wherein the signal peptide is derived from IgG1, GM-CSF and / or CD8α. In some embodiments, the engineered immune cells are from peripheral blood, cord blood, bone marrow and / or induced pluripotent stem cells. In some embodiments, the engineered immune cells are from peripheral blood, and wherein the peripheral blood cells are T cells, NK cells and / or NKT cells. In some embodiments, the infusion is intravenous. In some embodiments, administration includes infusion of about 1x10. 4 / kg body weight of engineered immune cells. In some embodiments, administration comprises infusing about 1x10 5 / kg body weight of engineered immune cells. In some embodiments, administration comprises infusing about 3x10 5 / kg body weight of engineered immune cells. In some embodiments, at least 20% of immune cells express CAR and / or TCR. In some embodiments, at least 40% of immune cells express CAR and / or TCR. In some aspects, the method further includes administering a second agent to a subject in need. In some embodiments, the second agent is a therapeutically effective amount of an immunostimulant, an immunosuppressant, an antifungal agent, an antibiotic, an antiangiogenic agent, a chemotherapeutic agent, a radioactive agent and / or an antiviral agent. In some embodiments, the immunostimulant is IL-2. In some aspects, the method further includes obtaining peripheral blood from the subject in need after infusion. In some embodiments, the engineered immune cells from the peripheral blood are quantified. In some embodiments, the level of cytokines is quantified. In some embodiments, cytokines are IL-10, IL-6, tumor necrosis factor α (TNF-α), IL-1β, IL-2, IL-4, IL-8, IL-12 and / or IFN-γ. In some embodiments, the method includes repeated infusions.
[0016] In some aspects, the populations provided herein are further characterized in that reduced depletion of cells in the population is observed compared to depletion of cells in a comparable population that has undergone ex vivo expansion for no more than 2 weeks or 1 week.
[0017] In one aspect, the reduced depletion of a population is characterized in that the population comprises fewer cells expressing PD1 and LAG3. In some embodiments, the population is further characterized in that greater proliferation, cytotoxicity, and / or bone marrow migration is observed in the population compared to the proliferation, cytotoxicity, and / or bone marrow migration of a comparable population that has undergone ex vivo expansion for no more than 2 weeks or 1 week. In one aspect, cytotoxicity is measured in an in vitro assay. In one aspect, cytotoxicity is measured in an in vivo assay. In one aspect, the cytotoxicity is at least 0.1-fold, 0.2-fold, 0.3-fold, 0.4-fold, 0.5-fold, 0.6-fold, 0.7-fold, 0.8-fold, 0.9-fold, 1.0-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater in a population comprising engineered immune cells compared to a comparable population comprising engineered immune cells that has undergone ex vivo expansion for no more than 2 weeks or 1 week when said population comprising engineered immune cells and comparable populations are contacted with a target.
[0018] In one aspect, the in vivo and / or in vitro proliferation in a population comprising engineered immune cells is at least 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 50-fold, 100-fold, 500-fold, 1000-fold, 5000-fold, or 10000-fold greater than a comparable population that undergoes ex vivo expansion for no more than 2 weeks or 1 week when the population and comparable population are contacted with a target.
[0019] In one aspect, bone marrow migration is at least 0.1-fold, 0.2-fold, 0.3-fold, 0.4-fold, 0.5-fold, 0.6-fold, 0.7-fold, 0.8-fold, 0.9-fold, 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater in a population comprising engineered immune cells compared to a comparable population that has undergone ex vivo expansion for no more than 2 weeks or 1 week when the population and comparable population are contacted with a target.
[0020] On the one hand, target can be cancer cell or chemokine.In some cases, chemokine is stromal cell derived factor-1 (SDF-1).In some cases, SDF-1 is expressed in the bone marrow of the subject of the cell therapy comprising engineered immune cells.On the one hand, compared with the comparable colonies no more than 2 weeks or 1 week of experience ex vivo expansion, the colonies comprising engineered immune cells have a larger percentage of CXCR4 positive cells.On the one hand, compared with the median percentage of CXCR4 positive cells expressed by comparable colonies no more than 2 weeks or 1 week of experience ex vivo expansion, the colonies comprising engineered immune cells have a larger median percentage of CXCR4 positive cells, and the median percentage is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90% or 100%. On the one hand, compared with the median percentage of CXCR4 positive cells expressed by comparable colonies no more than 2 weeks or 1 week of experience ex vivo expansion, the colony comprising engineered immune cells has a larger median percentage of CXCR4 positive cells, and the median percentage is at least 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times larger. On the one hand, compared with the CXCR4 density on the cell surface of comparable colonies no more than 2 weeks or 1 week of experience ex vivo expansion, the colony comprising engineered immune cells has a larger CXCR4 density on the cell surface of CXCR4 positive cells. On the one hand, density is measured by the mean fluorescence intensity (MFI) of CXCR4 on the cell surface of the CXCR4 positive cells assessed. CXCR4 positive cells can be CD3+, CD4+, CD8+ and any combination thereof. In some embodiments, in vivo assays can be used to measure cytotoxicity. On the one hand, when the subject is administered a population comprising engineered immune cells, a reduction in cancer burden is observed in the subject, compared to the cancer burden observed in comparable subjects of comparable populations that have undergone ex vivo expansion for no more than 2 weeks or 1 week. On the one hand, compared to comparable subjects of comparable populations that have undergone ex vivo expansion for no more than 2 weeks or 1 week, the cancer burden is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% in subjects treated with a population comprising engineered immune cells. On the other hand, the present disclosure provides a method for producing a population of engineered immune cells expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), comprising: (a) activating a cell population comprising immune cells with an activation portion; and simultaneously (b) introducing a polynucleotide encoding at least CAR, wherein the CAR comprises (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain; thereby producing an engineered immune cell population expressing the CAR.On the one hand, the activation part binds: CD3 / T cell receptor complex and / or provides co-stimulation. On the one hand, the activation part is any one of anti-CD3 antibody and / or anti-CD28 antibody. In some embodiments, the activation part is conjugated to a solid phase. In some embodiments, the solid phase is at least one of a bead, a plate and / or a matrix. On the one hand, the solid phase is a bead. On the one hand, the introduction includes transducing a cell population with a viral vector and / or a transposon vector. On the one hand, the viral vector is a retroviral vector, a lentiviral vector and / or an adeno-associated viral vector. In some embodiments, the transposon vector is a Sleeping Beauty vector and / or a PiggyBac vector. On the one hand, steps (a) and (b) are performed within 48 hours. On the one hand, steps (a) and (b) are performed within 24 hours. On the one hand, steps (a) and (b) are performed within 3 hours. On the one hand, steps (a) and (b) are performed within 1 hour. In some embodiments, steps (a) and (b) are performed within 30 minutes. In some embodiments, steps (a) and (b) are performed simultaneously. In some embodiments, transduction comprises adding an infectious agent. In some embodiments, the infectious agent is polybrene. In some embodiments, the transduction comprises adding an infectious agent. In some embodiments, the infectious agent is polybrene. 4 / mL to about 10 8In some embodiments, the cell colony is inoculated at a density of about 0.1 to about 10. In some embodiments, the viral vector is inoculated with a mean infectivity (MOI) plate of about 0.1 to about 10. In some embodiments, the method further comprises stimulating the cell colony with a cytokine. In some embodiments, the cytokine is IL2, IL7, IL15 and / or IL21. In some embodiments, the TCR comprises (i) a ligand binding domain specific for a ligand and (ii) a transmembrane domain. In some embodiments, the CAR comprises: (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some embodiments, the ligand of the TCR or CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, C D44V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, RANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRα, TCRβ, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79, Notch-1-4 and / or Claudin18.2. In some embodiments, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. In some embodiments, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS). In some embodiments, CAR comprises at least two intracellular signaling domains. In some embodiments, CAR comprises at least 3 intracellular signaling domains.In some embodiments, CAR also includes a hinge. In some embodiments, the hinge is from CD28, IgG1 and / or CD8α. In some embodiments, the method also includes enriching the immune cells before the engineering. In some embodiments, enrichment includes collecting monocytes. In some embodiments, enrichment includes sorting immune cells from the monocytes. In some embodiments, the enrichment includes sorting the immune cells based on the expression of one or more markers. In some aspects, one or more markers include CD3, CD28, CD4 and / or CD8. In some aspects, anti-CD3 antibodies or their antigen-binding fragments, and / or anti-CD28 antibodies or their antigen-binding fragments are used to sort the immune cells. In some embodiments, beads conjugated to the anti-CD3 antibodies or their antigen-binding fragments and / or beads conjugated to the anti-CD28 antibodies or their antigen-binding fragments are used to sort the immune cells. In some embodiments, the engineered immune cell population is characterized in that the cell memory T cells (TCM) in the population are more abundant than effector memory T cells (TEM). On the one hand, at least 2% of the population is stem cell-like memory T cells (TSCM). On the one hand, at least 5% of the population is stem cell-like memory T cells (TSCM). On the one hand, at least 10% of the population is stem cell-like memory T cells (TSCM). On the one hand, at least 15% of the population is stem cell-like memory T cells (TSCM). In some embodiments, at least 20% of the population is TSCM. In some embodiments, at least 25% of the population is TSCM. In some embodiments, at least 40% of the population is TSCM. In some embodiments, at least 50% of the population is TSCM. In some embodiments, at least 2%, 5%, 10%, 20%, 40%, 50% or at least 60% of the population is TSCM. On the one hand, the method also includes the step of infusing the engineered immune cell population to a subject in need within 72 hours after (a) and (b) are completed. On the one hand, the further feature of the population is that compared with the cell depletion in the comparable population of the comparable method where (a) and (b) are not performed simultaneously, it is observed that the cell depletion in the population is reduced. In one aspect, the reduced depletion of a population is characterized in that the population comprises fewer cells expressing PD1 and LAG3.
[0021] In one embodiment, the further feature of the colony is that, compared with the comparable populations of comparable methods that experience (a) and (b) are not carried out simultaneously, greater proliferation, cytotoxicity and / or bone marrow migration are observed in the colony. On the one hand, cytotoxicity is measured in an in vitro assay. On the one hand, cytotoxicity is measured in an in vivo assay. On the one hand, compared with the comparable populations that (a) and (b) are carried out for more than 24 hours when the colony comprising the engineered immune cell and the comparable population contact target, cytotoxicity is quantified, and at least 0.1 times, 0.2 times, 0.3 times, 0.4 times, 0.5 times, 0.6 times, 0.7 times, 0.8 times, 0.9 times, 1.0 times, 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 2.5 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times higher in the colony comprising the engineered immune cell.
[0022] In one aspect, the in vivo and / or in vitro proliferation in a population comprising engineered immune cells is at least 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 50-fold, 100-fold, 500-fold, 1000-fold, 5000-fold, or 10000-fold greater than a comparable population when (a) and (b) are performed for more than 24 hours when the population and comparable population are contacted with a target.
[0023] In one aspect, bone marrow migration is at least 0.1-fold, 0.2-fold, 0.3-fold, 0.4-fold, 0.5-fold, 0.6-fold, 0.7-fold, 0.8-fold, 0.9-fold, 1-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater in a population comprising engineered immune cells than in a comparable population when (a) and (b) are performed for greater than 24 hours.
[0024] On the one hand, the target can be a cancer cell or a chemokine.Chemokine is a stromal cell derived factor-1 (SDF-1), which can be expressed in the bone marrow of a subject receiving administration of a colony comprising engineered immune cells. In some embodiments, compared with (a) and (b) for a comparable colony for more than 24 hours, the colony comprising engineered immune cells has a larger percentage of CXCR4 positive cells. On the one hand, compared with (a) and (b) for a comparable colony for more than 24 hours, the colony comprising engineered immune cells has a larger percentage of CXCR4 positive cells, and the median percentage is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90% or 100%. On the one hand, compared with the median percentage of CXCR4 positive cells expressed by comparable populations for more than 24 hours (a) and (b), the colony comprising engineered immune cells has a larger median percentage of CXCR4 positive cells, and the median percentage is at least 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times larger. On the one hand, compared with the CXCR4 density on the cell surface of comparable populations for more than 24 hours (a) and (b), the colony comprising engineered immune cells has a larger CXCR4 density on the cell surface of CXCR4 positive cells. The density of cell surface receptors, such as CXCR4, can be measured by the mean fluorescence intensity (MFI) of CXCR4 on the cell surface of assessing CXCR4 positive cells. On the one hand, cytotoxicity is measured in vivo. In some cases, compared with the cancer burden observed in comparable subjects of comparable populations for more than 24 hours using (a) and (b), when the subject uses a colony comprising engineered immune cells, it is observed that cancer burden is reduced in the subject. In one aspect, cancer burden is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% in subjects treated with a population comprising engineered immune cells compared to comparable subjects of a comparable population administered (a) and (b) for more than 24 hours.
[0025] On the one hand, a point-of-care device comprising a cell infusion device is provided herein, configured to infuse an immune cell population, the immune cell population comprising engineered immune cells that have not undergone ex vivo expansion for 2 weeks or more or less than 13, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 days, wherein the immune cell population is further characterized in that: the cell memory T cells (TCM) in the population are more abundant than the effector memory T cells (TEM); or wherein at least 2% of the population are stem cell-like memory T cells (TSCM). In some embodiments, at least 5% of the population are stem cell-like memory T cells (TSCM). In some embodiments, at least 10% of the population are stem cell-like memory T cells (TSCM). In some embodiments, at least 15% of the population are stem cell-like memory T cells (TSCM). In some embodiments, at least 20% of the population are TSCM. In some embodiments, at least 40% of the population are TSCM. In some embodiments, at least 50% of the population are TSCM. In some embodiments, at least 2%, 5%, 10%, 20%, 40%, 50% or at least 60% of the population is TSCM. In some embodiments, TCM is 2 times more than TEM. In some embodiments, TCM is 4 times more than TEM. In some embodiments, the engineered immune cells have undergone less than 5 days of ex vivo expansion. In some embodiments, the engineered immune cells have undergone less than 3 days of ex vivo expansion. In some embodiments, the engineered immune cells have undergone less than 2 days of ex vivo expansion. In some embodiments, the engineered immune cells have undergone less than 1 day of ex vivo expansion. In some embodiments, the immune cells are T cells, NK cells and / or NKT cells. In some aspects, the population is also characterized by observing a reduction in cell depletion in the population, and wherein the reduction in depletion is characterized by the population comprising fewer cells expressing PD1 and LAG3.
[0026] Provided herein is a point-of-care device comprising a cell processing device configured to (a) receive a cell population comprising immune cells from a subject;
[0027] (b) activating the immune cell colony with an activation portion, while introducing a polynucleotide encoding at least a chimeric antigen receptor (CAR) into the immune cell, wherein the CAR comprises (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain; and (c) infusing the immune cell colony of (b) to the subject within 2 weeks or less from the time of performing (b). In some embodiments, step (c) is performed within 1 week or less from the time of performing (b). In some embodiments, the immune cell is a T cell, a NK cell, and / or a NKT cell. In some embodiments, the ligand of the CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD44 V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, RANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRα, TCRβ, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79, Notch-1-4 and / or Claudin18.2. In some embodiments, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. In some embodiments, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS). In some embodiments, CAR comprises at least two intracellular signaling domains. In some embodiments, CAR comprises at least 3 intracellular signaling domains. In some embodiments, CAR also comprises a hinge.In some embodiments, the hinge is from CD28, IgG1 and / or CD8α. In some embodiments, CAR further comprises a signal peptide, and wherein the signal peptide is derived from IgG1, GM-CSF and / or CD8α. In some embodiments, immune cells are T cells, NK cells and / or NKT cells. In some embodiments, the activation portion binds: CD3 / T cell receptor complex and / or provides co-stimulation. In some embodiments, the activation portion is any one of anti-CD3 antibodies and / or anti-CD28 antibodies. In some embodiments, viral vectors and / or transposon vectors comprise polynucleotides. On the one hand, viral vectors are retroviral vectors, lentiviral vectors and / or adeno-associated viral vectors. In some embodiments, steps (a) and (b) are performed within 24 hours. In some embodiments, steps (a) and (b) are performed within 3 hours. In some embodiments, steps (a) and (b) are performed within 1 hour. In some embodiments, steps (a) and (b) are performed within 30 minutes. In some aspects, the population is further characterized by observing reduced cellular depletion in the population, and wherein the reduced depletion is characterized in that the population comprises fewer cells expressing PD1 and LAG3.
[0028] On the one hand, there is provided herein a cell population comprising an engineered immune cell expressing a chimeric antigen receptor (CAR) and / or a T cell receptor (TCR), wherein the population is further characterized in that (i) central memory T cells (TCM) in the population are more abundant than effector memory T cells (TEM); and / or (ii) at least 2% of the cell population is a stem cell-like memory T cell (TSCM), and wherein the CAR comprises (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. On the one hand, at least 5% of the population is TSCM. On the one hand, at least 10% of the population is TSCM. In some embodiments, TCM is 2 times more than TEM. In some embodiments, TCM is 4 times more than TEM. In some embodiments, immune cells are T cells, NK cells, and / or NKT cells. In some embodiments, the ligand of the CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD44 In one aspect, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. In one aspect, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS).In some embodiments, CAR comprises at least two intracellular signaling domains. In some embodiments, CAR comprises at least 3 intracellular signaling domains. In some embodiments, CAR also comprises a hinge. In some embodiments, the hinge is from CD28, IgG1 and / or CD8α. In some embodiments, CAR further comprises a signal peptide, and wherein the signal peptide is derived from IgG1, GM-CSF and / or CD8α. On the one hand, immune cells are T cells, NK cells and / or NKT cells. On the one hand, the colony is cryopreserved. On the one hand, the colony is not cryopreserved. On the one hand, the colony is freshly derived or comprises cells from a fresh source. On the one hand, the colony is also characterized in that cell depletion is observed to be reduced in the colony, and wherein the depletion is reduced in that the colony comprises fewer cells expressing PD1 and LAG3.
[0029] In one aspect, provided herein is a method of treating cancer in a subject in need thereof, comprising infusing no more than about 2 x 10 6 An engineered immune cell colony expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), wherein the engineered immune cell has not been expanded in vitro for no more than 2 weeks or 1 week. On the one hand, compared with an engineered immune cell colony expressing the same chimeric antigen receptor (CAR) and / or engineered T cell receptor (TCR) but having been expanded in vitro for no more than 2 weeks or 1 week, the engineered immune cell colony exhibits a considerable level of anti-tumor activity in vivo. On the one hand, the engineered immune cell colony has been activated and transduced simultaneously with a construct expressing the CAR and / or TCR. On the one hand, the engineered immune cell colony has not undergone ex vivo expansion for a week. On the one hand, the engineered immune cell colony has not undergone ex vivo expansion for 72 hours. On the one hand, no more than about 1x10 6A population of engineered immune cells is prepared from peripheral blood mononuclear cells (PMBC) by a method of simultaneously activating and transducing with a construct expressing the CAR and / or TCR. In some embodiments, the infusion occurs within 1 week of simultaneous activation and transduction with a construct expressing the CAR and / or TCR. In some embodiments, simultaneous activation includes activation and transduction within 48 hours. In some embodiments, simultaneous activation includes activation and transduction within 24 hours. In some embodiments, simultaneous activation includes activation and transduction within 3 hours. In some embodiments, simultaneous activation includes activation and transduction within 1 hour. In some embodiments, simultaneous activation includes activation and transduction within 30 minutes. In some embodiments, simultaneous activation includes activation and transduction at the same time. In some embodiments, at least 2% of the population is stem cell-like memory T cells (TSCM). In some embodiments, at least 5% of the population is stem cell-like memory T cells (TSCM). In some embodiments, at least 10% of the population is stem cell-like memory T cells (TSCM). In some embodiments, at least 15% of the population is stem cell-like memory T cells (TSCM). In some embodiments, at least 20% of the population is TSCM. In some embodiments, at least 40% of the population is TSCM. In some embodiments, at least 50% of the population is TSCM. In some embodiments, at least 2%, 5%, 10%, 20%, 40%, 50%, or at least 60% of the population is TSCM. In some embodiments, no more than about 10 5 In some embodiments, no more than about 10 4 In some embodiments, no more than about 10 3In some embodiments, the engineered immune cell is a T cell, a NK cell and / or a NKT cell. In some embodiments, the TCR comprises (i) a ligand binding domain specific for a ligand and (ii) a transmembrane domain. In some embodiments, the CAR comprises: (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some embodiments, the ligand of the TCR or CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD 44V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, RANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRα, TCRβ, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79, Notch-1-4 and / or Claudin18.2. In some embodiments, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. In some embodiments, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS). In some embodiments, CAR comprises at least 2 intracellular signaling domains. In some embodiments, CAR comprises at least 3 intracellular signaling domains. In some embodiments, CAR further comprises a hinge. In some embodiments, the hinge is from CD28, IgG1 and / or CD8α. In some embodiments, CAR further comprises a signal peptide, and wherein the signal peptide is derived from IgG1, GM-CSF and / or CD8α.In some embodiments, the engineered immune cells are from peripheral blood, cord blood, bone marrow and / or induced pluripotent stem cells. In some embodiments, the engineered immune cells are from peripheral blood, and wherein the peripheral blood cells are T cells. On the one hand, the method also includes obtaining peripheral blood from the subject in need after the administration. On the one hand, the engineered immune cells in the subject are quantified from the peripheral blood. On the one hand, the growth factor levels in the subject are quantified. In some cases, the growth factor is selected from IL-10, IL-6, tumor necrosis factor α (TNF-α), IL-1β, IL-2, IL-4, IL-8, IL-12 and / or IFN-γ. In some embodiments, the method includes repeated infusions. In some embodiments, the immune cell colony is allogeneic for the subject in need. In some embodiments, the immune cell colony is autologous for the subject in need. In some embodiments, the subject suffers from cancer. On the one hand, cancer can be a target. On the one hand, cancer is hematological. On the one hand, the blood cancer is leukemia, myeloma, lymphoma and / or its combination. In some embodiments, leukemia is chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), T cell acute lymphocytic leukemia (T-ALL), B cell acute lymphocytic leukemia (B-ALL) and / or acute lymphocytic leukemia (ALL). In some embodiments, the lymphoma is mantle cell lymphoma (MCL), T cell lymphoma, Hodgkin lymphoma and / or non-Hodgkin lymphoma. In some embodiments, cancer is a target and is solid. In some embodiments, the solid cancer target is selected from: Wilms tumor, Ewing's sarcoma, neuroendocrine tumor, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, biliary tract cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma or bladder cancer. In some embodiments, the subject is pretreated with chemotherapy before the administration. In some embodiments, the chemotherapy includes the administration of fludarabine, cyclophosphamide and / or cytarabine. On the one hand, the further feature of the colony is that compared with the proliferation, cytotoxicity and / or bone marrow migration of a comparable colony that undergoes ex vivo expansion for no more than 2 weeks or 1 week, greater proliferation, cytotoxicity and / or bone marrow migration are observed in the colony. On the one hand, cytotoxicity is measured in an in vitro assay. On the one hand, cytotoxicity is measured in an in vivo assay.
[0030] On the one hand, it is provided herein that a method for administering a cell therapy comprising an engineered immune cell expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR) is provided herein, including infusing an immune cell colony comprising the engineered immune cell into a subject in need, wherein the engineered immune cell has not been subjected to ex vivo expansion for no more than 2 weeks or 1 week, and wherein the further feature of the colony is that compared with the proliferation of a comparable colony subjected to ex vivo expansion for no more than 2 weeks or 1 week, greater proliferation is observed in the colony. On the one hand, compared with a comparable colony subjected to ex vivo expansion for no more than 2 weeks or 1 week when the colony and comparable colony contact a target, the proliferation described in the colony is at least 1 times higher.
[0031] Provided herein is a method of administering a cell therapy comprising engineered immune cells expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), comprising infusing a population of immune cells comprising the engineered immune cells into a subject in need thereof, wherein the engineered immune cells have not undergone ex vivo expansion for no more than 2 weeks or 1 week, and wherein the population is further characterized in that greater cytotoxicity is observed in the population compared to the cytotoxicity of a comparable population that has undergone ex vivo expansion for no more than 2 weeks or 1 week. In one aspect, the cytotoxicity in the population is at least 0.1-fold, 0.2-fold, 0.3-fold, 0.4-fold, 0.5-fold, 0.6-fold, 0.7-fold, 0.8-fold, 0.9-fold, 1.0-fold, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater than in a comparable population that has undergone ex vivo expansion for no more than 2 weeks or 1 week when the population and comparable population are contacted with a target.
[0032] Provided herein is a method for administering a cell therapy comprising an engineered immune cell expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), comprising: infusing an immune cell colony comprising the engineered immune cell into a subject in need, wherein the engineered immune cell has not undergone ex vivo expansion for no more than 2 weeks or 1 week, and wherein the further feature of the colony is that compared with the bone marrow migration of a comparable colony that has undergone ex vivo expansion for no more than 2 weeks or 1 week, a greater bone marrow migration of the colony is observed. In some embodiments, compared with a comparable colony that has undergone ex vivo expansion for no more than 2 weeks or 1 week when the colony and the comparable colony contact the target, the bone marrow migration in the colony is at least 1 times higher. On the one hand, the colony is also characterized in that: the central memory T cells (TCM) in the colony are more abundant than effector memory T cells (TEM). On the one hand, TCM is CD45RO+CD62L+. On the one hand, TEM is CD45RO+CD62L-. On the one hand, the engineered immune cell has undergone ex vivo expansion for less than 5 days. On the one hand, engineered immune cells have undergone less than 4 days of ex vivo expansion. On the one hand, engineered immune cells have undergone less than 72 days of ex vivo expansion. On the one hand, engineered immune cells have undergone less than 48 days of ex vivo expansion. On the one hand, engineered immune cells have undergone less than 24 days of ex vivo expansion. On the one hand, the target is a ligand or chemokine of a cancer cell, TCR or CAR. In some embodiments, the chemokine is stromal cell derived factor-1 (SDF-1), and wherein the SDF-1 is expressed in the bone marrow of the subject. In some cases, compared with comparable populations that undergo ex vivo expansion no more than 2 weeks or 1 week, the population has a greater percentage of CXCR4 positive cells. On the one hand, compared with the median percentage of CXCR4 positive cells expressed by comparable populations that undergo ex vivo expansion no more than 2 weeks or 1 week, the population has a greater median percentage of CXCR4 positive cells, and the median percentage is at least 10% greater. On the one hand, compared with the CXCR4 density on the cell surface of the comparable population that is no more than 2 weeks or 1 week of ex vivo amplification, the population has a larger CXCR4 density on the cell surface of CXCR4-positive cells. On the one hand, density is measured by the mean fluorescence intensity (MFI) of CXCR4 on the cell surface of the CXCR4-positive cells assessed. On the one hand, cytotoxicity is measured in an in vivo assay. In some cases, compared with the cancer burden observed in comparable subjects of comparable populations that are no more than 2 weeks or 1 week of ex vivo amplification, a reduction in cancer burden is observed in the subject of the population.On the one hand, compared with comparable subjects of comparable groups experiencing ex vivo expansion no more than 2 weeks or 1 week, cancer burden is reduced in subjects treated with groups by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99%. On the one hand, compared with comparable subjects of comparable groups experiencing ex vivo expansion no more than 2 weeks or 1 week, cancer burden is reduced in subjects treated with groups by at least 0.5 times, 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times. On the one hand, compared with the cancer burden observed in comparable subjects of comparable groups experiencing ex vivo expansion no more than 2 weeks or 1 week, complete remission (CR) is observed in the subjects of the group. In some embodiments, compared with the cancer burden observed in comparable subjects of comparable groups experiencing ex vivo expansion no more than 2 weeks or 1 week, partial response (PR) is observed in the subjects of the group. In one aspect, the population comprises at most 1x10. 4 In one aspect, the population comprises about 1x10 4 Engineered immune cells from cells / kg / body weight to a maximum of approximately 1x10 5In some cases, the engineered immune cells are T cells, NK cells and / or NKT cells. In some cases, TCR comprises (i) a ligand binding domain specific to a ligand and (ii) a transmembrane domain. On the one hand, CAR includes: (i) a ligand binding domain specific to a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In one aspect, the ligand of the TCR or CAR is VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD44 In one aspect, the transmembrane domain is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152. On the one hand, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS). In some cases, CAR comprises at least 2 intracellular signaling domains. In some cases, CAR comprises at least 3 intracellular signaling domains. In some cases, CAR also comprises a hinge. The hinge may be from CD28, IgG1 and / or CD8α. On the one hand, the engineered immune cells are from peripheral blood, umbilical cord blood, bone marrow and / or induced pluripotent stem cells. In some cases, the engineered immune cells are from peripheral blood, and the peripheral blood cells are T cells.
[0033] Incorporation by reference
[0034] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] The novel features of the present invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by referring to the following detailed description and the accompanying drawings which illustrate illustrative embodiments in which the principles of the present invention are utilized, in which:
[0036] Figure 1 The ratio of multiplicity of infection (MOI) to the percentage of CAR positivity in F-CART cells is shown.
[0037] Figure 2 Comparison between the CAR positive expression percentages of cells generated by conventional CART (C-CART) and fast CART (F-CART) is shown.
[0038] Figure 3 Phenotypic analysis of control (starting material) and F-CART cells using flow cytometry is shown.
[0039] Figure 4A A linear graph of cell proliferation of anti-CD19F-CART against anti-CD19 C-CART cells is shown. Figure 4B The proliferation folds of anti-CD19F-CART versus anti-CD19 C-CART cells are shown.
[0040] Figure 5 The in vitro killing efficacy of anti-CD19F-CART cells against anti-CD19 C-CART cells over 50 hours is depicted.
[0041] Fig. 6A Shown is the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in control cells (non-transduced), F-CART, and C-CART when co-cultured with Molt4 (CD19-) or Raji (CD19+) tumor cells at a 1:1 ratio. Figure 6B Shown is the expression of TNF-α in control cells (non-transduced), F-CART, and C-CART when co-cultured with Molt4 (CD19-) or Raji (CD19+) tumor cells at a 1:1 ratio. Figure 6CShown is the expression of IL-2 in control cells, F-CART, and C-CART when co-cultured with Molt4 (CD19-) or Raji (CD19+) tumor cells at a 1:1 ratio. Fig.6D Shown is the expression of IFN-γ in control cells (non-transduced), F-CART, and C-CART when co-cultured with Molt4 (CD19-) or Raji (CD19+) tumor cells at a 1:1 ratio.
[0042] Fig. 7A Depicted are bioluminescent imaging of mice transplanted with Molt4 or Raji tumor cells and treated with control T cells (non-transduced), C-CART, or F-CART cells at a total dose of 2e6, 5e5, or 5e4 cells / mouse. Figure 7B Injection of 0.5x10 6 Graphical summary of the days of bioluminescence imaging after quantification of control (non-transduced) T cells, C-CART, or F-CART cells per mouse.
[0043] Figure 8 The transplantation of Raji tumor cells and subsequent treatment with 0.5x10 6 Body weight changes of mice treated with control (non-transduced), T cells, C-CART or F-CART cells with 10 cells / mouse.
[0044] Fig. 9 Shown are tumor volumes of mice transplanted with Raji tumor cells and subsequently treated with control, T cells, C-CART, or F-CART cells.
[0045] Fig.10 Figure 2 shows transplantation of Raji tumor cells followed by treatment with control (non-transduced) or high dose (2×10 6 cells / mouse), medium dose (5x10 5 cells / mouse) or low dose (5x10 4 Quantification of cells in the peripheral blood of mice treated with F-CART cells (cells / mouse).
[0046] Fig.11A Shown is the phenotypic analysis of Lag3 versus PD-1 on F-CART and C-CART cells from three individual donors on day 6 after stimulation with K562-CD19+ cells. Fig. 11B Shown is the phenotypic analysis of Lag3 versus PD-1 on F-CART and C-CART cells from three individual donors at day 10 after stimulation with K562-CD19+ cells. Fig. 11CShown are the average expression of PD1+Lag3+ cells on three individual donors on day 6 versus day 10 after stimulation with K562-CD19+ cells.
[0047] Fig.12 Depicted are flow cytometric graphs showing the number of TSCM, TCM, TEFF, and TEM cells in F-CART cells from three individual donors after stimulation with K562-CD19+ cells.
[0048] Fig.13A FAST-CAR in subject XF001 up to 56 days after infusion is shown + Cell expansion, persistence, and copy number. Fig. 13B Shown using FAST-CAR + Body temperature of subject XF001 after cell infusion. Fig. 13C Shown is the infusion of FAST-CAR + The concentration of IL-6 in the blood of subject XF001 after cell transplantation. Fig.13D Shown is the infusion of FAST-CAR + The concentration of C-reactive protein (CRP) in the blood of subject XF001 after cell transplantation.
[0049] Fig.14A Shown using FAST-CAR + Body temperature of subject F01 after cell infusion. Fig. 14B FAST-CAR in the peripheral blood of subject F01 is shown + Cell copy number, FAST-CAR + Copy number and FAST-CAR in bone marrow + Copy number. Fig. 14C Shown using FAST-CAR + Levels of growth factors (INF-γ, IL-10, sCD25, IL-6, and CRP) in the peripheral blood and body temperature of subject F01 after cell infusion.
[0050] Fig.15 The treatment outcomes and efficacy of F-CART in 9 different subjects are depicted: cytokine release syndrome (CRS), neurotoxicity (NT), complete remission (CR), mean residual disease (MRD), and allogeneic stem cell transplantation (Allo-SCT).
[0051] Fig.16A Flow cytometry graphs are shown showing the number of TSCM, TCM, TEFF, and TEM cells in F-CART vs. C-CART cells of a single donor. Fig. 16B A summary of flow cytometry results is shown. Fig. 16CShown is a graphical summary of the percentages of TSCM, TCM, TEM, and TEFF in F-CART vs. C-CART of three individual donors after stimulation with K562-CD19+ cells.
[0052] Fig.17A The fold expansion of F-CART versus C-CART cells at days 8, 12, and 18 after engineering is shown. Fig. 17B The PD-1 and LAG3 percentages on days 6 and 10 after F-CART and C-CART cell engineering are shown. Fig. 17C Flow cytometry results of C-CART and F-CART cells from a single donor stained with PD-1 and LAG3 are shown. Fig.17D Figure 2 shows the maintenance of in vitro cytotoxicity of C-CART and F-CART prepared from healthy donors in co-culture assay: using CD19 + C-CART cultured with tumor cells, using CD19 + F-CART in tumor cell culture, using CD19 + Tumor cell cultures were of non-transduced cells and tumor cells only (Hela-CD19).
[0053] Fig.18 Figure 2 shows IL-2 and IFNγ secretion by C-CART and F-CART prepared from healthy donors: + C-CART cultured with tumor cells, using CD19 + F-CART in tumor cell culture, using CD19 + Tumor cell cultures were made of non-transduced cells and medium-only controls.
[0054] Fig.19A The expansion of human sample GC007 FF-CART and C-CART cells is shown. Fig.19B The cellular phenotypes of F-CART and C-CART in sample GC007F are shown. Fig.19C A pie chart showing the cellular phenotype of sample GC007F. Fig.19D A graphical summary of the cell phenotype data by percentage of T cell subsets is shown. Fig.19E The percentages of PD1+LAG3+CAR-T cells on days 6 and 9, respectively, are shown in C-CART and F-CART cells.
[0055] Fig. 20A The maintenance of in vitro cytotoxicity in real-time cell analysis (RTCA) assays of C-CART and F-CART prepared from patients was shown: + C-CART cultured with tumor cells, using CD19 +F-CART in tumor cell culture, using CD19 + Tumor cell cultures were of non-transduced cells and tumor cells only (Hela-CD19). Fig. 20B Shown is the maintenance of the cytokine fraction in ELISA of supernatants of co-cultured cells. Fig. 20C Shown is the maintenance of cytotoxicity in C-CART by F-CAR prepared from patients as determined in a luciferase assay.
[0056] Fig.21A Shown are bioluminescent imaging of NOG mice transplanted with Raji tumor cells and treated with control (medium only), T cells, C-CART, or F-CART cells at doses of 2e6 cells / mouse (high dose) or 5e4 cells / mouse (low dose).
[0057] Fig.22A Schematic diagram showing tumor transplantation and treatment of leukemia mouse model. Fig. 22B Shown is the phenotypic analysis of the bone marrow of mice treated with F-CART or C-CART cells on day 10 after treatment. Fig. 22C The number of CD45+CD2+CART+ cells in the femurs of F-CART and C-CART treated mice is shown. Fig.22D Shown is the expression of CXCR4 in the CD4 fraction versus the CD8 fraction of F-CART and C-CART treated mice. Fig.22E Shown are the percentages of CXCR4 in the CD4 fraction versus the CD8 fraction of F-CART and C-CART treated mice. Fig.22F Shown are the MFI of CXCR4 fraction in the CD4 fraction versus the CD8 fraction in F-CART and C-CART treated mice. Figure 22G A graphic representation of the results of the transwell migration assay of F-CART vs. C-CART cells and mouse SDF-1α is shown. Fig.22H A graphic representation of the results of the transwell migration assay of F-CART vs. C-CART cells and human SDF-1α is shown.
[0058] Fig.23A Schematic representation of the presentation of NY-ESO-1 fragments by HLA-A*02 of cancer cells and the recognition of NY-ESO-1 fragments by T cells expressing engineered TCRs. Fig. 23B Shown is a comparison of the proliferative capacity of FTCRT cells and CTRCT cells, both of which were engineered to bind fragments of NY-ESO-1. Fig.23C Shown is a comparison of lymphocyte subsets in FTCRT cells and CTRCT cells, both of which were engineered to bind fragments of NY-ESO-1. Fig.23D Shown is a comparison of lymphocyte depletion in FTCRT cells and CTRCT cells, both of which were engineered to bind fragments of NY-ESO-1. Fig.23E Shown is a comparison of target cell cytotoxicity of FTCRT cells and CTRCT, both of which were engineered to bind fragments of NY-ESO-1. Fig.23F Shown is a comparison of target cell cytotoxicity in FTCRT cells and CTRCT cells, both of which were engineered to bind fragments of NY-ESO-1.
[0059] Fig.24A Graph showing the CAR transduction efficiency in GC022 cells by conventional CART method and FCART method. Fig. 24B The diagram shows the cytotoxicity of GC022 cells expressing CAR generated by conventional CART method and FCART method against target cells. Fig.24C The cell expansion capacity of CAR-expressing GC022 cells generated by conventional CART method and FCART method is shown. Fig.24D The diagram shows the cytotoxicity of GC022 cells expressing CAR against target cells generated by conventional CART method and FCART method, wherein GC022 cells expressing CAR are expanded by antigen stimulation. Fig.24E The figure shows the comparison of lymphocyte subsets in CAR-expressing GC022 cells generated by conventional CART method and FCART method. Fig.24F Graph showing comparison of depletion in CAR-expressing GC022 cells generated by conventional CART approach and FCART approach. Figure 24G Depicted are bioluminescent imaging of mice transplanted with tumor cells and treated with control T cells (non-transduced) or CAR-expressing GC022 cells generated by conventional CART approach and FCART approach. Fig.24H A graphical summary of bioluminescence imaging several days after injection of control (non-transduced) T cells or GC022 cells expressing CAR generated by conventional CART method and FCART method is shown. Fig.24I Shown are changes in body weight of mice transplanted with tumor cells and subsequently treated with control (non-transduced) T cells or CAR-expressing GC022 cells generated by conventional CART methods and FCART methods. DETAILED DESCRIPTION
[0060] Unless otherwise indicated, the practice of some methods disclosed herein employs conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, which are within the skill of the art. See, e.g., Sambrook and Green, Molecular Cloning: A Laboratory Manual, 4th edition (2012); the series Current Protocols in Molecular Biology (FM Ausubel et al., ed.); the series Methods In Enzymology (Academic Press, Inc.), PCR 2: A Practical Approach (MJ MacPherson, BD Hames, and GR Taylor, ed. (1995)), Harlow and Lane, ed. (1988) Antibodies, A Laboratory Manual, and Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6th edition (RI Freshney, ed. (2010)).
[0061] As used in the specification and claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. For example, the term "a chimeric transmembrane receptor polypeptide" includes a plurality of chimeric transmembrane receptor polypeptides.
[0062] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which error range will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to the practice in the art, "about" can mean within 1 or more than 1 standard deviation. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean that a value is within an order of magnitude, preferably within 5 times the value, and more preferably within 2 times the value. Where specific values are described in the application and claims, the term "about" should be assumed to mean within an acceptable error range for the specific value unless otherwise stated.
[0063] As used herein, "cell" generally refers to a biological cell. A cell can be the basic structure, function and / or biological unit of an organism. A cell can be derived from any organism having one or more cells. Some non-limiting examples include: prokaryotic cells, eukaryotic cells, bacterial cells, archaeal cells, cells of unicellular eukaryotic organisms, protozoan cells, cells from plants, animal cells, cells from invertebrates (e.g., fruit flies, cnidarians, echinoderms, nematodes, etc.), cells from vertebrates (e.g., fish, amphibians, reptiles, birds, mammals), cells from mammals (e.g., pigs, cattle, goats, sheep, rodents, rats, mice, non-human primates, humans, etc.), etc. Sometimes cells are not derived from natural organisms (e.g., cells can be synthetic, sometimes referred to as artificial cells). Of particular interest are immune cells from, for example, mammals (including experimental animals and humans).
[0064] As used herein, the term "antigen" refers to a molecule or fragment thereof that can be bound by a selective binding agent. For example, an antigen can be a ligand that can be bound by a selective binding agent such as a receptor. As another example, an antigen can be an antigen molecule that can be bound by a selective binding agent such as an immune protein (e.g., an antibody). Antigen can also refer to a molecule or fragment thereof that can be used in an animal to produce an antibody that can bind to the antigen. In some cases, an antigen can be bound to a substrate (e.g., a cell membrane). Alternatively, an antigen may not be bound to a substrate (e.g., a secreted molecule, such as a secreted polypeptide).
[0065] As used herein, the term "antibody" refers to a protein binding molecule with an immunoglobulin-like function. The term antibody includes antibodies (e.g., monoclonal and polyclonal antibodies) and derivatives, variants and fragments thereof. Antibodies include, but are not limited to, immunoglobulins (Ig) of different classes (i.e., IgA, IgG, IgM, IgD and IgE) and subclasses (such as IgG1, IgG2, etc.). Its derivatives, variants or fragments may refer to functional derivatives or fragments that retain the binding specificity (e.g., complete and / or partial) of the corresponding antibody. Antigen-binding fragments include Fab, Fab', F(ab')2, variable fragments (Fv), single-chain variable fragments (scFv), mini antibodies, double antibodies and single-domain antibodies ("sdAb" or "nano antibodies" or "camel"). The term antibody includes optimized, engineered or chemically coupled antibodies and antigen-binding fragments of antibodies. Examples of optimized antibodies include affinity-matured antibodies. Examples of engineered antibodies include Fc-optimized antibodies (e.g., antibodies optimized in the fragment crystallizable region) and multispecific antibodies (e.g., bispecific antibodies). In some cases, an antibody may exhibit binding specificities for at least 1, 2, 3, 4, 5 or more different antigens. In some cases, an antibody may exhibit binding specificities for up to 5, 4, 3, 2 or 1 antigens.
[0066] As used herein, the term "nucleotide" generally refers to a combination of base-sugar-phosphate. Nucleotide may include synthetic nucleotides. Nucleotide may include synthetic nucleotide analogs. Nucleotide may be a monomer unit of a nucleic acid sequence (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)). The term nucleotide may include ribonucleoside triphosphates, adenosine triphosphate (ATP), uridine triphosphate (UTP), cytosine triphosphate (CTP), guanosine triphosphate (GTP) and deoxynucleoside triphosphates, such as dATP, dCTP, dITP, dUTP, dGTP, dTTP or derivatives thereof. Such derivatives may include, for example, [αS] dATP, 7-deaza-dGTP and 7-deaza-dATP, as well as nucleotide derivatives that confer nuclease resistance to nucleic acid molecules containing them. As used herein, the term nucleotide may refer to dideoxynucleoside triphosphates (ddNTP) and derivatives thereof. Illustrative examples of dideoxynucleoside triphosphates may include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP and ddTTP. Nucleotide can be unlabeled, or detectably labeled by well-known technology. Labeling can also be carried out with quantum dots. Detectable labels can include, for example, radioisotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels. The fluorescent labeling of nucleotides can include, but is not limited to, fluorescein, 5-carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5-dichloro-6-carboxyfluorescein (JOE), rhodamine, 6-carboxyrhodamine (R6G), N, N, N', N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxyl-X-rhodamine (ROX), 4-(4'dimethylaminophenylazo) benzoic acid (DABCYL), Cascade Blue, Oregon Green, Texas Red, cyanine and 5-(2'-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS).Specific examples of fluorescently labeled nucleotides can include [R6G]dUTP, [TAMRA]dUTP, [R110]dCTP, [R6G]dCTP, [TAMRA]dCTP, [JOE]ddATP, [R6G]ddATP, [FAM]ddCTP, [R110]ddCTP, [TAMRA]ddGTP, [ROX]ddTTP, [dR6G]ddATP, [dR110]ddCTP, [dTAMRA]ddGTP, and [dROX]ddTTP available from Perkin Elmer, Foster City, Calif., FluoroLink deoxynucleotides, FluoroLink Cy3-dCTP, FluoroLink Cy5-dCTP, FluoroLink Fluor X-dCTP, FluoroLink Cy3-dUTP, and FluoroLink Cy5-dUTP; fluorescein-15-dATP, fluorescein-12-dUTP, tetramethyl-rhodamine-6-dUTP, IR770-9-dATP, fluorescein-12-ddUTP, fluorescein-12-UTP, and fluorescein-15-2′-dATP from Boehringer Mannheim, Indianapolis, Ind.; and fluorescein-15-2′-dATP from Molecular Probes, Eugene, Oregon. Probes, Eugene, Oreg.), BODIPY-FL-14-UTP, BODIPY-FL-4-UTP, BODIPY-TMR-14-UTP, BODIPY-TMR-14-dUTP, BODIPY-TR-14-UTP, BODIPY-TR-14-dUTP, Cascade Blue-7-UTP, Cascade Blue-7-dUTP, fluorescein-12-UTP, fluorescein-12-dUTP, Oregon Green 488-5-dUTP, Rhodamine Green-5-UTP, Rhodamine Green-5-dUTP, Tetramethylrhodamine-6-UTP, Tetramethylrhodamine-6-dUTP, Texas Red-5-UTP, Texas Red-5-dUTP and Texas Red-12-dUTP. Nucleotides can also be labeled or indicated by chemical modification. The chemically modified single nucleotide may be a biotin-dNTP.Some non-limiting examples of biotinylated dNTPs can include biotin-dATP (e.g., bio-N6-ddATP, biotin-14-dATP), biotin-dCTP (e.g., biotin-11-dCTP, biotin-14-dCTP), and biotin-dUTP (e.g., biotin-11-dUTP, biotin-16-dUTP, biotin-20-dUTP).
[0067] The terms "polynucleotide," "oligonucleotide," and "nucleic acid" are used interchangeably and refer to a polymeric form of nucleotides of any length, whether deoxynucleotides or ribonucleotides or their analogs, in single-stranded, double-stranded, or multi-stranded form. The polynucleotide may be exogenous or endogenous to the cell. The polynucleotide may be present in a cell-free environment. The polynucleotide may be a gene or a fragment thereof. The polynucleotide may be DNA. The polynucleotide may be RNA. The polynucleotide may have any three-dimensional structure and may perform any known or unknown function. The polynucleotide may contain one or more analogs (e.g., altered backbones, sugars, or nucleobases). If present, the nucleotide structure may be modified before or after polymer assembly. Some non-limiting examples of analogs include 5-bromouracil, peptide nucleic acids, xenologous nucleic acids, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to a sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, queussine, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of genes or gene fragments, loci defined by linkage analysis (locus), exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes and primers. The sequence of nucleotides may be interrupted by non-nucleotide components.
[0068] As used herein, the term "gene" refers to a nucleic acid (e.g., DNA and cDNA such as genomic DNA) and its corresponding nucleotide sequence involved in encoding RNA transcripts. The term as used herein relates to genomic DNA includes a non-coding region in the middle and a regulatory region, and may include 5' and 3' ends. In some uses, the term covers transcribed sequences, including 5' and 3' untranslated regions (5'-UTR and 3'-UTR), exons and introns. In some genes, the transcribed region will include an "open reading frame" encoding a polypeptide. In some uses of the term, a "gene" only includes a coding sequence (e.g., "open reading frame" or "coding region") required for encoding a polypeptide. In some cases, a gene does not encode a polypeptide, such as a ribosomal RNA gene (rRNA) and a transfer RNA (tRNA) gene. In some cases, the term "gene" includes not only a transcribed sequence, but also a non-transcribed region, including upstream and downstream regulatory regions, enhancers and promoters. A gene may refer to an "endogenous gene" or a natural gene in its natural position in the genome of an organism. A gene may refer to an "exogenous gene" or a non-natural gene. Non-natural genes can refer to genes that are not usually found in the host organism but are introduced into the host organism by gene transfer. Non-natural genes can also refer to genes that are not in their natural position in the genome of an organism. Non-natural genes can also refer to naturally occurring nucleic acids or polypeptide sequences (e.g., non-natural sequences) that contain mutations, insertions, and / or deletions.
[0069] As used herein, the terms "target polynucleotide" and "target nucleic acid" refer to nucleic acids or polynucleotides targeted by the actuator moiety of the present disclosure. The target polynucleotide can be DNA (e.g., endogenous or exogenous). DNA can refer to a template for various regulatory regions that produce mRNA transcripts and / or regulate mRNA transcription from a DNA template. The target polynucleotide can be a part of a larger polynucleotide, such as a chromosome or a chromosome region. The target polynucleotide can refer to an extrachromosomal sequence (e.g., an additional sequence, a minicircle sequence, a mitochondrial sequence, a chloroplast sequence, etc.) or a region of an extrachromosomal sequence. The target polynucleotide can be RNA. RNA can be, for example, an mRNA that can be used as a template for encoding a protein. A target polynucleotide comprising RNA can include various regulatory regions that regulate the translation of a protein from an mRNA template. The target polynucleotide can encode a gene product (e.g., a DNA encoding an RNA transcript or an RNA encoding a protein product) or comprise a regulatory sequence that regulates the expression of a gene product. In general, the term "target sequence" refers to a nucleic acid sequence on a single strand of a target nucleic acid. The target sequence can be a part of a gene, a regulatory sequence, a genomic DNA, a cell-free nucleic acid including cfDNA and / or cfRNA, a cDNA, a fusion gene, and an RNA including mRNA, miRNA, rRNA, and others. The target polynucleotide can cause gene expression and / or activity changes when being targeted by the actuator portion. The target polynucleotide can produce an edited nucleic acid sequence when being targeted by the actuator portion. The target nucleic acid may include a nucleic acid sequence that may not be associated with any other sequence in the nucleic acid sample by a single nucleotide replacement. The target nucleic acid may include a nucleic acid sequence that may not be associated with any other sequence in the nucleic acid sample by 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide replacements. In some embodiments, the replacement may not occur within 5, 10, 15, 20, 25, 30, or 35 nucleotides at the 5' end of the target nucleic acid. In some embodiments, the replacement may not occur within 5, 10, 15, 20, 25, 30, or 35 nucleotides at the 3' end of the target nucleic acid.
[0070] The term "expression" refers to one or more processes of transcribing polynucleotides from a DNA template (e.g., transcribing into mRNA or other RNA transcripts) and / or the process of subsequently translating the transcribed mRNA into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene products". If the polynucleotides are derived from genomic DNA, expression may include splicing mRNA in eukaryotic cells. With regard to expression, "up-regulation" generally refers to an increase in the expression level of a polynucleotide (e.g., RNA, such as mRNA) and / or a polypeptide sequence relative to its wild-type state, while "down-regulation" generally refers to a decrease in the expression level of a polynucleotide (e.g., RNA, such as mRNA) and / or a polypeptide sequence relative to its wild-type state.
[0071] As used herein, the terms "complement", "complement", "complementary" and "complementarity" generally refer to sequences that are completely complementary to and hybridizable with a given sequence. In some cases, a sequence that hybridizes with a given nucleic acid is referred to as the "complement" or "reverse complement" of a given molecule if the base sequence on a given region is able to complementarily bind to the base sequence of its binding partner, thereby forming, for example, AT, AU, GC and GU base pairs. Typically, a first sequence that can hybridize with a second sequence can specifically or selectively hybridize with the second sequence, such that hybridization with the second sequence or a second sequence group is more preferred (e.g., more thermodynamically stable under a given set of conditions, such as stringent conditions commonly used in the art) than hybridization with a non-target sequence during a hybridization reaction. Typically, hybridizable sequences have a degree of sequence complementarity over all or a portion of their respective lengths, such as between 25%-100% complementarity, including at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and 100% sequence complementarity. Sequence identity, e.g., for the purpose of assessing percent complementarity, can be measured by any suitable alignment algorithm, including, but not limited to, the Needleman-Wunsch algorithm (see, e.g., the EMBOSS Needle aligner available at www.ebi.ac.uk / Tools / psa / emboss_needle / nucleotide.html, optionally with default settings), the BLAST algorithm (see, e.g., the BLAST alignment tool available at blast.ncbi.nlm.nih.gov / Blast.cgi, optionally with default settings), or the Smith-Waterman algorithm (see, e.g., the EMBOSS Water aligner available at www.ebi.ac.uk / Tools / psa / emboss_water / nucleotide.html, optionally with default settings). Optimal alignment can be assessed using any suitable parameters of the selected algorithm, including the default parameters.
[0072] Complementarity can be perfect or substantial / sufficient. Perfect complementarity between two nucleic acids can mean that the two nucleic acids can form a duplex in which each base in the duplex is bonded to a complementary base by Watson-Crick pairing. Sufficient or sufficient complementarity can mean that the sequence in one chain is not completely and / or completely complementary to the sequence in the opposite chain, but sufficient binding occurs between the bases on the two chains to form a stable hybrid complex under a set of hybridization conditions (e.g., salt concentration and temperature). These conditions can be predicted by using the sequence and standard mathematical calculations to predict the Tm of the hybrid chain, or by empirical determination of the Tm using conventional methods.
[0073] As used herein, the term "modulate" with respect to expression or activity refers to changing the level of expression or activity. Modulation may occur at the transcriptional level and / or the translational level.
[0074] The terms "peptide", "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of at least two amino acid residues connected by a peptide bond. The term does not mean a polymer of a specific length, nor is it intended to imply or distinguish whether the peptide is produced using recombinant technology, chemical or enzymatic synthesis, or is naturally occurring. The term applies to naturally occurring amino acid polymers and amino acid polymers comprising at least one modified amino acid. In some cases, the polymer may be interrupted by non-amino acids. The term includes amino acid chains of any length, including full-length proteins and proteins with or without secondary and / or tertiary structures (e.g., domains). The term also includes amino acid polymers that have been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, oxidation, and any other operation such as conjugation with a labeling component. As used herein, the term "amino acid" generally refers to natural and non-natural amino acids, including but not limited to modified amino acids and amino acid analogs. Modified amino acids may include natural amino acids and non-natural amino acids, which have been chemically modified to include non-natural groups or chemical moieties on amino acids. Amino acid analogs may refer to amino acid derivatives. The term "amino acid" includes D-amino acids and L-amino acids.
[0075] The terms "derivative", "variant" and "fragment", when used herein in reference to a polypeptide, refer to a polypeptide that is related to a wild-type polypeptide (e.g., by amino acid sequence, structure (e.g., secondary and / or tertiary), activity (e.g., enzymatic activity) and / or function). Derivatives, variants and fragments of a polypeptide may comprise one or more amino acid changes (e.g., mutations, insertions and deletions), truncations, modifications or a combination thereof compared to a wild-type polypeptide.
[0076] As used herein, the term "percent identity (%)" refers to the percentage of amino acid (or nucleic acid) residues of a candidate sequence that are identical to the amino acid (or nucleic acid) residues of a reference sequence after aligning the sequences and introducing gaps, if necessary, to obtain the maximum percent identity (i.e., for optimal alignment, gaps can be introduced in one or both of the candidate and reference sequences, and non-homologous sequences can be ignored for comparison purposes). For the purpose of determining percent identity, alignment can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. By using BLAST to align a test sequence with a comparison sequence, determining the number of amino acids or nucleotides that are identical to the amino acid or nucleotide at the same position in the comparison sequence in the aligned test sequence, and dividing the number of identical amino acids or nucleotides by the number of amino acids or nucleotides in the comparison sequence, the percent identity of the two sequences can be calculated.
[0077] As used herein, the term "peripheral blood lymphocytes" (PBL) and grammatical equivalents thereof may refer to lymphocytes circulating in the blood (e.g., peripheral blood). Peripheral blood lymphocytes may refer to lymphocytes that are not localized to an organ. Peripheral blood lymphocytes may include T cells, NK cells, B cells, or any combination thereof.
[0078] As used interchangeably herein, the terms "subject", "individual" and "patient" refer to vertebrates, preferably mammals, such as humans. Mammals include, but are not limited to, rodents, monkeys, humans, farm animals, sports animals and pets. It also includes tissues, cells and their progeny of biological entities obtained in vivo or cultured in vitro.
[0079] As used herein, the terms "treatment" and "treating" refer to methods for obtaining beneficial or desired results, including but not limited to therapeutic benefit and / or preventive benefit. For example, treatment can include administering a system or cell population disclosed herein. Therapeutic benefit refers to any therapeutically relevant improvement or effect on one or more diseases, conditions, or symptoms being treated. For preventive benefit, the composition can be administered to a subject at risk for developing a particular disease, condition, or symptom, or to a subject reporting one or more physiological symptoms of a disease, even though the disease, condition, or symptom may not yet be manifested.
[0080] As used herein, the term "TIL" or tumor infiltrating lymphocytes and grammatical equivalents thereof may refer to cells separated from a tumor. For example, TIL may be cells that have migrated to a tumor. TIL may also be cells that have infiltrated a tumor. TIL may be any cell found within a tumor. For example, TIL may be a T cell, a B cell, a monocyte, a natural killer (NK) cell, or any combination thereof. TIL may be a mixed cell population. A TIL population may include cells of different phenotypes, cells of different degrees of differentiation, cells of different lineages, or any combination thereof.
[0081] The term "effective amount" or "therapeutically effective amount" refers to an amount of a composition, e.g., a composition comprising immune cells such as lymphocytes (e.g., T lymphocytes and / or NK cells) comprising a system of the present disclosure, sufficient to produce the desired activity when administered to a subject in need thereof. In the context of the present disclosure, the term "therapeutically effective" refers to an amount of a composition sufficient to delay manifestation, prevent progression, alleviate or mitigate at least one symptom of a disorder treated by the methods of the present disclosure.
[0082] On the one hand, the present disclosure provides a method of administering a cell therapy comprising engineered immune cells expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR). On the one hand, the method comprises infusing a population of immune cells comprising engineered immune cells into a subject in need thereof. On the one hand, the engineered immune cells have not undergone ex vivo expansion for 2 weeks or more. On the one hand, the population is further characterized in that central memory T cells (TCM) in the population are more abundant than effector memory T cells (TEM). On the one hand, the present disclosure provides a cell population comprising engineered immune cells expressing a chimeric antigen receptor (CAR) and / or a T cell receptor (TCR). On the one hand, the cell population is further characterized in that (i) central memory T cells (TCM) in the population are more abundant than effector memory T cells (TEM); and / or (ii) at least 2% of the cell population are stem cell-like memory T cells (TSCM). On the one hand, the present disclosure provides a method of treating cancer in a subject in need thereof, comprising infusing no more than about 1x10 6 In one aspect, no more than about 1x10 6 The cell population of engineered immune cells has not undergone ex vivo expansion for 2 weeks or more.
[0083] In some embodiments, the engineered immune cells have undergone less than 1 week of ex vivo expansion. In one aspect, the engineered immune cells have undergone less than 6 days, less than 5 days, less than 4 days, less than 3 days, less than 2 days, less than 1 day, less than 12 hours, less than 6 hours, less than 3 hours of ex vivo expansion or no expansion. In one aspect, the engineered immune cells have undergone less than 1 week, less than 72 hours, less than 48 hours, or less than 24 hours of ex vivo expansion.
[0084] In one aspect, the present disclosure provides a method of treating cancer in a subject in need thereof, comprising infusing no more than about 1×10 6 In one aspect, no more than about 1x10 6 The cell colonies of individual engineered immune cells have not been subjected to ex vivo expansion for 2 weeks or more weeks.In some aspects, compared with expressing the same chimeric antigen receptor (CAR) and / or engineered T cell receptor (TCR) but having undergone ex vivo expansion for 2 weeks or more weeks of more than 10 times of engineered immune cell colonies, the engineered immune cell colonies show considerable levels of anti-tumor activity in vivo.In some aspects, compared with expressing the same chimeric antigen receptor (CAR) and / or engineered T cell receptor (TCR) but having undergone ex vivo expansion for 2 weeks or more weeks of 18 times, 15 times, 12 times, 10 times, 8 times, 6 times, 5 times, 4 times, 3 times, 2 times, 1 times of more engineered immune cell colonies, the engineered immune cell colonies show considerable levels of anti-tumor activity in vivo.
[0085] In some embodiments, the engineered immune cells are phenotypical and include central memory T cells (TCM). In some embodiments, TCM cells are CD45RO+CD62L+. In some embodiments, the engineered immune cells include effector memory T cells (TEM). In some embodiments, TEM are CD45RO+CD62L-. In some embodiments, the engineered immune cells are phenotypical and include effector T cells (TEFF). In some embodiments, TEFF cells are CD45RO+CD62L-. - CD62L - In some embodiments, the engineered immune cells are phenotypically and comprise stem central memory T cells (TSCM). In some embodiments, the TSCM cells are CD45RO - CD62L +. In some embodiments, the cells that can be used in the methods provided herein can be positive or negative for a given factor. In some embodiments, the cells utilized in the methods provided herein can be CD3+ cells, CD3- cells, CD5+ cells, CD5- cells, CD7+ cells, CD7- cells, CD14+ cells, CD14- cells, CD8+ cells, CD8- cells, CD103+ cells, CD103- cells, CD11b+ cells, CD11b- cells, BDCA1+ cells, BDCA1- cells, L-selectin+ cells, L-selectin- cells, CD25+, CD25- cells, CD27+, CD27- cells, CD28+ cells, C D28-cells, CD44+ cells, CD44- cells, CD56+ cells, CD56- cells, CD57+ cells, CD57- cells, CD62L+ cells, CD62L- cells, CD69+ cells, CD69- cells, CD45RO+ cells, CD45RO- cells, CD127+ cells, CD127- cells, CD132+ cells, CD132- cells, IL-7+ cells, IL-7- cells IL-15+ cells, IL-15- cells, lectin-like receptor G1 positive cells, lectin-like receptor G1 negative cells or differentiated or dedifferentiated cells thereof. The examples of factors expressed by cells are not intended to be limiting, and those skilled in the art will appreciate that cells may be positive or negative for any factor known in the art. In some embodiments, cells may be positive for two or more factors. For example, cells may be CD4 + and CD8 +. In some embodiments, the cell may be negative for two or more factors. For example, the cell may be CD25-, CD44- and CD69-. In some embodiments, the cell may be positive for one or more factors and negative for one or more factors. For example, the cell may be CD4+ and CD8-. In some aspects, the cell markers provided herein may be used to select, enrich or deplete a cell population. In some aspects, enrichment includes selecting a monocyte fraction. In some aspects, enrichment includes sorting an immune cell population from a monocyte fraction. In some embodiments, cells may be selected for having or not having one or more given factors (e.g., cells may be separated based on the presence or absence of one or more factors). In some embodiments, the selected cells may also be transduced and / or amplified in vitro. The selected cells may be amplified in vitro prior to infusion. In some embodiments, the selected cells may be transduced with the vectors provided herein. It should be understood that the cells used in any method disclosed herein may be a mixture of any cells disclosed herein (e.g., two or more different cells). For example, the method of the present disclosure may include cells, and the cells are CD4 + Cells and CD8 + In another example, the method of the present disclosure may include cells, and the cells are CD4 + A mixture of cells and immature cells. In some cases, the cell can be a stem cell-like memory T cell composed of CD45RO(-), CCR7(+), CD45RA(+), CD62L+ (L-selectin), CD27+, CD28+ and IL-7Rα+, and the stem cell-like memory cell can also express CD95, IL-2Rβ, CXCR3 and LFA-1, and show many stem cell-like memory cells. Functional attributes unique to cells. The cell provided herein can also be a central memory TCM cell comprising L-selectin and CCR7, wherein the central memory cell can secrete, for example, IL-2, but does not secrete IFNγ or IL-4. The cell can also be an effector memory TEM cell comprising L-selectin or CCR7, and produces, for example, effector cytokines, such as IFNγ and IL-4. In some cases, a cell population can be introduced into a subject. For example, a cell population can be a combination of T cells and NK cells. In other cases, a group can be immature cells ( The cell population may be a combination of TILs and effector cells.
[0086] In some embodiments, the method provided herein may include the activation of a cell colony. As used herein, activation may refer to the process in which a cell is transformed from a quiescent state to an active state. The process may include response, migration and / or phenotype or genetic changes to an antigen to a functionally active state. In some aspects, activation may refer to the stepwise process of T cell activation. In some cases, T cells may require one or more signals to be activated. For example, T cells may require at least two signals to be fully activated. The first signal may occur after TCR engages with an antigen-MHC complex, and the second signal may occur through the engagement of a co-stimulatory molecule. In vitro, anti-CD3 antibodies (or their functional variants) may simulate the first signal, and anti-CD28 antibodies (or their functional variants) may simulate the second signal.
[0087] In some aspects, the methods provided herein may include activation of a cell colony. Activation can be performed by contacting a cell colony with a surface having a reagent attached thereto that can stimulate CD3 TCR complex-related signals and a ligand that can stimulate co-stimulatory molecules on the cell surface. In particular, a T cell colony can be, for example, contacted with an anti-CD3 antibody or its antigen-binding fragment, or an anti-CD2 antibody immobilized on the surface, or contacted with a protein kinase C activator (such as bryostatin) that is sometimes bound to a calcium ion carrier and stimulated in vitro. In order to costimulate the auxiliary molecules on the surface of T cells, a ligand that binds to the auxiliary molecules can be used. For example, a cell colony can be contacted with an anti-CD3 antibody and an anti-CD28 antibody under conditions that can stimulate T cell proliferation. In some cases, 4-1BB can be used to stimulate cells. For example, cells can be stimulated with 4-1BB and IL-21 or another cytokine. In order to activate CD4 T cells or CD8 T cells, anti-CD3 antibodies and anti-CD28 antibodies can be used. For example, the reagent providing the signal can be in solution or conjugated with a solid surface. The ratio of particles to cells can depend on the granularity relative to the target cell. In other embodiments, cells (e.g., T cells) can be bound to reagent-coated beads, where the beads and cells can then be separated and optionally cultured. Each bead can be coated with an anti-CD3 antibody or an anti-CD28 antibody, or in some cases a combination of both. In alternative embodiments, the reagent-coated beads and cells are not separated prior to culture, but rather cultured together. Cell surface proteins can be conjugated by contacting paramagnetic beads (3x28 beads) with T cells, to which anti-CD3 antibodies and anti-CD28 antibodies can be attached. In one embodiment, cells and beads (e.g., in a 1:1 ratio) are placed in a culture vessel. M-450 CD3 / CD28 T paramagnetic beads) are combined in a buffer, such as phosphate buffered saline (PBS) (e.g., without divalent cations such as calcium and magnesium). Any cell concentration can be used. The mixture can be cultured for about several hours (e.g., about 3 hours) to about 14 days, or any hourly integer value therebetween. In another embodiment, the mixture can be cultured for about 21 days or up to about 21 days. Conditions suitable for T cell culture may include appropriate culture media (e.g., minimum essential culture fluid or RPMI culture medium 1640 or X-vivo 5, (Lonza)), which may include factors required for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin 2 (IL-2), insulin, IFN-g, IL-4, IL-7, GM-CSF, IL-10, IL-21, IL-15, TGFβ and TNFα or any other additives for cell growth. Other additives for cell growth include, but are not limited to, surfactants, human plasma protein powder, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. The culture medium may include RPMI 1640, A1 MV, DMEM, MEM, α-MEM, F-12, X-Vivo 1 and X-Vivo 20, optimizer, with added amino acids, sodium pyruvate and vitamins (serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and / or cytokines in an amount sufficient to grow and expand T cells. Antibiotics (such as penicillin and streptomycin) may be included only in experimental cultures and may not be included in cell cultures to be infused into a subject. Target cells can be maintained under conditions necessary to support growth; for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% CO2). In some cases, T cells that have been exposed to different stimulation times may exhibit different characteristics. . In some cases, a soluble monospecific tetrameric antibody against human CD3, CD28, CD2, or any combination thereof may be used. In some embodiments, activation may utilize an activation moiety, a co-stimulator, and any combination thereof. In some aspects, the activation moiety binds to: a CD3 / T cell receptor complex and / or provides co-stimulation. In some aspects, the activation moiety is any one of an anti-CD3 antibody and / or an anti-CD28 antibody. In some aspects, the solid phase is at least one of a bead, a plate, and / or a matrix. In some aspects, the solid phase is a bead. Alternatively or additionally, the activation moiety may not be conjugated to a substrate, for example, the activation moiety may float freely in a medium.
[0088] In some cases, cell colonies can be activated or amplified by co-culturing with tissues or cells. Cells can be antigen presenting cells. Artificial antigen presenting cells (aAPCs) can express ligands of T cell receptors and co-stimulatory molecules, and can activate and amplify T cells to transfer, while improving their efficacy and function in some cases. aAPCs can be engineered to express any gene for T cell activation. aAPCs can be engineered to express any gene for T cell amplification. aAPCs can be beads, cells, proteins, antibodies, cytokines, or any combination. aAPCs can deliver signals to cell colonies that can undergo genome transplantation. For example, aAPCs can deliver signal 1, signal 2, signal 3, or any combination. Signal 1 can be an antigen recognition signal. For example, signal 1 can be the connection of TCR through a peptide-MHC complex, or the combination of an agonist antibody for CD3, which can lead to the activation of a CD3 signal transduction complex. Signal 2 can be a co-stimulatory signal. For example, the costimulatory signal can be anti-CD28, inducible costimulator (ICOS), CD27 and 4-1BB (CD137) combined with ICOS-L, CD70 and 4-1BBL, respectively. Signal 3 can be a cytokine signal. The cytokine can be any cytokine. The cytokine can be IL-2, IL-7, IL-12, IL-15, IL-21 or any combination thereof. In some cases, artificial antigen presenting cells (aAPC) can be used to activate and / or amplify cell colonies. In some cases, the artifact may not induce allotype specificity. In some cases, aAPC may not express HLA. AAPC can be genetically modified to stably express genes that can be used for activation and / or stimulation. In some cases, K562 cells can be used for activation. K562 cells can also be used for amplification. K562 cells can be human erythroleukemia cell lines. K562 cells can be engineered to express target genes. K562 cells may not endogenously express HLA class I, class II, or CD1d molecules, but may express ICAM-1 (CD54) and LFA-3 (CD58). K562 may be engineered to deliver signal 1 to T cells. For example, K562 cells may be engineered to express HLA class I. In some cases, K562 cells may be engineered to express additional molecules, such as B7, CD80, CD83, CD86, CD32, CD64, 4-1BBL, anti-CD3, anti-CD3 mAb, anti-CD28, anti-CD28 mAb, CD1d, anti-CD2, membrane-bound IL-15, membrane-bound IL-17, membrane-bound IL-21, membrane-bound IL-2, truncated CD19, or any combination. In some cases, in addition to CD80 and CD83, engineered K562 cells may also express a membrane form of anti-CD3 mAb, clone OKT3.In some cases, engineered K562 cells may express a membrane form of an anti-CD3 mAb, clone OKT3, a membrane form of an anti-CD28 mAb, in addition to CD80 and CD83.
[0089] aAPC can be a bead. Spherical polystyrene beads can be coated with anti-CD3 and anti-CD28 antibodies and used for T cell activation. The beads can have any size. In some cases, the beads can be 3 and 6 microns or can be about 3 and 6 microns. The size of the beads can be 4.5 microns or can be about 4.5 microns. The beads can be used in any cell-to-bead ratio. For example, a three-to-one bead-to-cell ratio of one million cells per milliliter can be used. aAPC can also be a rigid spherical particle, a polystyrene latex microbead, a magnetic nanoparticle or microparticle, a nanosized quantum dot, 4, poly (lactic acid-co-glycolic acid) (PLGA) microspheres, non-spherical particles, 5, carbon nanotube bundles, 6, ellipsoidal PLGA microparticles, 7, nanoworms, systems containing fluid lipid bilayers, 8, 2D supported lipid bilayers (2D-SLB), 9, liposomes, 10, RAFTsomes / microdomain liposomes, 11, SLB particles, or any combination thereof. In some cases, aAPCs can expand CD4 T cells. For example, aAPCs can be engineered to mimic the antigen processing and delivery pathways of HLA class II restricted CD4 T cells. K562 can be engineered to express HLA-D, DPα, DPβ chain, Ii, DMα, DMβ, CD80, CD83, or any combination thereof. For example, engineered K562 cells can be pulsed with HLA restricted peptides to expand HLA restricted antigen-specific CD4 T cells. In some cases, aAPCs can be used in combination with exogenously introduced cytokines for T cell activation, expansion, or any combination. After the genome-transplanted cells are administered to a subject, the cells can also be expanded in vivo, for example in the subject's blood.
[0090] In some embodiments, the methods provided herein can include transduction of a cell colony. In some embodiments, the method includes introducing a polynucleotide encoding a cell receptor (such as a chimeric antigen receptor and / or a T cell receptor). In some cases, transfection of cells can be performed.
[0091] In some embodiments, a viral supernatant containing polynucleotides encoding cell receptors such as CAR and / or TCR is produced. In some embodiments, the viral vector may be a retroviral vector, a lentiviral vector and / or an adeno-associated viral vector. Packaging cells can be used to form viral particles capable of infecting host cells. Such cells may include 293 cells (e.g., for packaging adenovirus) and Psi2 cells or PA317 cells (e.g., for packaging retrovirus). Viral vectors can be produced by producing a cell line that packages nucleic acid vectors into viral particles. The vector may include packaging and subsequent integration into the minimum viral sequence required for the host. The vector may include other viral sequences replaced by the expression cassette of the polynucleotide to be expressed. The missing viral function may be provided trans by the packaging cell line. For example, an AAV vector may include an ITR sequence from an AAV genome, which is required for packaging and integration into the host genome. Viral DNA may be packaged in a cell line, which may include a helper plasmid encoding other AAV genes (i.e., rep and cap), but lacks an ITR sequence. The cell line may also be infected with adenovirus as a helper virus. The helper virus can promote the replication of the AAV vector and the expression of the AAV genes in the helper plasmid. Adenovirus contamination can be reduced by, for example, heat treatment to which adenovirus is more sensitive than AAV. Other methods of delivering nucleic acids to cells can be used, for example, as described in US20030087817, which is incorporated herein by reference.
[0092] In some embodiments, host cells can be transiently or non-transiently transfected with one or more vectors described herein. Cells can be transfected as they occur naturally in a subject. Cells can be taken from or derived from a subject and transfected. Cells can be derived from cells obtained from a subject, such as cell lines. In some embodiments, cells transfected with one or more vectors described herein are used to establish new cell lines comprising one or more vector-derived sequences. Non-limiting examples of vectors for eukaryotic host cells include, but are not limited to, pBs, pQE-9 (Qiagen), phagescript, PsiX174, pBluescript SK, pBsKS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR54O, pRIT5 (Pharmacia). Eukaryotic pWL-neo, pSv2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPv, pMSG, pSVL (Pharmiacia). In addition, any other plasmids and vectors can be used as long as they are reproducible and viable in the selected host. Any vector and commercially available ones (and variants or derivatives thereof) can be engineered to include one or more recombination sites for the method. Such vectors can be obtained from, for example, Vector Laboratories Inc., Invitrogen, Promega, Novagen, NEB, Clontech, Boehringer Mannheim, Pharmacia, EpiCenter, OriGenes Technologies Inc., Stratagene, PerkinElmer, Pharmingen, and Research Genetics.Other target vectors include eukaryotic expression vectors such as pFastBac, pFastBacHT, pFastBacDUAL, pSFV, and pTet-Splice (Invitrogen), pEUK-C1, pPUR, pMAM, pMAMneo, pBI101, pBI121, pDR2, pCMVEBNA, and pYACneo (Colex), pSVK3, pSVL, pMSG, pCH110, and pKK232-8 (Pharmacia), p3'SS, pXT1, pSG5, pPbac, pMbac, pMClneo, and pOG44 (Strata Genetics), and pYES2, pAC360, pBlueBa-cHis A, B, and C, pVL1392, pBlueBac111, pCDM8, pcDNA1, pZeoSV, pcDNA3 pREP4, pCEP4 and pEBVHis (Invitrogen) and their variants or derivatives. Other vectors include pUC18, pUC19, pBlueScript, pSPORT, cosmids, phagemids, YAC (yeast artificial chromosome), BAC (bacterial artificial chromosome), P1 (Escherichia colicoli) phage), pQE70, pQE60, pQE9 (quagan), pBS vector, PhageScript vector, BlueScript vector, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene), pcDNA3 (Invitrogen), pGEX, pTrsfus, pTrc99A, pET-5, pET-9, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pSPORT1, pSPORT2, pCMVSPORT2.0 and pSYSPORT1 (Invitrogen), and variants or derivatives thereof. Additional target vectors may include pTrxFus, pThioHis, pLEX, pTrcHis, pTrcHis2, pRSET, pBlueBa-cHis2, pcDNA3.1 / His, pcDNA3.1(-) / Myc-His, pSecTag, pEBVHis, pPIC9K, pPIC3.5K, pA081S, pPICZ, pPICZA, pPICZB, pPICZC, pGAPZA, pGAPZB, pGAPZC, pBlue-Bac4.5, pBlueBacHis2, pMel Bac, pSinRep5, pSinHis, pIND, pIND(SP1), pVgRXR, pcDNA2.1, pYES2, pZEr01.1, pZErO-2.1, pCR-Blunt, pSE280, pSE380, pSE420, pVL13 92. pVL1393, pCDM8, pcDNA1.1, pcDNA1.1 / Amp, pcDNA3.1, pcDNA3.1 / Zeo, pSe, SV2, pRc / CMV2, pRc / RSV, pREP4, pREP7, pREP8, pREP9, pREP 10, pCEP4, pEBVHis, pCR3.1, pCR2.1, pCR3.1-Uni and pCRBac; X ExCell, X gt11, pTrc99A, pKK223-3, pGEX-1X from PharmaciaT, pGEX-2T, pGEX-2TK, pGEX-4T-1, pGEX-4T-2, pGEX-4T-3, pGEX-3X, pGEX-5X-1, pGEX-5X-2, pGEX-5X-3, pEZZ18, pRIT2T, pMC1871, pSVK3, pSVL, pMSG, pCH110, pKK232-8, pSL1180, pNEO, and pUC4K from Anolon; pSCREEN-lb(+), pT7Blue(R), pT7Blue-2, pCITE-4-abc(+), pOCUS-2, pTAg, pET-32L1C, pET-30LIC, pBAC-2cp LIC, pBACgus-2cp LIC, pT7Blue-2 LIC, pT7Blue-2, X SCREEN-1, XB1ueSTAR, pET-3abcd, pET-7abc, pET9abcd, pET11 abcd, pET12abc, pET-14b, pET-15b, pET-16b, pET-17b-pET-17xb, pET-19b, pET-20b(+), pET- 21abcd(+), pET-22b(+), pET-23abcd(+), pET-24abcd(+), pET-25b(+), pET-26b(+), pET-27b( +), pET-28abc(+), pET-29abc(+), pET-30abc(+), pET-31b(+), pET-32abc(+), pET-33b(+), p BAC-1, pBACgus-1, pBAC4x-1, pBACgus4x-1, pBAC-3cp, pBACgus-2cp, pBACsurf-1, plg, Signal plg, pYX, Vecta-Neo, Selecta Vecta-Hyg and Selecta Vecta-Gpt; pLexA, pB42AD, pGBT9, pAS2-1, pGAD424, pACT2, pGAD GL, pGAD GH, pGAD10, pGilda, pEZM3, pEGFP, pEGFP-1, pEGFPN, pEGFP-C, pEBFP, pGFPuv, pGFP, p6xHis-GFP, pSEAP2-Basic, pSEAP2-Control, pSEAP2-Promoter, pSEAP2-Enhancer, p I3gal-Basic, p I3gal-Control, p I3gal-Promoter, pI3gal-enhancer, pCMV, pTet-Off, pTet-On, pTK-Hyg, pRetro-Off, pRetro-On, pIRES1neo, pIRES1hyg, pLXSN, pLNCX, pLAPSN, pMAMneo, pMAMneo-CAT, pMAMneo-LUC, pPUR, pSV2neo, pYEX4T-1 / 2 / 3, pYEX-S1, pBacPAK-His, pBacPAK8 / 9, pAcUW31, BacPAK6, pTriplEx, 2Xgt10, Xgt11, pWE15, and XTriplEx; λZAP II from Stratagene, pBK-CMV, pBK-RSV, pBluescript II KS+ / -, pBluescript II SK+ / -, pAD-GAL4, pBD-GAL4 Cam, pSurfscript, λFIX Ii, λDASH, λEMBL3, λEMBL4, SuperCos, pCR-Scrigt Amp, pCR-Script Cam, pCR-Script Direct, pBS+ / -, pBC KS+ / -, pBC SK+ / -, Phag-escript, pCAL-n-EK, pCAL-n, pCAL-c, pCAL-kc, pET-3abcd, pET-llabcd, pSPUTK, pESP-1, pCMVLacI, pOPRSVI / MCS, pOPI3 CAT, pXT1, pSG5, pPbac, pMbac, pMClneo, pMClneo Poly A, pOG44, pOG45, pFRTI3GAL, pNE0I3GAL, pRS403, pRS404, pRS405, pRS406, pRS413, pRS414, pRS415 and pRS416, pPC86, pDBLeu, pDBTrp, pPC97, p2.5, pGAD1-3, pGAD10, pACt, pACT2, pGADGL, pGADGH, pAS2-1, pGAD424, pGBT8, pGBT9, pGAD-GAL4, pLexA, pBD-GAL4, pHISi, pHISi-1, placZi, pB42AD, pDG202, pJK202, pJG4-5, pNLexA, pYESTrp, and variants or derivatives thereof. In some embodiments, the vector can be a minicircle vector. The vectors provided herein can be used to deliver polypeptides encoding CAR and / or TCR.
[0093] Transduction and / or transfection can be performed by any of the following methods: non-viral transfection, gene gun, chemical transfection, electroporation, nuclear transfection, heat shock transfection, lipofection, microinjection or viral transfection. In some embodiments, the methods provided include viral transduction, and the viral transduction includes lentivirus. Viral particles can be used to deliver viral vectors containing polypeptide sequences encoding cell receptors to cells in vitro or in vivo. In some cases, viral vectors as disclosed herein can be measured in pfu (plaque forming units). In some cases, the pfu of the recombinant virus or viral vector of the compositions and methods of the present disclosure can be about 10 8 About 5×10 10 In some cases, the recombinant virus of the present disclosure is at least about 1×10 8 , 2×10 8 , 3×10 8 , 4×10 8 , 5×10 8 , 6×10 8 ,7×10 8 , 8×10 8 ,9×10 8 , 1×10 9 , 2×10 9 , 3×10 9 , 4×10 9 , 5×10 9 , 6×10 9 ,7×10 9 , 8×10 9 ,9×10 9 , 1×10 10 , 2×10 10 , 3×10 10 , 4×10 10 and 5×10 10 In some cases, the recombinant virus of the present disclosure is at most about 1×10 8 , 2×10 8 , 3×10 8 , 4×10 8 , 5×10 8 , 6×10 8 ,7×10 8 , 8×10 8 ,9×10 8 , 1×10 9 , 2×10 9 , 3×10 9 , 4×10 9 , 5×10 9 , 6×10 9 ,7×10 9 , 8×109 ,9×10 9 , 1×10 10 , 2×10 10 , 3×10 10 , 4×10 10 and 5×10 10 pfu. In some aspects, the viral vectors of the present disclosure can be measured as vector genomes. In some cases, the recombinant viruses of the present disclosure are 1×10 10 Up to 3×10 12 vector genome, or 1 × 10 9 Up to 3×10 13 vector genome, or 1 × 10 8 Up to 3×10 14 vector genomes, or at least about 1 × 10 1 , 1×10 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 , 1×10 16 , 1×10 17 and 1×10 18 vector genome, or 1 × 10 8 Up to 3×10 14 vector genomes, or up to approximately 1 × 10 1 , 1×10 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 , 1×10 16 , 1×10 17 and 1×10 18Vector genome. In some cases, the viral vectors provided herein can be measured using a multiplicity of infection (MOI). In some cases, MOI can refer to the ratio or multiple of vector or viral genome to the cells to which the nucleic acid can be delivered. In some cases, MOI can be 1×10 6 In some cases, the MOI may be 1×10 5 Up to 1×10 7 In some cases, the MOI may be 1×10 4 Up to 1×10 8 In some cases, the recombinant virus of the present disclosure is at least about 1×10 1 , 1×10 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 , 1×10 16 , 1×10 17 and 1×10 18 In some cases, the MOI of the recombinant virus of the present disclosure is 1×10 8 Up to 3×10 14 MOI, or at most about 1×10 1 , 1×10 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 , 1×10 16 , 1×10 17 and 1×10 18 In some cases, the viral vector was expressed at an MOI of approximately 1 × 10 per cell. 5 , 2×10 5 , 3×105 , 4×10 5 , 5×10 5 , 6×10 5 ,7×10 5 , 8×10 5 ,9×10 5 , 1×10 6 , 2×10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 ,7×10 6 , 8×10 6 ,9×10 6 , 1×10 7 , 2×10 7 , 3×10 7 , or at most about 9×10 9 A multiplicity of infection (MOI) of 10 genome copies / viral particle was introduced.
[0094] The transfection (e.g., transduction) efficiency of cells with any nucleic acid delivery platform described herein can be or can be about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or greater than 99.9%. In some embodiments, the method can include adding an infectious agent to a composition comprising a cell colony. The infectious agent can include polybrene. In some aspects, the infectious agent can enhance the efficiency of viral infection. The infectious agent can increase viral infectivity by about 100 to 1,000 times. Polybrene can be added to the composition at a concentration of about 5ug to 10ug per milliliter.
[0095] In some embodiments, the methods provided herein may include non-viral methods for introducing cell receptors into cells. Non-viral methods may include, but are not limited to, CRISPR-associated proteins (Cas proteins, such as Cas9), zinc finger nucleases (ZFNs), transcriptional activator effector nucleases (TALENs), Argonaute nucleases, and meganucleases. Nucleases may be naturally occurring, genetically modified, and / or recombinant nucleases. Non-viral methods may also be performed using transposon-based systems (e.g., PiggyBac, Sleeping Beauty).
[0096] In some embodiments, the method provided herein can utilize the PiggyBac system to introduce exogenous polypeptides into cells. The PiggyBac system comprises two components, a transposon and a transposase. The PiggyBac transposase promotes the transposon to be specifically integrated at the "TTAA" site randomly dispersed in the genome. The frequency of "TTAA" expected in the genome is about 1 in every 256 base pairs of the DNA sequence. Unlike other transposons, the PB transposase can also excise the transposon in a completely seamless manner, leaving no sequence or mutation. In addition, PiggyBac provides a large cargo capacity (proven to be more than 200kb), without a known upper limit. The PB performance level can be improved by codon optimization strategies, mutations, deletions, additions, substitutions, or any combination thereof. In some cases, PB may have a larger carrying capacity (approximately 9.1-14.3kb), higher transposition activity, and its footprint-free characteristics make it attractive as a gene editing tool. In some aspects, PB may include some characteristics: high efficiency of transposition; large carrying capacity; long-term stable expression; transgene integration in single copy; in vivo tracking of target genes by non-invasive markers rather than traditional methods such as PCR; easy determination of integration sites and their combinations.
[0097] In some aspects, the method provided herein can utilize the Sleeping Beauty (SB) system to introduce polypeptides encoding cell receptors into cells. SB is engineered from ancient Tc1 / mariner transposon fossils found in salmon genomes by in vitro evolution. SBITR (230bp) contains an incomplete direct repeat sequence (DR) of 32bp in length, which can be used as a recognition signal for transposase. The binding affinity and spacing between DR elements in ITR participate in transposition activity. SB transposase can be a 39kDa protein with a DNA binding polypeptide, a nuclear localization signal (NLS) and a catalytic domain, characterized by a conserved amino acid motif (DDE). Various screenings of the primary amino acid sequence of the mutagenic SB transposase result in a highly active transposase version. In some cases, modified SB can be used. Modified SB can include mutations, deletions and additions in the ITR of the original SB transposon. Modified SB can include: pT2, pT3, pT2B, pT4, SB100X and combinations thereof. Non-limiting examples of modified SB can be selected from SB10, SB11 (3 times higher than SB10), SB12 (4 times higher than SB10), HSB1-HSB5 (up to 10 times higher than SB10), HSB13-HSB17 (HSB17 is 17 times higher than SB10), SB100X (100 times higher than SB10), SB150X (130 times higher than SB10) and any combination thereof. In some cases, SB100X has 100 times higher activity compared to the original reconstructed transposase (SB10). In some aspects, SB transposition excision leaves a footprint (3 bp) at the carrying site. Integration occurs in the TA dinucleotide of the genome and results in target site duplication generated by the host repair mechanism. In some cases, SB appears to have an almost unbiased, near-random distribution of integration. Transposon integration can be artificially targeted (about 10%) to a predetermined genomic locus in wild-type systems, however, in the chimeric systems provided herein, SB transposon integration can be directed to a predetermined locus with an efficiency exceeding 10%.
[0098] In some aspects, non-viral methods can be used to introduce exogenous polynucleic acids into cell populations. In some aspects, non-viral vectors or nucleic acids can be delivered without the use of viruses, and can be measured based on the amount of nucleic acid. Generally, any suitable amount of nucleic acid can be used in the compositions and methods of the present disclosure. In some cases, the nucleic acid can be at least about 1pg, 10pg, 100pg, 1pg, 10pg, 100pg, 200pg, 300pg, 400pg, 500pg, 600pg, 700pg, 800pg, 900pg, 1μg, 10μg, 100μg, 200μg, 300μg, 400μg, 500μg, 600μg, 700μg, 800μ ... g, 900μg, 1ng, 10ng, 100ng, 200ng, 300ng, 400ng, 500ng, 600ng, 700ng, 800ng, 900ng, 1mg , 10mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, 900mg, 1g, 2g, 3g, 4g or 5g. In some cases, the nucleic acid may be at most about 1 pg, 10 pg, 100 pg, 1 pg, 10 pg, 100 pg, 200 pg, 300 pg, 400 pg, 500 pg, 600 pg, 700 pg, 800 pg, 900 pg, 1 μg, 10 μg, 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg. , 900μg, 1ng, 10ng, 100ng, 200ng, 300ng, 400ng, 500ng, 600ng, 700ng, 800ng, 900ng, 1mg, 10mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 700mg, 800mg, 900mg, 1g, 2g, 3g, 4g or 5g.
[0099] In some embodiments, non-viral methods of introducing CAR and / or TCR sequences into cells may include electroporation. Electroporation can be performed using, for example, Transfection system (ThermoFisher Scientific) or Nucleofection Biosystems). Electroporation parameters can be adjusted to optimize transfection efficiency and / or cell viability. Electroporation equipment can have pulse settings in a variety of electric wave forms, such as exponential decay, time constant and square wave. Each cell type has a unique optimal field strength (E), which depends on the applied pulse parameters (such as voltage, capacitance and resistance). Applying the optimal field strength causes electrical permeability by inducing transmembrane voltage, which allows nucleic acids to pass through the cell membrane. In some cases, the electroporation pulse voltage, electroporation pulse width, pulse number, cell density and tip type can be adjusted to optimize transfection efficiency and / or cell viability.
[0100] In some embodiments, the electroporation pulse voltage can be varied to optimize transfection efficiency and / or cell viability. In some cases, the electroporation voltage can be less than about 500 volts. In some cases, the electroporation voltage can be at least about 500 volts, at least about 600 volts, at least about 700 volts, at least about 800 volts, at least about 900 volts, at least about 1000 volts, at least about 1100 volts, at least about 1200 volts, at least about 1300 volts, at least about 1400 volts, at least about 1500 volts, at least about 1600 volts, at least about 1700 volts, at least about 1800 volts, at least about 1900 volts, at least about 2000 volts, at least about 2100 volts, at least about 2200 volts, at least about 2300 volts, at least about 2400 volts, at least about 2500 volts, at least about 2600 volts, at least about 2700 volts, at least about 2800 volts, at least about 2900 volts, or at least about 3000 volts. In some cases, the electroporation pulse voltage required for optimal transfection efficiency and / or cell viability can be cell type specific. In some cases, for a given cell type, the range of electroporation voltage may be optimal. For example, for people 578T cells, an electroporation voltage of about 1000 volts to about 1300 volts may be optimal (for example, providing the highest viability and / or transfection efficiency). In some cases, primary cells may be primary lymphocytes. In some cases, primary cell colonies may be lymphocyte colonies.
[0101] In some embodiments, the electroporation pulse width can be varied to optimize transfection efficiency and / or cell viability. In some cases, the electroporation pulse width can be less than about 5 milliseconds. In some cases, the electroporation width can be at least about 5 milliseconds, at least about 6 milliseconds, at least about 7 milliseconds, at least about 8 milliseconds, at least about 9 milliseconds, at least about 10 milliseconds, at least about 11 milliseconds, at least about 12 milliseconds, at least about 13 milliseconds, at least about 14 milliseconds, at least about 15 milliseconds, at least about 16 milliseconds, at least about 17 milliseconds, at least about 18 milliseconds, at least about 19 milliseconds, at least about 20 milliseconds, at least about 21 milliseconds, at least about 22 milliseconds, at least about 23 milliseconds, at least about 24 milliseconds, at least about 25 milliseconds, at least about 26 milliseconds, at least about In some cases, the electroporation pulse width required for optimal transfection efficiency and / or cell viability may be cell type specific. For example, for macrophages, the electroporation pulse width of 30 milliseconds may be optimal (for example, providing the highest viability and / or transfection efficiency). In another example, for Jurkat cells, the electroporation width of about 10 milliseconds may be optimal (for example, providing the highest viability and / or transfection efficiency). In some cases, a range of electroporation widths may be optimal for a given cell type. For example, for human 578T cells, an electroporation width of about 20 milliseconds to about 30 milliseconds may be optimal (e.g., providing the highest viability and / or transfection efficiency).
[0102] In some embodiments, the number of electroporation pulses can be changed to optimize transfection efficiency and / or cell viability. In some cases, electroporation may include a single pulse. In some cases, electroporation may include more than one pulse. In some cases, electroporation may include 2 pulses, 3 pulses, 4 pulses, 5 pulses, 6 pulses, 7 pulses, 8 pulses, 9 pulses or 10 or more pulses. In some cases, the number of electroporation pulses required for optimal transfection efficiency and / or cell viability may be cell type specific. For example, for macrophages, electroporation using a single pulse may be optimal (for example, providing the highest viability and / or transfection efficiency). In another example, for primary cells, electroporation using 3 pulses may be optimal (for example, providing the highest viability and / or transfection efficiency). In some cases, for a given cell type, the scope of electroporation width may be optimal. For example, for human cells, electroporation using about 1 to about 3 pulses may be optimal (for example, providing the highest viability and / or transfection efficiency).
[0103] In some cases, the starting cell density for electroporation can be varied to optimize transfection efficiency and / or cell viability. In some cases, the starting cell density for electroporation can be less than about 1×10 5 In some cases, the starting cell density for electroporation can be at least about 1×10 5 cells, at least about 2×10 5 cells, at least about 3×10 5 cells, at least about 4×10 5 cells, at least about 5×10 5 cells, at least about 6×10 5 cells, at least about 7×10 5 cells, at least about 8×10 5 cells, at least about 9×10 5 cells, at least about 1×10 6 cells, at least about 1.5×10 6 cells, at least about 2×10 6 cells, at least about 2.5×10 6 cells, at least about 3×10 6 cells, at least about 3.5×10 6 cells, at least about 4×10 6 cells, at least about 4.5×10 6 cells, at least about 5×10 6 cells, at least about 5.5×10 6 cells, at least about 6×10 6 cells, at least about 6.5×10 6cells, at least about 7×10 6 cells, at least about 7.5×10 6 cells, at least about 8×10 6 cells, at least about 8.5×10 6 cells, at least about 9×10 6 cells, at least about 9.5×10 6 cells, at least about 1×10 7 cells, at least about 1.2×10 7 cells, at least about 1.4×10 7 cells, at least about 1.6×10 7 cells, at least about 1.8×10 7 cells, at least one about 2×10 7 cells, at least about 2.2×10 7 cells, at least about 2.4×10 7 cells, at least about 2.6×10 7 cells, at least about 2.8×10 7 cells, at least about 3×10 7 cells, at least about 3.2×10 7 cells, at least about 3.4×10 7 cells, at least about 3.6×10 7 cells, at least about 3.8×10 7 cells, at least about 4×10 7 cells, at least about 4.2×10 7 cells, at least about 4.4×10 7 cells, at least about 4.6×10 7 cells, at least about 4.8×10 7 cells, or at least about 5×10 7 In some cases, the starting cell density for electroporation required for optimal transfection efficiency and / or cell viability may be cell type specific. For example, for macrophages, 1.5 × 10 6 The starting cell density for electroporation of 5×10 cells may be optimal (e.g., to provide the highest viability and / or transfection efficiency). In another example, for human cells, 5×10 6 The starting cell density for electroporation of 5.6×10 cells may be optimal (e.g., to provide the highest viability and / or transfection efficiency). In some cases, a range of starting cell densities for electroporation may be optimal for a given cell type. For example, for human cells such as T cells, the starting cell density for electroporation is 5.6×10 6 and 5×10 7The concentration of a protein may be optimal (eg, providing the highest viability and / or transfection efficiency) between individual cells.
[0104] The efficiency of integrating the nucleic acid sequence encoding the CAR and / or TCR into the genome of a cell having, for example, a CRISPR, Piggy Bac and / or Sleeping Beauty system can be or can be about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or more than 99.9%.
[0105] In some embodiments, the method provided herein for producing an engineered immune cell colony expressing a chimeric antigen receptor (CAR) may include (a) activating a cell colony comprising immune cells with an activation portion; and simultaneously (b) introducing a polynucleotide encoding at least CAR. In some embodiments, CAR comprises (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some embodiments, steps (a) and (b) are performed within 48 hours. In some embodiments, steps (a) and (b) are performed within 24 hours. In some embodiments, steps (a) and (b) are performed within 3 hours. In some embodiments, steps (a) and (b) are performed within 1 hour. In some embodiments, steps (a) and (b) are performed within 30 minutes. In some embodiments, steps (a) and (b) are performed simultaneously. In some embodiments, steps (a) and (b) can be carried out in about 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 20 hours, 15 hours, 13 hours, 10 hours, 8 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 3 minutes, 1 minute and / or simultaneously. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 1 week from (a) and (b) to the subject. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 5 days from (a) and (b) to the subject. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 72 hours from (a) and (b) to the subject. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 24 hours from (a) and (b) to the subject. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 12 hours from (a) and (b) to the subject. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 6 hours from (a) and (b) to the subject. In some aspects, the method provided herein may also include completing the engineered immune cell colony in about 3 hours from (a) and (b) to the subject.
[0106] In some embodiments, the method provided herein for producing an engineered immune cell colony expressing a chimeric antigen receptor (CAR) may include (a) activating a cell colony comprising immune cells with an activation portion; and simultaneously (b) introducing a polynucleotide encoding at least CAR. In some aspects, the method may further include freezing and preserving a colony of engineered immune cells comprising expressing CAR and / or TCR. Cryopreservation can be performed at any time after cell engineering. Cryopreservation can be performed after (a) and (b) about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 10 hours, 15 hours, 20 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 1.5 weeks, 2 weeks or more than 2 weeks. On the one hand, a colony comprising an engineered immune cell may be of a fresh origin. For example, a colony of a fresh origin can be obtained from a subject and the method provided herein can be applied without cryopreservation.
[0107] In some embodiments, the method provided herein for producing an engineered immune cell colony expressing a chimeric antigen receptor (CAR) may include (a) activating a cell colony comprising immune cells with an activation portion; and (b) introducing a polynucleotide encoding at least CAR at the same time, wherein (a) and (b) are performed for no more than about 48 hours. In some cases, (a) and (b) may be performed for no more than 48 hours, 36 hours, 24 hours, 22 hours, 20 hours, 18 hours, 16 hours, 14 hours, 12 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour or less. In some cases, when processes (a) and (b) do not completely overlap, the total time for performing (a) and (b) may be no more than 48 hours. In some cases, when processes (a) and (b) do not completely overlap, the total time for performing (a) and (b) may be no more than 48 hours, 36 hours, 24 hours, 22 hours, 20 hours, 18 hours, 16 hours, 14 hours, 12 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour or less.
[0108] In one example, the method for generating an engineered immune cell colony expressing a chimeric antigen receptor (CAR) provided herein may include (a) activating a cell colony comprising immune cells with an activation portion; and simultaneously (b) introducing a polynucleotide encoding at least CAR, wherein (a) and (b) are performed for no more than about 24 hours. In another example, the method for generating an engineered immune cell colony expressing a chimeric antigen receptor (CAR) provided herein may include (a) activating a cell colony comprising immune cells with an activation portion; and simultaneously (b) introducing a polynucleotide encoding at least CAR, wherein the total time for performing (a) and (b) may be no more than 24 hours.
[0109] In some aspects, compared with comparable methods without simultaneous activation and transduction, compared with effector memory T cells, provided herein is a method that can produce more central memory T cells. In some aspects, due to the use of FAST-CAR methods provided herein to produce cells, compared with effector memory T cells (TEM), central memory T cells (TCM) can be at least increased by 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 25 times, 30 times, 35 times, 40 times, 45 times, 50 times or more. In some aspects, due to the use of FAST-CAR methods provided herein to produce cells, compared with TEM, TCM can be increased by at most 50 times, 45 times, 40 times, 35 times, 30 times, 25 times, 20 times, 15 times, 10 times, 9 times, 8 times, 7 times, 6 times, 5 times, 4 times, 3 times, 2 times, 1 times or less. In some embodiments, the methods provided herein can produce more TSCMs than comparable methods without simultaneous activation and transduction. In some embodiments, at least 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, or up to about 100% of the cell population is TSCM. In some embodiments, up to 100%, 95%, 90%, 80%, 70%, 60%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or less of the cell population is TSCM. TSCM can be CD45RO-CD62L+. In some embodiments, the methods provided herein may include administering a cell therapy comprising an engineered immune cell expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR). In some aspects, the method may include infusing an immune cell colony comprising an engineered immune cell into a subject in need. In some aspects, the engineered immune cell has not undergone ex vivo expansion for 2 weeks or more. In some aspects, the engineered immune cell comprises at least 2% of stem cell-like memory T cells (TSCM).
[0110] In some cases, the subject's cells (e.g., T cells) may not be pre-activated (e.g., by CD3 / CD28 beads) prior to simultaneous activation and transduction. In this case, after simultaneous activation and transduction, the duration of activation and transduction of the subject's cells may be substantially the same.
[0111] In some embodiments, the populations produced by the methods provided herein are further characterized by lower abundance in PD1 and LAG3. In some aspects, the populations produced by the methods provided herein may comprise lower expression of cell markers associated with exhaustion. Markers associated with cell exhaustion include: PD-1, LAG3, CTLA-4, TIM-3, 2B4 / CD244 / SLAMF4, CD160, TIGIT, CXCR5, ICOS, to name a few. In some aspects, markers of cell exhaustion may include: loss of IL-2 production, loss of proliferative capacity, loss of ex vivo cytolytic activity, impaired production of TNF-α, IFN-γ and cc(β) chemokines, degranulation; high levels of expression of granzyme B, poor response to IL-7 and IL-15, altered expression of GATA-3, Bcl-6 and Helios, in the case of CD4+, exhaustion may include a bias towards a T follicular helper (Tfh) cell phenotype, secretion of IL-4, IL-6 and / or IL-21, expression of transcription factors: Bcl-6, IRF4, STAT4 and any combination thereof.
[0112] In some aspects, the immune cells used in the methods provided herein are T cells, NK cells, NKT cells, stem cells, induced pluripotent stem cells, B cells, to name a few. In some embodiments, the cells used in the methods provided herein are obtained from peripheral blood, cord blood, bone marrow and / or induced pluripotent stem cells. Cells can be obtained from many non-restrictive sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumors. In addition, any T cell line can be used. Alternatively, cells can be obtained from healthy donors, patients diagnosed with cancer or patients diagnosed with infection. In another case, cells can be part of a mixed cell population presenting different phenotypic characteristics. Cells can also be obtained from a cell therapy library. On the one hand, cell colonies can also be selected before engineering. Selection can include at least one of the following: magnetic separation, flow cytometry selection, antibiotic selection. On the one hand, cell colonies can include blood cells, such as peripheral blood mononuclear cells (PBMC), lymphocytes, monocytes or macrophages. On the one hand, immune cells can be lymphocytes, B cells or T cells. Cells can also be obtained from whole blood (whole food), apheresis or a tumor sample of a subject. Cells can be tumor infiltrating lymphocytes (TIL). In some cases, apheresis can be leukocyte apheresis. Leukocyte apheresis can be the process of separating blood cells from blood. During leukocyte apheresis, blood can be taken out from a needle on the subject's arm, by the circulation of a machine that divides whole blood into red blood cells, plasma and lymphocytes, and then plasma and red blood cells are returned to the subject by a needle on another arm. In some cases, cells are separated after applying treatment regimen and cell therapy. For example, apheresis can be performed sequentially or simultaneously with cell administration. In some cases, apheresis is performed at most about 6 weeks before and after applying a cell product. In some cases, -3 weeks, -2 weeks, -1 week, 0, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years or at most about 10 years after using the cell product, single blood component method is carried out. In some cases, the cell obtained by single blood component method can experience specific lysis test (such as cytotoxicity test), cytokine release, metabolomics research, bioenergetics research, intracellular FAC, ELISA point detection and lymphocyte subgroup analysis of cytokine production. In some cases, the sample of cell product or single product can be frozen and preserved for retrospective analysis of cell phenotype and function of infusion.
[0113] The methods provided herein may include activating T cells and simultaneously introducing a vector into (e.g., transducing or transfecting) T cells. The vector may be a viral vector (e.g., a lentiviral vector). The T cell may be a dormant (e.g., static) T cell or a non-dormant (e.g., activated) T cell. The T cell may be an exhausted T cell. In some cases, the T cell introduced with the vector may be a T cell colony comprising dormant T cells, non-dormant T cells, and / or exhausted T cells. The T cell colony may be a mixture of dormant T cells, non-dormant T cells, and exhausted T cells.
[0114] Compared with the efficiency of transducing dormant T cells with viral vectors without activating T cells at the same time, the efficiency of activating T cells simultaneously with viral vector transduction cells can be higher. The efficiency of transducing cells activating T cells simultaneously can be at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more higher than the efficiency of transducing dormant T cells without activating T cells at the same time. Because the efficiency of transduction and activation can be very high, the amount of viral vector used in the method provided herein can be very low. The amount of viral vector used for transduction and activation can be at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more lower than the amount used for transducing dormant T cells without activating T cells at the same time.
[0115] The T cells used in the methods described herein can be recovered from frozen cells (e.g., cryopreserved cells). Compared with activated T cells, dormant T cells can have a lower recovery efficiency (e.g., the percentage of viable cells recovered in a cell population). For example, the recovery efficiency of dormant T cells after 24 hours of cryopreservation can be at most about 80%, 70%, 60%, 50%, 40%, 30%, 20% or lower. The recovery efficiency of activated T cells after 24 hours of cryopreservation can be at least about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or higher. The recovery efficiency of activated T cells can be maintained after 24 hours.
[0116] The engineered cells prepared using the simultaneous transduction and activation methods described herein can effectively control or inhibit tumor growth.For example, compared with the engineered cells prepared using the method for transducing dormant T cells with viral vectors without simultaneous activation under the same or substantially the same conditions (e.g., animal models, dosages and experimental conditions), the engineered cells prepared herein can have higher efficiency in controlling tumor growth. The engineered cells prepared using the simultaneous transduction and activation methods described herein can effectively control the side effects associated with the administration of engineered T cells (e.g., CAR-T cells). Side effects include, but are not limited to, cytokine release syndrome (CRS) and hemophagocytic lymphohistiocytosis (HLH), also referred to as macrophage activation syndrome (MAS). The symptoms of CRS include high fever, nausea, transient hypotension, hypoxia, etc. The engineered cells prepared using the simultaneous transduction and activation methods described herein have less CRS than the engineered cells prepared using the method for transducing dormant T cells with viral vectors without simultaneous activation. Compared to engineered cells prepared using a method comprising transducing dormant T cells with a viral vector without simultaneous activation, engineered cells prepared using the simultaneous transduction and activation method described herein may produce lower proinflammatory cytokines. The proinflammatory cytokines may be IFN-γ, TNFα, GM-CSF, IL-2 and / or IL-6.
[0117] In some embodiments, the methods provided herein include introducing a T cell receptor (TCR) into a cell. In some embodiments, the TCR comprises (i) a ligand binding domain specific for a ligand and (ii) a transmembrane domain.
[0118] In some embodiments, TCR can be a membrane-anchored heterodimeric protein connected by a disulfide bond. The TCR provided herein may include variable α (α) and / or β (β) chains. In some aspects, α and / or β chains may be expressed as part of a complex with an invariant CD3 chain molecule. In some aspects, TCR may include variable γ (γ) and / or δ (δ) chains, referred to as γδT cells. In some aspects, the TCR chain may include an extracellular domain: variable (V) region, constant (C) region, immunoglobulin superfamily (IgSF) domains form antiparallel β-sheets. In some embodiments, the constant region is close to the cell membrane, followed by a transmembrane domain and a short cytoplasmic tail, and the variable region, such as a ligand binding domain, binds to a peptide / MHC complex. In some embodiments, a peptide may be a ligand. In some aspects, the variable domains of the TCR α-chain and β-chain may each have a hypervariable region or a complementary determining region (CDR).
[0119] In some embodiments, chimeric antigen receptors are provided herein. CAR includes: (i) a ligand binding domain specific for a ligand, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some embodiments, the ligand binding domain of the CAR of the subject method can be connected to the intracellular signaling domain through a transmembrane domain. The transmembrane domain can be a transmembrane segment. The transmembrane domain of the subject CAR can anchor the CAR to the plasma membrane of a cell (eg, an immune cell). In some embodiments, the transmembrane segment comprises a polypeptide. The transmembrane polypeptide connecting the ligand binding domain of the CAR and the intracellular signaling domain can have any suitable polypeptide sequence. In some cases, the transmembrane polypeptide comprises a polypeptide sequence of the transmembrane portion of an endogenous or wild-type transmembrane protein. In some embodiments, the transmembrane polypeptide comprises a polypeptide sequence having at least 1 (eg, at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid substitutions, deletions, and insertions compared to the transmembrane portion of an endogenous or wild-type transmembrane protein. In some embodiments, the transmembrane polypeptide comprises a non-natural polypeptide sequence, such as a sequence of a polypeptide linker. The polypeptide linker can be flexible or rigid. The polypeptide linker can be structured or unstructured. In some embodiments, the transmembrane polypeptide transmits the signal from the extracellular region of the cell to the intracellular region through the ligand binding domain. The natural transmembrane portion of CD28 can be used in CAR. In other cases, the natural transmembrane portion of CD8α can also be used in CAR. In some embodiments, the transmembrane domain of the subject CAR is from CD8α, CD4, CD28, CD45, PD-1 and / or CD152.
[0120] In some embodiments, the intracellular signaling domain of the CAR of the subject method may include a signaling domain or any derivative, variant or fragment thereof that participates in immune cell signaling. The intracellular signaling domain of CAR can induce the activity of immune cells containing CAR. The intracellular signaling domain can transduce effector function signals and instruct cells to perform specific functions. The signaling domain may include the signaling domain of other molecules. Although the signaling domain of another molecule can usually be used in CAR, in many cases, it is not necessary to use the entire chain. In some cases, a truncated portion of the signaling domain is used in CAR. In some embodiments, the intracellular signaling domain includes multiple signaling domains involved in immune cell signaling, or any derivative, variant or fragment thereof. For example, the intracellular signaling domain may include at least 2 immune cell signaling domains, such as at least 2, 3, 4, 5, 7, 8, 9 or 10 signaling domains. In some aspects, the subject CAR includes at least 2 intracellular signaling domains. In some aspects, the subject CAR includes at least 3 intracellular signaling domains.
[0121] The immune cell signaling domain may be involved in regulating the primary activation of the TCR complex in a stimulatory or inhibitory manner. The intracellular signaling domain may be a signaling domain of a T cell receptor (TCR) complex. The intracellular signaling domain of the subject's CAR may include a signaling domain of an Fcγ receptor (FcγR), an Fcε receptor (FcεR), an Fcα receptor (FcαR), a neonatal Fc receptor (FcRn), CD3, CD3ζ, CD3γ, CD3δ, CD3ε, CD4, CD5, CD8, CD21, CD22, CD28, CD32, CD40L (CD154), CD45, CD66d, CD79a, CD79b, CD80, CD86, CD278 (also known as ICOS), CD247ζ, CD247η, DAP10, DAP12, FYN, LAT, Lck, MAPK, MHC complex, NFAT, NF-κB, PLC-γ, iC3b, C3dg, C3d, and Zap70. In some embodiments, the signaling domain includes an immunoreceptor tyrosine-based activation motif or ITAM. The signaling domain comprising ITAM may comprise two repeats of the amino acid sequence YxxL / I, separated by 6-8 amino acids, wherein each x is independently any amino acid, generating a conserved motif YxxL / Ix(6-8)YxxL / I. For example, when the ligand binding domain binds to the epitope, the signaling domain comprising ITAM can be modified by phosphorylation. Phosphorylated ITAMs can serve as docking sites for other proteins (e.g., proteins involved in various signaling pathways). In some embodiments, the primary signaling domain comprises a modified ITAM domain, such as a mutated, truncated and / or optimized ITAM domain, which has an altered (e.g., increased or decreased) activity compared to a native ITAM domain. In some embodiments, the intracellular signaling domain of the subject's CAR comprises an FcγR signaling domain (e.g., ITAM). The FcγR signaling domain may be selected from FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a) and FcγRIIIB (CD16b). In some embodiments, the intracellular signaling domain comprises an FcεR signaling domain (e.g., ITAM). The FcεR signaling domain may be selected from FcεRI and FcεRII (CD23). In some embodiments, the intracellular signaling domain comprises an FcαR signaling domain (e.g., ITAM). The FcαR signaling domain may be selected from FcαRI (CD89) and Fcα / μR. In some embodiments, the intracellular signaling domain comprises a CD3ζ signaling domain. In some embodiments, the primary signaling domain comprises an ITAM of CD3ζ.In some embodiments, the intracellular signaling domain is from CD3ζ, CD28, CD54 (ICAM), CD134 (OX40), CD137 (4-1BB), GITR, CD152 (CTLA4), CD273 (PD-L2), CD274 (PD-L1), DAP10 and / or CD278 (ICOS).
[0122] In some embodiments, the intracellular signaling domain of the subject CAR comprises an inhibitory motif or ITIM based on immunoreceptor tyrosine. The signaling domain comprising ITIM may be included in a conserved amino acid sequence (S / I / V / LxYxxI / V / L) found in the cytoplasmic tail of some inhibitory receptors of the immune system. The primary signaling domain comprising ITIM can be modified by enzymes such as Src kinase family members (e.g., Lck), such as phosphorylation. After phosphorylation, other proteins, including enzymes, can be recruited to ITIM. These other proteins include, but are not limited to, enzymes such as phosphotyrosine phosphatases SHP-1 and SHP-2, inositol phosphatases called SHIP, and proteins (e.g., ZAP70) with one or more SH2 domains.Intracellular signaling domains may include BTLA, CD5, CD31, CD66a, CD72, CMRF35H, DCIR, EPO-R, FcγRIIB (CD32), Fc receptor-like protein 2 (FCRL2), Fc receptor-like protein 3 (FCRL3), Fc receptor-like protein 4 (FCRL4), Fc receptor-like protein 5 (FCRL5), Fc receptor-like protein 6 (FCRL6), protein G6b (G6B), interleukin 4 receptor (IL4R), immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), immunoglobulin superfamily receptor translocation-associated 2 (IRTA2), killer cell Immunoglobulin-like receptor 2DL1 (KIR2DL1), killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2), killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3), killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4), killer cell immunoglobulin-like receptor 2DL5 (KIR2DL5), killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1), killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2), leukocyte immunoglobulin-like receptor subfamily B member 1 (LIR1), leukocyte immunoglobulin-like receptor subfamily B member 2 (LIR 2), leukocyte immunoglobulin-like receptor subfamily B member 3 (LIR3), leukocyte immunoglobulin-like receptor subfamily B member 5 (LIR5), leukocyte immunoglobulin-like receptor subfamily B member 8 (LIR8), leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1), mast cell function-associated antigen (MAFA), NKG2A, natural cytotoxicity triggering receptor 2 (NKp44), NTB-A, programmed cell death protein 1 (PD-1), PILR, SIGLECL1, sialic acid-binding Ig-like lectin 2 (SIGLEC2 or CD22), sialic acid-binding Ig-like lectin 3 (SIGLEC3 or CD33), sialic acid-binding Ig-like lectin 5 (SIGLEC5 or CD170), sialic acid-binding Ig-like lectin 6 (SIGLEC6), sialic acid-binding Ig-like lectin 7 (SIGLEC7), sialic acid-binding Ig-like lectin 10 (SIGLEC10), sialic acid-binding Ig-like lectin 11 (SIGLEC11), sialic acid-binding Ig-like lectin 4 (SIGLEC4), sialic acid-binding Ig-like lectin 8 (SIGLEC8), sialic acid-binding Ig-like lectin 9 (SIGLEC9), platelet and endothelial cell adhesion molecule 1 (PECAM-1), signal regulatory protein (SIRP 2), and signaling threshold regulating transmembrane adaptor 1 (SIT) signaling domain (e.g., ITIM).In some embodiments, the intracellular signaling domain comprises a modified ITIM domain, such as a mutated, truncated and / or optimized ITIM domain, which has an altered (e.g., increased or decreased) activity compared to a native ITIM domain. In some embodiments, the intracellular signaling domain comprises at least 2 ITAM domains (e.g., at least 3, 4, 5, 6, 7, 8, 9, or 10 ITAM domains). In some embodiments, the intracellular signaling domain comprises at least 2 ITIM domains (e.g., at least 3, 4, 5, 6, 7, 8, 9, or 10 ITIM domains) (e.g., at least 2 primary signaling domains). In some embodiments, the intracellular signaling domain includes an ITAM domain and an ITIM domain.
[0123] In some cases, the intracellular signaling domain of the subject CAR may include a co-stimulatory domain. In some embodiments, for example, a co-stimulatory domain from a co-stimulatory molecule can provide a co-stimulatory signal for immune cell signaling, such as signaling from ITAM and / or ITIM domains, for example, for activating and / or inactivating immune cell activity. In some embodiments, the co-stimulatory domain is operable to regulate proliferation and / or survival signals in immune cells. In some embodiments, the co-stimulatory signaling domain includes MHC class I proteins, MHC class II proteins, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA or Toll ligand receptor signaling domains. In some embodiments, the costimulatory domain comprises a signaling domain selected from the group consisting of 2B4 / CD244 / SLAMF4, 4-1BB / TNFSF9 / CD137, B7-1 / CD80, B7-2 / CD86, B7-H1 / PD-L1, B7-H2, B7-H3, B7-H4, B7-H6, B7-H7, BAFF R / TNFRSF13C, BAFF / BLyS / TNFSF13B, BLAME / SLAMF8, BTLA / CD272, CD100(SEMA4D), CD103, CD11a, CD11b, CD11c, CD11d, CD150, CD160(BY55), CD18, CD19, CD2, CD200, CD229 / SLAMF3, CD27 Ligand / TNFSF7, CD27 / TNFRSF7, CD28, CD29, CD2F-10 / SLAMF9, CD30 Ligand / TNFSF8, CD30 / TNFRSF8, CD300a / LMIR1, CD4, CD40 Ligand / TNFSF5, CD40 / TNFRSF5, CD48 / SLAMF2, CD49a, CD49 D. CD49f, CD5, CD53, CD58 / LFA-3, CD69, CD7, CD8α, CD8β, CD82 / Kai-1, CD84 / SLAMF5, CD90 / Thy1, CD96, CDS, CEACAM1, CRACC / SLAMF7, CRTAM, CTLA-4, DAP12, Dectin-1 / CLEC7A, DN AM1(CD226), DPPIV / CD26, DR3 / TNFRSF25, EphB6, GADS, Gi24 / VISTA / B7-H5, GITR ligand / TNFSF18, GITR / TNFRSF18, HLA class I, HLA-DR, HVEM / TNFRSF14, IA4, ICAM-1, ICOS / CD278, Ikaros,IL2Rβ, IL2Rγ, IL7Rα, integrin α4 / CD49d, integrin α4β1, integrin α4β7 / LPAM-1, IPO-3, ITGA4, ITGA6, ITGAD, ITGAE, ITGAL, ITGAM, ITGAX, ITGB1, ITGB2, ITGB7, KIRDS2, LAG-3, LAT, LIGHT / TNFSF14, LTBR, Ly108, Ly9(CD229), lymphocyte function-associated antigen-1(LFA-1), lymphotoxin-α / TNF-β, NKG2C, NKG2D, NKp30, NKp44, NKp46, NKp80(K In some embodiments, the intracellular signaling domain comprises a plurality of costimulatory domains, e.g., at least two, e.g., at least 3, 4, or 5 costimulatory domains. The co-stimulatory signaling region can provide a signal that cooperates with the primary effector activation signal and can complete the requirements for activating T cells. In some embodiments, adding a co-stimulatory domain to the CAR can enhance the efficacy and persistence of the immune cells provided herein.
[0124] Examples of costimulatory signaling domains are provided in the table below.
[0125]
[0126]
[0127]
[0128] As an example, CAR may include CD3 ζ chains (sometimes referred to as first generation CAR). As another example, CAR may include CD-3 ζ chains and a single costimulatory domain (e.g., CD28 or 4-1BB) (sometimes referred to as second generation CAR). As another example, CAR may include CD-3 ζ chains and two costimulatory domains (CD28 / OX40 or CD28 / 4-1BB) (sometimes referred to as third generation CAR). Together with co-receptors such as CD8, these signal moieties can produce downstream activation of kinase pathways, thereby supporting gene transcription and functional cell responses.
[0129] In some embodiments, the subject CAR may include a hinge or a spacer. A hinge or a spacer may refer to a segment between a ligand binding domain and a transmembrane domain. In some embodiments, a hinge may be used to provide flexibility to a ligand binding domain such as scFv. In some embodiments, a hinge may be used to detect the expression of CAR on a cell surface, for example, when an antibody detecting scFv is not functional or available. In some cases, the hinge is derived from an immunoglobulin molecule and may be optimized according to the position of the first epitope or the second epitope on the target. In some cases, the hinge may not belong to an immunoglobulin molecule, but to another molecule, such as a natural hinge of a CD8α molecule. The CD8α hinge may include cysteine and proline residues, which play a role in the interaction between CD8 co-receptors and MHC molecules. In some embodiments, cysteine and proline residues may affect the performance of CAR and may therefore be engineered to affect CAR performance.
[0130] The hinge can be any suitable length. In some embodiments, the hinge of CAR can be size-adjustable and can compensate to a certain extent for the orthogonal synaptic distance between the cells expressing CAR and the target cells. This topographic map of the immune synapse between the cells expressing CAR and the target cells can also define the distance that cannot be functionally bridged by CAR due to the membrane distal epitopes on the cell surface target molecules, even with short hinge CAR, and the synaptic distance cannot be close to the approximate value of signal transduction. Similarly, near-membrane CAR target antigen epitopes have been described, and their signal output is only observed in the context of long hinge CAR. The hinge disclosed herein can be adjusted according to the single-chain variable fragment region that can be used. In some aspects, the hinge can be from CD28, IgG1 and / or CD8α.
[0131] As an example, a CAR may comprise an extracellular ligand binding domain, a transmembrane domain, and an intracellular signaling domain, such as Figure 3As shown. CAR may generally include a ligand binding domain, a hinge domain (H) or a spacer region derived from a single-chain antibody, a transmembrane domain (TM) providing anchoring to the plasma membrane, and a signaling domain responsible for T cell activation. CAR may include an immune cell signaling domain, such as a CD3ζ chain. CAR may include an immune cell signaling domain and a first co-stimulatory domain, such as a CD3ζ chain and 4-1BB. CAR may include an immune cell signaling domain and at least two co-stimulatory domains, such as a CD3ζ chain, 4-1BB, and OX40. In some embodiments, universal CAR may also be used in the methods provided herein. Universal CAR may include an intracellular signaling domain fused to a protein domain that binds to a label (e.g., fluorescein isothiocyanate or biotin) on a monoclonal antibody. Various combinations of immune cell signaling domains and co-stimulatory domains can be used for subject CAR. In some embodiments, the immune cell signaling domain may be from CD3, CD4, and / or CD8. The co-stimulatory domain may be from 4-1BB, OX40, CD28, etc.
[0132] In some embodiments, the ligand of the subject TCR or subject CAR can be any of the following or can be a portion of any of the following: VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, CD123, cd171, CD276, B7H4, BCMA, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Fl t1, KDR, Flt4, CD44V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothelin, NY-ESO-1, R ANK, ROR1, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRα, TCRβ, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79, Notch-1-4 and / or Claudin18.2. In some embodiments, the ligand of the subject TCR or subject CAR can be any of the following or can be a part of any of the following: a cancer cell, an endogenous cell, a cell of the vasculature, a cell of the tumor microenvironment, and any combination thereof.
[0133] In some embodiments, the subject CAR further comprises a signal peptide. In some aspects, the CAR of the present disclosure may comprise a signal peptide so that when the CAR is expressed in a cell such as an immune cell, the nascent protein is directed to the endoplasmic reticulum and then to the cell surface, where it can be expressed. The core of the signal peptide may comprise a long stretch of hydrophobic amino acids with a tendency to form a single α-helix. The signal peptide may begin with a short stretch of positively charged amino acids, which helps to strengthen the correct topological structure of the polypeptide during translocation. At the end of the signal peptide there may be a stretch of amino acids recognized and cut by a signal peptidase. The signal peptidase may be cut during or after the translocation to produce a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease. The signal peptide may be at the amino terminus of the molecule. In some embodiments, the subject CAR may have a general formula: signal peptide-ligand binding domain-spacer domain-transmembrane domain / intracellular T cell signaling domain. The signal peptide may be IgG1, GM-CSF and / or CD8α or may be derived from IgG1, GM-CSF and / or CD8α.
[0134] In some embodiments, the method may include administering, and the administration includes infusing the engineered cells provided herein. In some aspects, the infusion may be intravenous. In some embodiments, the administration includes infusing about 1x10 2 / kg body weight of engineered immune cells. In some embodiments, administration comprises infusing about 1x10 3 / kg body weight. In some embodiments, administration comprises infusion of about 1x10 4 / kg body weight. In some aspects, administration comprises infusion of about 1x10 5 / kg body weight. In some aspects, administration comprises infusion of about 3x10 5 / kg body weight. In some aspects, administration comprises infusion of about 1x10 5 / kg body weight to about 3×10 5 / kg body weight. In some aspects, administration comprises infusion of about 0.5x10 5 / kg body weight to about 1×10 5 / kg body weight. In some aspects, administration comprises infusion of about 1x10 4 / kg body weight to about 4×10 5 / kg body weight. In some aspects, administration comprises infusion of about 0.5x10 5 / kg body weight to about 1×10 5 / kg body weight. In some aspects, administration comprises infusion of about 0.5x10 5 / kg body weight to about 1.5×10 5 / kg body weight. In some embodiments, administration comprises infusion of about 1x10 3 / kg body weight.
[0135] In some embodiments, a total of about 5 x 10 10 cells. In some cases, about 5x10 10 The median amount of cells administered to a subject is represented by the cells. In some embodiments, about 5x10 10 In some embodiments, a total concentration or dose (cells / kg body weight) of at least about 1 x 10 6 cells, at least about 2x10 6 cells, at least about 3x10 6 cells, at least about 4x10 6 cells, at least about 5x10 6 cells, at least about 6x10 6 cells, at least about 6x10 6 cells, at least about 8x10 6 cells, at least about 9x10 6 cells, 1x10 7 cells, at least about 2x10 7 cells, at least about 3x10 7 cells, at least about 4x10 7 cells, at least about 5x10 7 cells, at least about 6x10 7 cells, at least about 6x10 7 cells, at least about 8x10 7 cells, at least about 9x10 7 cells, at least about 1x10 8 cells, at least about 2x10 8 cells, at least about 3x10 8 cells, at least about 4x10 8 cells, at least about 5x10 8 cells, at least about 6x10 8 cells, at least about 6x10 8 cells, at least about 8x10 8 cells, at least about 9x10 8 cells, at least about 1x10 9 cells, at least about 2x10 9 cells, at least about 3x10 9 cells, at least about 4x10 9 cells, at least about 5x10 9 cells, at least about 6x10 9 cells, at least about 6x10 9 cells, at least about 8x109 cells, at least about 9x10 9 cells, at least about 1x10 10 cells, at least about 2x10 10 cells, at least about 3x10 10 cells, at least about 4x10 10 cells, at least about 5x10 10 cells, at least about 6x10 10 cells, at least about 6x10 10 cells, at least about 8x10 10 cells, at least about 9x10 10 cells, at least about 1x10 11 cells, at least about 2x10 11 cells, at least about 3x10 11 cells, at least about 4x10 11 cells, at least about 5x10 11 cells, at least about 6x10 11 cells, at least about 6x10 11 cells, at least about 8x10 11 cells, at least about 9x10 11 cells or at least about 1x10 12 cells or dosed according to body weight (cells / kg body weight). For example, about 5x10 10 In another example, from 3x10 6 Starting from 10 cells, the cells can be expanded to about 5x10 10 In some cases, the cells are expanded to a sufficient number for treatment. For example, 5x10 7 The cells can be rapidly expanded to produce sufficient numbers for therapeutic use. In some embodiments, a total of less than about 1 x 10 6 cells. In some cases, about 1x10 6 The cells represent the median amount of cells administered to a subject. In some cases, up to about 9 x 10 5 cells, up to about 8x10 5 cells, up to about 7x10 5 cells, up to about 6x10 5 cells, up to about 5x10 5 cells, up to about 4x10 5 cells, up to about 3x10 5 cells, up to about 2x10 5 cells, up to about 1x10 5cells, up to about 9x10 4 cells, up to about 8x10 4 cells, up to about 7x10 4 cells, up to about 6x10 4 cells, up to about 5x10 4 cells, up to about 4x10 4 cells, up to about 3x10 4 cells, up to about 2x10 4 cells, up to about 1x10 4 cells, up to about 9x10 3 cells, up to about 8x10 3 cells, up to about 7x10 3 cells, up to about 6x10 3 cells, up to about 5x10 3 cells, up to about 4x10 3 cells, up to about 3x10 3 cells, up to about 2x10 3 or up to about 1x10 3 Cells were administered per kg body weight or per kg body weight (cells / kg body weight).
[0136] In some embodiments, the method provided herein does not have cell expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 3 weeks of ex vivo expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 2 weeks of ex vivo expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 1 week of ex vivo expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 5 days of ex vivo expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 3 days of ex vivo expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 2 days of ex vivo expansion. In some aspects, engineered cells, such as immune cells, have undergone less than 1 day of ex vivo expansion. In some cases, the whole number of cells (e.g., F-CART cells) can be administered to a subject by a single administration. Alternatively, the entire number of cells (e.g., F-CART cells) can be administered to a subject in multiple rounds, for example, by two separate administrations separated by at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, 24 hours or more.
[0137] In some cases, a sufficient amount for therapeutic use may be about 5 x 10 4Any number of cells may be infused for therapeutic use and may be included in a pharmaceutical composition. For example, a patient may be infused with 1x10 4 to 5x10 12 / kg / body weight (including 1x10 4 / kg / bodyweight and 5x10 12 / kg / body weight). As many cells as possible produced for the patient can be infused. In some aspects, the production of cells is not amplified. In some cases, not all cells in the infused patient are engineered. For example, at least 90% of the cells in the infused patient can be engineered. In other cases, at least 40% of the cells in the infused patient can be engineered. The amount of cells required for effective treatment in the patient can vary according to the viability of the cells and the efficiency with which the cells are modified. In some cases, the product of cell viability after genetic modification (e.g., proliferation) can correspond to a therapeutic cell aliquot that can be used for administration to a subject. In some cases, the increase in cell viability after modification can correspond to a reduction in the amount of cells required for effective treatment of the patient. In some aspects, at least about 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to about 100% of the immune cells express the CAR and / or the TCR. In some aspects, engineered cells can be selected for administration. In some aspects, at least 20% of immune cells express CAR and / or TCR. In some aspects, at least 25% of immune cells express CAR and / or TCR. In some aspects, at least 30% of immune cells express CAR and / or TCR. In some aspects, at least 40% of immune cells express CAR and / or TCR.
[0138] In some embodiments, the subject method may further include administering a second agent to a subject in need. The second agent may be a therapeutically effective amount of an immunostimulant, an immunosuppressant, an antifungal agent, an antibiotic, an antiangiogenic agent, a chemotherapeutic agent, a radioactive agent, and / or an antiviral agent. The second agent may be a pharmaceutical composition.
[0139] In some embodiments, an immunostimulatory agent can be introduced into a cell or subject. An immunostimulatory agent can be specific or nonspecific. A specific immunostimulatory agent can provide antigen specificity, such as a vaccine or an antigen. A nonspecific immunostimulatory agent can enhance an immune response or stimulate an immune response. A nonspecific immunostimulatory agent can be an adjuvant. An immunostimulatory agent can be any of a vaccine, a colony stimulating agent, an interferon, an interleukin, a virus, an antigen, a co-stimulatory agent, an immunogenic agent, an immunomodulator, or an immunotherapeutic agent. An immunostimulatory agent can be a cytokine, such as an interleukin. One or more cytokines can be introduced together with the cells of the provided method. Cytokines can be used to promote the amplification of cytotoxic T lymphocytes (including adoptively transferred tumor-specific cytotoxic T lymphocytes) in a tumor microenvironment. In some cases, IL-2 can be used to promote the amplification of cells described herein. Cytokines such as IL-15 can also be used. Other related cytokines in the field of immunotherapy, such as IL-2, IL-7, IL-12, IL-15, IL-21, or any combination thereof, can also be used. In some cases, IL-2, IL-7 and IL-15 are used to culture the cells of the invention. The interleukin may be IL-2 or aldeskeukin.
[0140] In some aspects, an immunostimulant may be administered to a subject. Aldesleukin may be administered at low or high doses. The high-dose aldeskeukin regimen may include intravenous administration of aldeskeukin every 8 hours, as tolerated, up to about 14 doses, with a dose of about 0.037 mg / kg (600,000 IU / kg). An immunostimulant (e.g., aldeskeukin) may be administered within 24 hours after cell administration. An immunostimulant (e.g., aldeskeukin) may be administered in an infusion form within about 15 minutes (about once every 8 hours) after cell infusion for up to about 4 days. The immunostimulant (e.g., aldeskeukin) can be administered at a dose of about 100,000 IU / kg, 200,000 IU / kg, 300,000 IU / kg, 400,000 IU / kg, 500,000 IU / kg, 600,000 IU / kg, 700,000 IU / kg, 800,000 IU / kg, 900,000 IU / kg, or up to about 1,000,000 IU / kg. In some cases, aldeskeukin can be administered at a dose of about 100,000 IU / kg to 300,000 IU / kg, 300,000 IU / kg to 500,000 IU / kg, 500,000 IU / kg to 700,000 IU / kg, 700,000 IU / kg to about 1,000,000 IU / kg. The immunostimulant (e.g., aldeskeukin) can be administered from about 1 dose to about 14 doses. The immunostimulant (e.g., aldeskeukin) can be administered for at least about 1 dose, 2 doses, 3 doses, 4 doses, 5 doses, 6 doses, 7 doses, 8 doses, 9 doses, 10 doses, 11 doses, 12 doses, 13 doses, 14 doses, 15 doses, 16 doses, 17 doses, 18 doses, 19 doses, or up to about 20 doses. In some cases, an immunostimulant such as aldeskeukin can be administered from about 1 to 3 doses, 3 to 5 doses, 5 to 8 doses, 8 to 10 doses, 10 to 14 doses, from 14 to 20 doses. In some cases, aldeskeukin is administered for more than 20 doses. In some cases, an immunostimulant, such as aldeskeukin, can be administered sequentially or simultaneously with cell administration. For example, an immunostimulant can be administered from about -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 days or up to about the 14th day. In some cases, an immunostimulant, such as aldeskeukin, is administered from day 0 to day 4 after administration of a cell population.In some cases, immunostimulant (e.g., aldeskeukin) is used for about 10min, 15min, 20min, 30min, 40min, 50min, 1 hour, 2 hours or a time period of about 3 hours at most. In some cases, immunostimulant (e.g., aldeskeukin) can be used for about 4 days after using engineered cells before about 24 hours to using engineered cells. Immunostimulant (e.g., aldeskeukin) can be used for -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 days or about 20 days at most after using engineered cells.
[0141] In some embodiments, the immunostimulator is a colony stimulating factor. The colony stimulating factor can be G-CSF (filgrastim). Filgrastim can be stored in 300mcg / ml and 480ug / 1.6mL vials. Filgrastim can be administered subcutaneously every day. Filgrastim administration can be about 5mcg / kg / day. Filgrastim administration may be about 1mcg / kg / day, filgrastim administration may be about 2mcg / kg / day, filgrastim administration may be about 3mcg / kg / day, filgrastim administration may be about 4mcg / kg / day, filgrastim administration may be about 5mcg / kg / day, filgrastim administration may be about 6mcg / kg / day, filgrastim administration may be about 7mcg / kg / day, filgrastim administration may be about 8mcg / kg / day, filgrastim administration may be about 9mcg / kg / day, filgrastim administration may be about 10mcg / kg / day. In some cases, filgrastim can be administered at a dose of about 0.5mcg / kg / day to about 1.0mcg / kg / day, about 1.0mcg / kg / day to 1.5mcg / kg / day, about 1.5mcg / kg / day to about 2.0mcg / kg / day, about 2.0mcg / kg / day to about 3.0mcg / kg / day, about 2.5mcg / kg / day to about 3.5mcg / kg / day, about 3.5mcg / kg / day to about 4.0mcg / kg / day, about 4.0mcg / kg / day to about 4.5mcg / kg / day. Filgrastim administration can be continued daily until the neutrophil count is at least about 1.0x10 9 / LX 3 days or at least about 5.0x10 9 / L. An immunostimulant such as filgrastim can be administered from day -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or up to about 20 days after administration of the engineered cells.
[0142] In some embodiments, the method may also include administering an immunosuppressant to the subject. In some cases, the subject may receive an immunosuppressant as part of a treatment regimen. The immunosuppressant may refer to a radiotherapeutic agent, a biological agent, or a chemical agent. In some cases, the immunosuppressant may include a chemical agent. For example, the chemical agent may include at least one member selected from the group consisting of cyclophosphamide, mechlorethamine, chlorambucil, melphalan, ifosfamide, thiotepa, hexamethylmelamine, busulfan, fludarabine, nitrosoureas, platinum, methotrexate, azathioprine, mercaptopurine, procarbazine, dacarbazine, temozolomide, carmustine, lomustine, streptozotocin, fluorouracil, actinomycin D, anthracycline antibiotics, mitomycin C, bleomycin, and mithramycin. The chemical agent may be cyclophosphamide or fludarabine.
[0143] In addition, immunosuppressants can include glucocorticoids, cell growth inhibitors, antibodies, anti-immunophilins or any derivatives thereof. Glucocorticoids can suppress allergic reactions, inflammation and autoimmune diseases. Glucocorticoids can be prednisone, dexamethasone and hydrocortisone. Immunosuppressive therapy can include any therapy that suppresses the immune system. Immunosuppressive therapy can help alleviate, minimize or eliminate the transplant rejection of the recipient. For example, immunosuppressive therapy can include immunosuppressive drugs. Immunosuppressive drugs that may be used before, during and / or after transplantation include, but are not limited to, MMF (mycophenolate mofetil (Cellcept)), ATG (antithymocyte globulin), anti-CD154 (CD4OL), anti-CD40 (2C10, ASKP1240, CCFZ533X2201), alemtuzumab (Campath), anti-CD20 (rituximab), anti-IL-6R antibodies (tocilizumab, Actemra), anti-IL-6 antibodies (sarilumab, olokizumab), CTLA4-Ig (Abatacept / Orencia), belatacept (LEA2 9Y), sirolimus (Rapimune), everolimus, tacrolimus (Prograf), daclizumab (Ze-napax), basiliximab (Simulect), infliximab (Remicade), cyclosporine, deoxyspergualin, soluble complement receptor 1, cobra venom factor, compstatin, anti-C5 antibody (eculizumab / Soliris), methylprednisolone, FTY720, everolimus, leflunomide, anti-IL-2R-Ab, rapamycin, anti-CXCR3 antibody, anti-ICOS antibody, anti-OX40 antibody, and anti-CD122 antibody. In addition, one or more than one immunosuppressant / drug can be used together or sequentially. One or more than one immunosuppressant / drug can be used for induction therapy or maintenance therapy. The same or different drugs can be used in the induction and maintenance phases. In some cases, daclizumab (Cenapax) can be used for induction therapy, and tacrolimus (Prograf) and sirolimus (Rapimune) can be used for maintenance therapy. Daclizumab (Cenapax) can also be used for induction therapy, and low-dose tacrolimus (Prograf) and low-dose sirolimus (Rapimune) can be used for maintenance therapy. Non-drug regimens can also be used to achieve immunosuppression, including but not limited to total body irradiation, thymic irradiation, and total and / or partial splenectomy.
[0144] In some cases, a cell growth inhibitor can be administered to perform immunosuppression. The cell inhibitor can inhibit cell division. The cell inhibitor can be a purine analog. The cell inhibitor can be an alkylating agent, an antimetabolite such as methotrexate, azathioprine or mercaptopurine. The cell inhibitor can be at least one of cyclophosphamide, methylchloroethylamine, chlorambucil, melphalan, ifosfamide, thiotepa, hexamethylmelamine, busulfan, fludarabine, nitrosoureas, platinum, methotrexate, azathioprine, mercaptopurine, procarbazine, dacarbazine, temozolomide, carbendazim, lomustine, streptozotocin, fluorouracil, actinomycin D, anthracycline antibiotics, mitomycin C, bleomycin and mithramycin.
[0145] In some cases, an immunosuppressant such as fludarabine may be administered as part of the treatment regimen. Fludarabine phosphate may be a synthetic purine nucleoside that differs from physiological nucleosides in that the sugar moiety may be arabinose rather than ribose or deoxyribose. Fludarabine may be a purine antagonist antimetabolite. Fludarabine may be supplied in 50 mg vials as a white lyophilized solid block of fludarabine phosphate powder. The pH of the solution is 7.7 after reconstitution with 2 mL of sterile water for injection to a concentration of 25 mg / mL. Fludarabine powder is stable for at least 18 months at 2-8°C; after reconstitution, fludarabine is stable for at least 16 days at room temperature. Due to the absence of preservatives, reconstituted fludarabine is typically administered within 8 hours. Specialized reference materials should be consulted for specific compatibility information. Fludarabine can be dephosphorylated in serum, transported intracellularly and converted to the nucleotide triphosphate fludarabine; this 2-fluoro-ara-ATP molecule is thought to be necessary for the drug's cytotoxic effects. Fludarabine inhibits DNA polymerase, ribonucleotide reductase, DNA primase, and can interfere with chain elongation and RNA and protein synthesis. Fludarabine can be infused intravenously in 100 ml of 0.9% sodium chloride USP for 15 to 30 minutes. The dose will be based on body surface area (BSA). If the patient is obese (BMI>35), the drug dose will be calculated using actual body weight. In some cases, immunosuppressants such as fludarabine can be taken at about 20 mg / m 2 To about 30mg / m 2 In some cases, immunosuppressants such as fludarabine can be administered at about 5 mg / m 2 About 10 mg / m 2 of the subject's body surface area, approximately 10 mg / m 2 Up to about 15 mg / m 2 , about 15mg / m 2 About 20 mg / m 2 of the subject's body surface area, about 20 mg / m 2 About 25 mg / m2 of the subject's body surface area, approximately 25 mg / m 2 To about 30mg / m 2 of the subject's body surface area, about 30 mg / m 2 Up to about 40 mg / m 2 In some cases, immunosuppressants such as fludarabine can be administered at about 1 mg / m 2 , 2mg / m 2 , 3mg / m 2 , 4mg / m 2 , 5mg / m 2 , 6mg / m 2 , 7mg / m 2 , 8mg / m 2 , 9mg / m 2 , 10mg / m 2 , 11mg / m 2 , 12mg / m 2 , 13mg / m 2 , 14mg / m 2 , 15mg / m 2 , 16mg / m 2 , 17mg / m 2 , 18mg / m 2 , 19mg / m 2 , 20mg / m 2 , 21mg / m 2 , 22mg / m 2 , 23mg / m 2 , 24mg / m 2 , 25mg / m 2 , 26mg / m 2 , 27mg / m 2 , 28mg / m 2 , 29mg / m 2 , 30mg / m 2 , 31mg / m 2 , 32mg / m 2 , 33mg / m 2 , 34mg / m 2 , 35mg / m 2 , 36mg / m 2 , 37mg / m 2 , 38mg / m 2 , 39mg / m 2 , 40mg / m 2 41mg / m 2 42mg / m 2 43mg / m 2 44mg / m2 、45mg / m 2 、46mg / m 2 、47mg / m 2 、48mg / m 2 、49mg / m 2 、50mg / m 2 、51mg / m 2 、52mg / m 2 、53mg / m 2 、54mg / m 2 、55mg / m 2 、56mg / m 2 、57mg / m 2 、58mg / m 2 、59mg / m 2 、60mg / m 2 、61mg / m 2 、62mg / m 2 、63mg / m 2 、64mg / m 2 、65mg / m 2 、66mg / m 2 、67mg / m 2 、68mg / m 2 、69mg / m 2 、70mg / m 2 、71mg / m 2 、72mg / m 2 、73mg / m 2 、74mg / m 2 、75mg / m 2 、76mg / m 2 、77mg / m 2 、78mg / m 2 、79mg / m 2 、80mg / m 2 、81mg / m 2 、82mg / m 2 、83mg / m 2 、84mg / m 2 、85mg / m 2 、86mg / m 2 、87mg / m 2 、88mg / m 2 、89mg / m 2 、90mg / m 2 、91mg / m 2 、92mg / m 2 、93mg / m 2 、94mg / m2 , 95mg / m 2 , 96mg / m 2 , 97mg / m 2 , 98mg / m 2 , 99mg / m 2 , up to about 100 mg / m 2 In some cases, immunosuppressants such as fludarabine are administered at a dose of 25 mg / m2 in 100 ml of 0.9% sodium chloride USP. 2 , and infused over about 15 to about 30 minutes.
[0146] In some cases, immunosuppressants such as cyclophosphamide may be administered as part of the treatment regimen. Cyclophosphamide can be an alkylating agent derived from nitrogen mustard. After conversion to active metabolites in the liver, cyclophosphamide acts as an alkylating agent; the drug also has potent immunosuppressive activity. The serum half-life after intravenous administration is 3-12 hours; the drug and / or its metabolites can be detected in the serum up to 72 hours after administration. After reconstitution with sterile water for injection as directed, cyclophosphamide is stable at room temperature for 24 hours, or at 2-8°C for 6 days. Cyclophosphamide can be diluted in 250mL D5W and infused within one hour. The dose will be based on the subject's weight. If the subject is obese (BMI>35), the drug dose will be calculated using the actual body weight as described. In some cases, immunosuppressants such as cyclophosphamide can be used at about 1 mg / kg to about 3 mg / kg, about 3 mg / kg to about 5 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 20 mg / kg, 20 mg / kg to about 30 mg / kg, about 30 mg / kg to about 40 mg / kg, about 40 mg / kg to about 50 mg / kg, about 50 mg / kg to about 60 mg / kg, about 60 mg / kg to about 70 mg / kg, about 70 mg / kg to about 80 mg / kg, about 80 mg / kg to about 90 mg / kg, about 90 mg / kg to about 100 mg / kg. In some cases, immunosuppressants such as cyclophosphamide are used in excess of 50 mg / kg of the subject.In some cases, an immunosuppressant such as cyclophosphamide can be administered at about 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 21 mg / kg, 22 mg / kg, 23 mg / kg, 24 mg / kg of a subject. / kg, 25mg / kg, 26mg / kg, 27mg / kg, 28mg / kg, 29mg / kg, 30mg / kg, 31mg / kg, 32mg / kg, 33mg / kg, 34mg / kg, 35mg / kg, 36mg / kg, 37m g / kg, 38mg / kg, 39mg / kg, 40mg / kg, 41mg / kg, 42mg / kg, 43mg / kg, 44mg / kg, 45mg / kg, 46mg / kg, 47mg / kg, 48mg / kg, 49mg / kg, 50 mg / kg, 51mg / kg, 52mg / kg, 53mg / kg, 54mg / kg, 55mg / kg, 56mg / kg, 57mg / kg, 58mg / kg, 59mg / kg, 60mg / kg, 61mg / kg, 62mg / kg, 6 3mg / kg, 64mg / kg, 65mg / kg, 66mg / kg, 67mg / kg, 68mg / kg, 69mg / kg, 70mg / kg, 71mg / kg, 72mg / kg, 73mg / kg, 74mg / kg, 75mg / kg, In some cases, immunosuppressants such as cyclophosphamide can be administered within at least about 1 day to about 3 days, 3 days to 5 days, 5 days to 7 days, 7 days to about 10 days, 10 days to about 14 days, 14 days to about 20 days. In some cases, the dose of cyclophosphamide may be about 60 mg / kg, diluted in 250 ml of 5% dextrose in water and infused over one hour.
[0147] The immunosuppressant may be, for example, a regimen of cyclophosphamide and fludarabine. For example, a cyclophosphamide fludarabine regimen may be administered to a subject receiving engineered cell therapy. The cyclophosphamide fludarabine regimen may be administered at 60 mg / kg qd2 days and 25 mg / m 2 The 5-day regimen of qd can be administered. A chemotherapy regimen, such as cyclophosphamide fludarabine, can be administered 1 hour to 14 days before the engineered cells of the present invention are administered. The chemotherapy regimen can be administered at different doses. For example, a subject can receive a higher initial dose followed by a lower dose. A subject can receive a lower initial dose followed by a higher dose.
[0148] In some cases, the immunosuppressant may be an antibody. The antibody may be administered at a therapeutically effective dose. The antibody may be a polyclonal antibody or a monoclonal antibody. The polyclonal antibody that may be administered may be an anti-lymphocyte or anti-thymocyte antigen. The monoclonal antibody may be an anti-IL-2 receptor antibody, an anti-CD25 antibody, or an anti-CD3 antibody. Anti-CD20 antibodies may also be used. B cell ablation therapy, such as an agent that reacts with CD20, e.g., Rituxan, may also be used as an immunosuppressant.
[0149] The immunosuppressant may also be an anti-immunophilin. The anti-immunophilin may be cyclosporine, tacrolimus, everolimus or sirolimus. Other immunosuppressants may be interferons, such as IFN-β, opioids, anti-TNF binding agents, mycophenolate mofetil or fingolimod.
[0150] In some embodiments, the method may further include administering radiation therapy to the subject. Radiation therapy may include radiation. Whole body radiation may be administered at 12 Gy. The radiation dose may include a cumulative dose of 12 Gy to the whole body including healthy tissue. The radiation dose may include 5 Gy to 20 Gy. The radiation dose may be 5 Gy, 6 Gy, 7 Gy, 8 Gy, 9 Gy, 10 Gy, 11 Gy, 12 Gy, 13 Gy, 14 Gy, 15 Gy, 16 Gy, 17 Gy, 18 Gy, 19 Gy or up to 20 Gy. The radiation may be whole body radiation or local body radiation. In the case where the radiation is whole body radiation, it may be uniform or non-uniform. For example, when the radiation may be non-uniform, a narrower area of the body (such as the neck) may receive a higher dose than a wider area (such as the buttocks).
[0151] In some embodiments, the methods provided herein may further include administering a chemotherapeutic agent. The chemotherapeutic agent or compound may be a compound used to treat cancer. Exemplary chemotherapeutic agents that may be used in combination with the disclosed methods include, but are not limited to, nuclear division-inhibiting substances (vinca alkaloids). These include vincristine, vinblastine, vindesine, and Navelbine TM(Vinorelbine, 5'-noranhydroblastine). In other cases, chemotherapeutic cancer drugs include topoisomerase I inhibitors, such as camptothecin compounds. As used herein, "camptothecin compounds" include Camptosar TM (Irinotecan HCL), Hycamtin TM (topotecan HCL) and other compounds derived from camptothecin and its analogs. Another class of chemotherapeutic cancer agents that can be used in the methods and compositions disclosed herein are podophyllotoxin derivatives, such as etoposide, teniposide and mitoposide. The present disclosure also includes other chemotherapeutic cancer agents called alkylating agents, which alkylate the genetic material in tumor cells. These include, but are not limited to, cisplatin, cyclophosphamide, nitrogen mustard, trimethylenethiophosphoramide, carmustine, busulfan, chlorambucil, lomustine, uracil nitrogen mustard, chlomaphazin and dacarbazine. The present disclosure includes antimetabolites as chemotherapeutic agents. Examples of such drugs include cytarabine, fluorouracil, methotrexate, mercaptopurine, azathioprine and procarbazine. Another class of chemotherapeutic cancer agents that can be used in the methods and compositions disclosed herein include antibiotics. Examples include, but are not limited to, doxorubicin, bleomycin, actinomycin D, daunorubicin, mithramycin, mitomycin, mitomycin C and daunomycin. There are many commercially available liposomal formulations that can be used for these compounds. The present disclosure also encompasses other chemotherapeutic cancer agents, including, but not limited to, anti-tumor antibodies, dacarbazine, azacytidine, amsacrine, melphalan, ifosfamide, and mitoxantrone.
[0152] In some embodiments, the method may also include administering an antiviral agent to the subject. In some cases, the antiviral agent may be administered as part of a treatment regimen. In some cases, a herpes simplex virus preventive may be administered to the subject as part of a treatment regimen. The herpes simplex virus preventive may be valacyclovir (valacyclovir tablets (Valtrex)). In subjects with positive HSV serological tests, valacyclovir tablets may be used orally to prevent the occurrence of herpes simplex virus infection. Other antiviral agents that may be administered include, but are not limited to, anti-hepatitis B virus (HBV), anti-hepatitis C virus (HCV), anti-human papillomavirus (HPV) and anti-Epstein-Barr virus (EBV).
[0153] In some embodiments, the method may further include administering an antibiotic to the subject. The antibiotic may be administered at a therapeutically effective dose. The antibiotic may kill or inhibit the growth of bacteria. The antibiotic may be a broad-spectrum antibiotic that may target a variety of bacteria. A third-generation or fourth-generation broad-spectrum antibiotic may be a cephalosporin or a quinolone. The antibiotic may also be a narrow-spectrum antibiotic that targets a specific type of bacteria. The antibiotic may target the bacterial cell wall, such as penicillins and cephalosporins. The antibiotic may target the cell membrane, such as polymyxins. The antibiotic may interfere with essential bacterial enzymes, such as antibiotics: rifamycins, lipiarmycins, quinolones, and sulfonamides. The antibiotic may also be a protein synthesis inhibitor, such as macrolides, lincosamides, and tetracyclines. The antibiotic may also be a cyclic lipopeptide (such as daptomycin), a glycylcycline (glycylcyclines) (such as tigecycline), an oxazolidinedione (such as linezolid), and a lipomycin (such as fedamicin). In some cases, antibiotics can be 1st, 2nd, 3rd, 4th or 5th generation. First generation antibiotics can have narrow spectrum. Examples of first generation antibiotics can be penicillins (penicillin G or penicillin V), cephalosporins (cefazolin, cephalothin, cefpirin, cephalethin (Cephalethin), cephradine or cephadroxin). In some cases, antibiotics can be second generation. Second generation antibiotics can be penicillins (amoxicillin or ampicillin), cephalosporins (cefuroxime, cefamandole, cefoxitin, cefaclor, cephrozil, loracarb). In some cases, antibiotics can be third generation. Third generation antibiotics can be penicillins (carbenicillin and ticarcillin) or cephalosporins (cefotaxime, ceftriaxone, cefotaxime, ceftizoxime and ceftazidime). Antibiotics can also be 4th generation antibiotics. 4th generation antibiotics can be Cephipime. Antibiotics can also be 5th generation. The 5th generation antibiotics can be Cephtaroline or Cephtobiprole. In some cases, antibiotics can be bacterial wall targeting agents, cell membrane targeting agents, bacterial enzyme interfering agents, bactericides, protein synthesis inhibitors or antibacterial agents. Bacterial wall targeting agents can be penicillin derivatives (penicillanes), cephalosporins (cephems), monobacterium amines and carbapenems. β-lactam antibiotics have bactericidal or antibacterial effects, and play a role by inhibiting the synthesis of the peptidoglycan layer of the bacterial cell wall. In some cases, antibiotics can be protein synthesis inhibitors. Protein synthesis inhibitors can be ampicillin, which acts as an irreversible inhibitor of transpeptidase, and bacteria need transpeptidase to make cell walls. It inhibits the third and final stages of bacterial cell wall synthesis in binary fission, ultimately leading to cell lysis; therefore, ampicillin is generally bactericidal. In some cases, bactericides can be cephalosporins or quinolones.In other cases, the bacteriostatic agent is trimethoprim, sulfamethoxazole, or pentamidine.
[0154] In some cases, drugs for preventing PCP pneumonia can be administered. For example, trimethoprim and sulfamethoxazole can be administered to prevent pneumonia. The dosage of trimethoprim and sulfamethoxazole (TMP / SMX; exemplary sulfonamide drugs) can be 3 times a week, 1 tablet per day PO, on non-consecutive days, at or after the first dose of chemotherapy, and continue for at least about 6 months, until the CD4 count of at least 2 consecutive laboratory studies is greater than 200. In some cases, trimethoprim can be administered at 160 mg. Trimethoprim can be administered at about 100 to about 300 mg. Trimethoprim can be administered at about 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, or at most about 300 mg. In some cases, sulfamethoxazole is administered at 800 mg. Sulfamethoxazole can be administered at about 500 mg to about 1000 mg. Sulfamethoxazole is administered at about 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, or at most about 1000 mg. In some cases, the TMP / SMX regimen can be administered in a therapeutically effective amount. TMP / SMX can be administered from about 1X to about 10X per day. TMP / SMX can be administered 1X, 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 10X, 11X, 12X, 13X, 14X, 15X, 16X, 17X, 18X, 19X, or at most about 20X per day. In some cases, TMP / SMX can be administered on a weekly basis. For example, TMP / SMX can be administered weekly 1X, 2X, 3X, 4X, 5X, 6X or up to about 7X. The TMP / SMX regimen can be administered from about -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 days or up to about the 14th day after administering cell therapy (such as AST-CART).
[0155] In some embodiments, the methods provided herein can be used in combination with anti-angiogenic agents. Suitable anti-angiogenic agents for the disclosed methods and compositions include anti-VEGF antibodies, including humanized and chimeric antibodies, anti-VEGF aptamers and antisense oligonucleotides. Other angiogenesis inhibitors that can be used with the provided methods and compositions include angiostatin, endostatin, interferon, interleukin 1 (including α and β), interleukin 12, retinoic acid and tissue inhibitors of metalloproteinase-1 and metalloproteinase-2 (TIMP-1 and TIMP-2). Small molecules can also be used, including topoisomerases, such as razoxane, a topoisomerase II inhibitor with anti-angiogenic activity.
[0156] In some embodiments, the method may include administering additional therapies, such as antifungal therapy. In some cases, an antifungal agent is administered to a subject to whom a composition comprising an engineered cell is administered. An antifungal agent may be a drug that kills or prevents fungal growth. The targets of an antifungal agent may include sterol biosynthesis, DNA biosynthesis, and beta-glucan biosynthesis. An antifungal agent may also be a folate synthesis inhibitor or a nucleic acid crosslinker. A folate synthesis inhibitor may be a sulfonamide. For example, a folate synthesis inhibitor may be an agent or competitive inhibitor that inhibits fungal synthesis of folate. A sulfonamide or folate synthesis inhibitor may be methotrexate or sulfamethoxazole. In some cases, an antifungal agent may be a nucleic acid crosslinker. A crosslinker may inhibit DNA or RNA processes in fungi. For example, a crosslinker may be 5-fluorocytosine, which may be a fluorinated analog of cytosine. 5-fluorocytosine may inhibit the synthesis of DNA and RNA by conversion to 5-fluorouracil in the cytoplasm. Other antifungal agents may be griseofulvin. Griseofulvin is an antifungal antibiotic produced by Penicillium griseofulvin. Griseofulvin inhibits fungal mitosis and can be considered a cross-linking agent. Other cross-linking agents may be allylamines (naftifine and terbinafine) that inhibit ergosterol synthesis at the level of squalene epoxidase; a morphene derivative (amorolfine) that inhibits subsequent steps in the ergosterol pathway.
[0157] In some embodiments, the antifungal agent can be from polyene, azole, allylamine or echinocandin. In some embodiments, the polyene antifungal agent is amphotericin B, candidacidin, filipin, hamycin, natamycin, nystatin or mitomycin. In some cases, the antifungal agent can be from azoles. Azoles antifungal agents can inhibit lanosterol 14α-demethylase. Azoles antifungal agents can be imidazoles, such as bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole, moconazole, orzoconazole, sertaconazole, sukiconazole or tioconazole. Azoles antifungal agents can be triazoles, such as albaconazole, efinaconazole, fluconazole, isavuvonazole, itraconazole, posaconazole, propiconazole, ravuconazole, terconazole or voriconazole. In some cases, azoles can be thiazoles, such as abafungin. Antifungal agents can be allylamines, such as amorolfin, butenafine, naftifine or terbinafine. Antifungal agents can also be echinocandin, such as anidulafungin, caspofungin or micafungin. Other agents that can be used as antifungal agents can be aurone, benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin, tolnaftate, undecylenic acid, gentian violet or Peruvian balsam. Those skilled in the art can appropriately determine which known antifungal drugs to use according to the fungus of the infected individual. In some cases, the subject will receive fluconazole combined with engineered cells. Antifungal therapy can be used preventively.
[0158] In some aspects, the subject treated can be monitored after the composition produced by the methods provided herein is administered. In some embodiments, peripheral blood can be obtained from the subject after the engineered cells are administered. In some embodiments, serum can be separated from the peripheral blood of the subject after the engineered cells are administered. In some embodiments, spinal puncture samples can be collected from the subject after the engineered cells are administered. In some embodiments, the engineered immune cells from the sample of the treated subject can be quantified from the sample. In some aspects, the sample from the subject who has undergone the administration of the engineered cells can be peripheral blood. In some embodiments, the engineered cells can be monitored by quantitative PCR (qPCR). The qPCR determination of the adoptively transplanted cells can indicate the level of engineered cells present in the subject after administration. In some cases, flow cytometry can be used to monitor the cells of adoptive transfer. For example, flow cytometry can determine the level of 4-1BB to TCR. In some cases, single cell TCR PCR can be performed. The level of adoptively transferred cells can be determined on the 7th day after infusion. The level of adoptively transferred cells, such as modified cells, can be determined on any of the following days following infusion: day 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or up to day 200.
[0159] In some embodiments, the growth factor level of the subject to which the engineered cells have been applied is quantified. Determining the level of growth factor in the subject can indicate the reaction of the subject to the engineered cells applied. In some aspects, the level of quantitative growth factor is to monitor the tolerance of the subject to the cells of adoptive transfer. In some aspects, the level of quantitative growth factor can indicate that intervention is necessary for prevention, stability or maximum toxicity. In some aspects, toxicity can be cytokine release syndrome. In some embodiments, the growth factor that can be quantified and / or monitored from the sample of the subject is selected from IL-10, IL-6, tumor necrosis factor alpha (TNF-α), IL-1β, IL-2, IL-4, IL-8, IL-12 and / or IFN-γ.
[0160] In some aspects, the cell colony comprising the engineered cells is repeatedly administered. In some aspects, the subject may undergo about 1, 2, 3, 4, 5, 6, 7, 8, 9 or up to 10 infusions of the cell colony comprising the engineered cells. In some aspects, the engineered cells are allogeneic for the subject to be administered. In some aspects, the engineered cells are autologous for the subject to be administered.
[0161] In some embodiments, the method provided herein can be used for treating disease. In some aspects, the method provided herein can be used for treating cancer by targeting cancer with engineered immune cell colonies. In some embodiments, the subject of the subject's engineered cells is suffering from cancer. In some aspects, cancer is a target and is hematological. In some embodiments, hematological cancers include leukemia, myeloma, lymphoma and / or its combination. In some aspects, leukemia can be chronic lymphocytic leukemia (CLL), T cell acute lymphocytic leukemia (T-ALL), acute myeloid leukemia (AML), B cell acute lymphocytic leukemia (B-ALL) and / or acute lymphocytic leukemia (ALL). In some embodiments, lymphoma can be mantle cell lymphoma (MCL), T cell lymphoma, Hodgkin lymphoma and / or non-Hodgkin lymphoma. In some aspects, cancer is a target and is solid. In some embodiments, the solid cancer target or liquid cancer target is selected from Wilms tumor, Ewing's sarcoma, neuroendocrine tumor, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, biliary tract cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma, or bladder cancer. Non-limiting examples of cancer include cells of cancer, cancers include acanthoma, acinar cell carcinoma, acoustic neuroma, acromelanoma, spirochete tumor, acute eosinophilic leukemia, acute lymphocytic leukemia, acute megakaryocytic leukemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloid dendritic cell leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adamantium, adenocarcinoma, adenoid cystic carcinoma, adenoma, odontogenic adenoma, adrenal cortical carcinoma, adult T-cell leukemia, aggressive NK-cell leukemia, AIDS-related cancer, AIDS-related lymphoma, alveolar soft part sarcoma, ameloblastic fibroma, anal cancer, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, appendix cancer, astrocytic cell tumor, atypical teratoid rhabdoid tumor, basal cell carcinoma, basaloid carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, biliary tract cancer, bladder cancer, germ cell tumor, bone cancer, bone tumor, brain stem glioma, brain tumor, breast cancer, Brenner tumor, bronchial tumor, bronchioalveolar carcinoma, brown tumor, Burkitt lymphoma, cancer of unknown primary site, carcinoid tumor, carcinoma, carcinoma in situ, penile cancer, cancer of unknown primary site, carcinosarcoma, Castleman disease, embryonal tumor of the central nervous system, cerebellar astrocytoma, brain astrocytoma, cervical cancer, bile duct cancer, chondroma, chondrosarcoma, chordoma, choriocarcinoma, choroid plexus papilloma, chronic lymphocytic leukemia, chronic monocytic leukemia, chronic myeloproliferative disease, chronic neutrophilic leukemia,Clear cell tumor, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, Degos' disease, dermatofibrosarcoma protuberans, dermoid cyst, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, embryonal carcinoma, endodermal sinus tumor, endometrial carcinoma, endometrial uterine cancer, endometrioid tumor, enteropathy-associated T-cell lymphoma, ependymoblastoma, ependymoma, epithelioid sarcoma, erythroleukemia, esophageal cancer, esthesioneuroblastoma, Ewing's sarcoma family, Ewing's family sarcoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, extramammary Paget's disease, fallopian tube cancer, fetus in fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid Adenocarcinoma, Gallbladder cancer, Gallbladder cancer, Ganglioglioma, Gangliocytoma, Gastric cancer, Gastric lymphoma, Gastrointestinal cancer, Gastrointestinal carcinoid tumor, Gastrointestinal stromal tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germ cell tumor, Gestational choriocarcinoma, Gestational trophoblastic tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebral, Glomus tumor, Glucagonoma, Gonadoblastoma, Granular cell tumor, Hairy cell leukemia, Hairy cell leukemia, Head and neck cancer, Head and neck cancer, Heart cancer, Hemangioblastoma, Hemangiopericytoma, Angiosarcoma, Hematological malignancies, Hepatocellular carcinoma, Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin lymphoma, Hodgkin lymphoma, Hypopharyngeal cancer, Hypothalamus Glioma, Inflammatory Breast Cancer, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Tumor, Juvenile Myelomonocytic Leukemia, Kaposi's Sarcoma, Kaposi's Sarcoma, Kidney Cancer, Klatskin Tumor, Krukenberg Tumor, Laryngeal Cancer, Laryngeal Cancer, Malignant Melanoma, Leukemia, Leukemia, Lip and Oral Cancer, Liposarcoma, Lung Cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid Leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Histiocytoma, Malignant Fibrous Histiocytoma, Malignant Bone Fibrous Histiocytoma, Malignant Glioma, Malignant Mesothelioma, Malignant Peripheral Nerve Sheath Tumor, Malignant Rhabdoid Tumor, Malignant Salamander Tumor, MALT Lymphoma, Mantle Cell Lymphoma, Mast Cell Leukemia, Mediastinal Germ Cell Tumor, Mediastinal Septal tumor, medullary thyroid cancer, medulloblastoma, medulloblastoma, medullary epithelioma, melanoma, melanoma, meningioma, Merkel cell carcinoma, mesothelioma, mesothelioma, metastatic squamous neck cancer with occult primary, metastatic urothelial carcinoma, mixed mullerian tumor, monocytic leukemia, oral cancer, mucinous tumor, multiple endocrine neoplasia syndrome, multiple myeloma, multiple myeloma, mycosis fungoides, myelodysplastic disease, myelodysplastic syndrome, myeloid leukemia, myeloid sarcoma, myeloproliferative disease, myeloid leukemia, myeloid sarcoma, myeloproliferative disease, myxoma, nasal cancer, nasopharyngeal tumor, nasopharyngeal carcinoma, neoplasm, schwannoma, neuroblastoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, non-Hodgkin lymphoma,Non-Hodgkin lymphoma, Non-melanoma skin cancer, Non-small cell lung cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral cancer, Oral cancer, Oropharyngeal cancer, Osteosarcoma, Osteosarcoma, Ovarian cancer, Ovarian epithelial cancer, Ovarian germ cell tumor, Ovarian low malignant potential tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic cancer, Pancreatic cancer, Thyroid papillary carcinoma, Papillomatosis, Paraganglioma, Paranasal sinus cancer, Parathyroid cancer, Penile cancer, Perivascular epithelioid cell tumor, Pharyngeal cancer, pheochromocytoma, intermediately differentiated pineal parenchymal tumor, pinealoblastoma, pituitary cell tumor, pituitary adenoma, pituitary tumor, plasmacytoma, pleuropulmonary blastoma, multiblastoma, precursor T lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary hepatocellular carcinoma, primary liver cancer, primary peritoneal cancer, primary neuroectodermal tumor, prostate cancer, pseudomyxoma peritonei, rectal cancer, renal cell carcinoma, respiratory tract cancer involving the NUT gene on chromosome 15, retinoblastoma, Rhabdomyoma, rhabdomyosarcoma, Richter's transformation, sacrococcygeal teratoma, salivary gland carcinoma, sarcoma, schwannomatosis, sebaceous gland carcinoma, secondary tumors, seminoma, serous tumor, male cell tumor, sex cord-stromal cell tumor, Sezary syndrome, signet ring cell carcinoma, skin cancer, small blue round cell tumor, small cell carcinoma, small cell lung cancer, small cell lymphoma, small intestinal cancer, soft tissue sarcoma, somatostatinoma, sooty warts, spinal cord tumor, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, gastric cancer, superficial spreading black sarcoma, supratentorial primitive neuroectodermal tumor, surface epithelial-stromal tumor, synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocytic leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, teratoma, terminal lymphoma, testicular cancer, thecoma, laryngeal cancer, thymic cancer, thymoma, thyroid cancer, renal pelvis and ureter transitional cell carcinoma, transitional cell carcinoma, urachal carcinoma, urethral cancer, genitourinary tumors, uterine sarcoma, uveal melanoma, vaginal cancer, Verner Morrison syndrome, verrucous carcinoma, optic pathway glioma, vulvar cancer, Waldenstrom macroglobulinemia, Warthin tumor,Wilms tumor and combinations thereof. In some embodiments, the targeted cancer cells represent a subpopulation within a cancer cell population, such as cancer stem cells. In some embodiments, the cancer belongs to a hematopoietic lineage, such as a lymphoma. The antigen may be a tumor-associated antigen. In some aspects, the subject may suffer from minimal residual disease (MRD) after treatment or administration. MRD may include any of the above-mentioned cancers or cancer cells. In some embodiments, MRD is acute lymphoblastic leukemia. On the one hand, the cancer provided herein may express chemokines such as SDF-1. On the one hand, cells of the tumor microenvironment of the cancer provided herein express chemokines. Chemokines can attract immune cells, such as engineered immune cells provided herein. On the one hand, engineered immune cells, such as F-CART, can migrate to cancers or tumor microenvironments with high expression of chemokines (such as SDF-1). On the one hand, cancers expressing chemokines such as SDF-1 can be treated with engineered immune cells provided herein. 、
[0162] In some embodiments, the subject has a BCR-ABL mutation. In some embodiments, the BCR-ABL mutation is in the BCR-ABL kinase domain or a portion thereof. In some embodiments, the subject has a T315I and / or V299L mutation in the BCR-ABL kinase domain or a portion thereof. In some cases, the subject shows resistance to tyrosine kinase inhibitors.
[0163] In some embodiments, the subject has received a previous treatment. For example, the subject may have received a first-line treatment for a disease such as cancer. In some aspects, the subject may be resistant to the first-line treatment and / or susceptible to a tumor after the first-line treatment such as chemotherapy. In some aspects, the subject is pretreated with chemotherapy before administering the subject's engineered cells.
[0164] The present invention can provide a method for applying a treatment regimen to a subject suffering from a disease such as cancer. In some cases, a cell composition (for example, a pharmaceutical composition comprising engineered immune cells) can be provided in a unit dosage form. The cell composition can be resuspended in a solution and administered by infusion. The treatment regimen including an immunostimulant, an immunosuppressant, an antibiotic, an antifungal, an antiemetic, a chemotherapeutic agent, radiotherapy and any combination thereof can also be provided herein. The treatment regimen including any of the above can be lyophilized and reconstructed in an aqueous solution (e.g., a saline solution). In some cases, treatment is administered by a route selected from subcutaneous injection, intramuscular injection, intradermal injection, transdermal administration, intravenous ("iv") administration, intranasal administration, intralymphatic injection and oral administration. In some cases, a cell composition comprising engineered cells is infused to a subject by a microcatheter in the lymphatic vessel.
[0165] Drugs used in conjunction with the cell therapy of the present disclosure can be administered orally as liquids, capsules, tablets, or chewable tablets. Because the oral route is the most convenient, and is generally the safest and cheapest, it is the most commonly used route. However, it has limitations due to the way drugs typically pass through the digestive tract. For drugs administered orally, absorption can begin in the mouth and stomach. However, most drugs are typically absorbed from the small intestine. The drug passes through the intestinal wall and enters the liver, and is then transported to its target site through the bloodstream. The intestinal wall and liver chemically change (metabolize) many drugs, reducing the amount of drug that reaches the blood. Therefore, when injected intravenously, these drugs are usually administered in smaller doses to produce the same effect.
[0166] For subcutaneous administration of drugs used in conjunction with cell therapy of the present disclosure, a needle is inserted into the fatty tissue just below the skin. After the drug is injected, it enters small blood vessels (capillaries) and is carried away by the bloodstream. Alternatively, the drug reaches the bloodstream through lymphatic vessels. When a larger volume of drug product is required, the intramuscular route is preferred over the subcutaneous route. Because the muscle is located below the skin and fatty tissue, a longer needle is used. The drug is usually injected into the muscles of the upper arm, thigh, or buttocks. The speed at which the drug is absorbed into the bloodstream depends in part on the blood supply to the muscle: the less blood supply, the longer it takes for the drug to be absorbed. For the intravenous route, the needle is inserted directly into the vein. The solution containing the drug can be administered in a single dose or continuously infused. For infusion, the solution is moved by gravity (from a collapsible plastic bag) or more commonly by an infusion pump through a thin hose into a tube (catheter) inserted into a vein (usually in the forearm). In some cases, cells or treatment regimens are administered as infusions. The infusion can be performed over a period of time. For example, the infusion can be the administration of cells or treatment regimens over a period of about 5 minutes to about 5 hours. The infusion may be performed over a period of about 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, or up to about 5 hours.
[0167] In some embodiments, intravenous administration is used to deliver precise doses throughout the body quickly and in a well-controlled manner. It is also used for irritating solutions that, if administered by subcutaneous or intramuscular injection, can cause pain and damage tissue. Intravenous injections are more difficult to administer than subcutaneous or intramuscular injections because it can be difficult to insert a needle or catheter into a vein, especially if the person is obese. When administered intravenously, the drug is immediately delivered to the bloodstream and takes effect faster than when administered by any other route. Therefore, healthcare practitioners closely monitor people who receive intravenous injections for signs that the drug is working or causing adverse side effects. In addition, the effects of drugs administered by this route tend to last for a shorter period of time. Therefore, some drugs must be administered by continuous infusion to keep their effects constant. For the intrathecal route, a needle is inserted between two vertebrae in the lower spine and into the space around the spinal cord. The drug is then injected into the spinal canal. A small amount of local anesthetic is usually used to numb the injection site. This route is used when a drug is needed to have a rapid or local effect on the brain, spinal cord, or the layers of tissue that cover them (meninges) - for example, to treat infections in these structures.
[0168] Inhalable drugs used in conjunction with the cell therapy of the present disclosure can be administered orally because they are atomized into smaller droplets than those administered by the nasal route. In this way, the drug can enter the lungs through the trachea (tube). Smaller droplets can penetrate deep into the throat, thereby increasing the amount of drug absorbed. In the lungs, they are absorbed into the bloodstream. Drugs applied to the skin are generally used for their local effects and are therefore most commonly used to treat superficial skin diseases such as psoriasis, eczema, skin infections (viruses, bacteria and fungi), itching and dry skin. The drug is mixed with an inactive substance. Depending on the consistency of the inactive substance, the preparation can be an ointment, cream, lotion, solution, powder or gel.
[0169] In some cases, the treatment regimen may be administered based on the subject's weight. For subjects determined to be obese (BMI>35), actual body weight may need to be used. BMI is calculated as: BMI = weight (kg) / [height (m)] 2 The ideal weight for men can be calculated as 50kg + 2.3*(number of inches over 60 inches) or ideal weight for women can be calculated as 45.5kg + 2.3 (number of inches over 60 inches). For subjects who are 20% over their ideal body weight, an adjusted body weight can be calculated. The adjusted body weight can be the sum of ideal body weight + (0.4 x (actual body weight - ideal body weight)). In some cases, body surface area can be used to calculate the dose. Body surface area (BSA) can be calculated as follows: BSA (m2) = √ height (cm) * weight (kg) / 3600.
[0170] In some cases, the pharmaceutical composition comprising the cell therapy can be administered alone or with a pharmaceutically acceptable carrier or excipient by any route, and such administration can be performed in single and multiple doses. More specifically, the pharmaceutical composition can be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, lozenges, candies, powders, sprays, aqueous suspensions, injections, elixirs, syrups, etc. Such carriers include solid diluents or fillers, sterile aqueous media, and various non-toxic organic solvents, etc. In addition, such oral pharmaceutical preparations can be appropriately sweetened and / or flavored by various types of agents commonly used for such purposes.
[0171] In some cases, the treatment regimen can be administered with a carrier or excipient. Exemplary carriers and excipients can include dextrose, sodium chloride, sucrose, lactose, cellulose, xylitol, sorbitol, maltitol, gelatin, PEG, PVP, and any combination thereof. In some cases, the percentage of excipients such as dextrose or sodium chloride can be about 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 11%, 11.5%, 12%, 12.5%, 13%, 13.5%, 14%, 14.5%, or up to about 15%.
[0172] Described herein is a method for treating a disease (e.g., cancer) in a recipient, comprising transplanting one or more cells (including organs and / or tissues) comprising engineered immune cells to the recipient. Cells prepared by the provided methods can be used to treat cancer. In some cases, the disease level can be determined sequentially or simultaneously with the treatment regimen or cell administration. The disease level of the target lesion can be measured as a complete response (CR): all target lesions disappear, a partial response (PR): the sum of the longest diameter (LD) of the target lesion is reduced by at least 30% with reference to the baseline sum LD, progression (PD): the sum of the LD of the target lesion is increased by at least 20% with reference to the minimum total LD recorded since the start of treatment or the appearance of one or more new lesions, stable disease (SD): with reference to the minimum sum LD, neither enough to shrink to obtain PR nor enough to increase to obtain PD. In other cases, non-target lesions can be measured. The disease level of non-target lesions can be a complete response (CR): all non-target lesions disappear and tumor marker levels normalize, a non-complete response: the persistence of one or more non-target lesions, and a progression (PD): one or more new lesions appear. Clear progress of existing non-target lesions. In some cases, the best overall response of subjects who have undergone treatment regimens and cell administration can be evaluated. The best overall response can be the best response recorded from the start of treatment to disease progression / recurrence (taking the minimum measured value recorded since the start of treatment as a reference for progressive disease). The best response distribution of the subject may depend on the realization of the measurement and confirmation criteria. Progression time can be calculated from the randomization date. On the one hand, response can refer to monitoring the cancer burden or tumor burden of the subject. On the one hand, compared with the cancer burden observed in comparable subjects of comparable groups (such as C-CART) that have undergone ex vivo amplification for 2 weeks or more, when the subject administers a colony (such as F-CART) comprising engineered immune cells, a reduction in cancer burden is observed in the subject. On the one hand, compared with comparable subjects of comparable groups (such as C-CART) that have been subjected to ex vivo expansion for 2 weeks or more, the cancer burden is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% in subjects treated with a colony (such as F-CART) comprising engineered immune cells. On the one hand, the subject described herein can be a mammal. The mammal can be a human, dog, horse, pig, mouse, rat or monkey.
[0173] To obtain PR or CR status, changes in tumor measurements must be confirmed by repeated studies, which should be conducted at least about 4 weeks after the response criteria are first met. In the case of SD, follow-up measurements must meet the SD criteria at least once, at a minimum interval of 6-8 weeks after entering the study. In some cases, the duration of overall response can be measured from the time when the CR / PR measurement criteria are met (whichever is recorded first) to the first date of objectively recording recurrent or progressive disease (using the minimum measurement recorded since the start of treatment as a reference for progressive disease). The duration of overall complete response can be measured from the time when the measurement criteria for CR are first met until the first date of objectively recording recurrent disease. Stable disease can be measured from the start of treatment to meeting the progression criteria, and the minimum measurement recorded since the start of treatment is used as a reference. In some cases, measurable disease can be obtained and recorded in metric notation using a ruler or caliper. All baseline assessments can be performed as close to the start of treatment as possible. When the lesion is superficial (e.g., skin nodules and palpable lymph nodes) and the caliper diameter is used to exceed at least about 10mm, the lesion can be considered measurable. In some cases, color photography may be performed.
[0174] In other cases, computed tomography (CT) or magnetic resonance imaging (MRI) may be performed. CT may be performed on slices 5 mm thick or thinner. If the slice thickness of the CT scan is greater than 5 mm, the minimum dimension of the measurable lesion should be twice the slice thickness. In some cases, an FDG-PET scan may be used. FDG-PET can be used to evaluate new lesions. A negative FDG-PET at baseline and a positive FDG-PET at follow-up are signs of progressive disease (PD) based on new lesions. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at follow-up corresponds to a new site of disease confirmed on CT, it is PD. If the positive PDG-PET at follow-up corresponds to a pre-existing site of disease on CT that may not have progressed based on the anatomical images, this may not be PD. In some cases, FDG-PET can be used to enhance the response to CR in a manner similar to a biopsy, in which case the residual radiographic abnormality is thought to represent fibrosis or scarring. A positive FDG-PET scan lesion is one that is FDG avid with uptake greater than twice that of the surrounding tissue on attenuation-corrected images.
[0175] In some cases, lesions may be assessed. A complete response (CR) can be the disappearance of all target lesions. Any pathological lymph node (target or non-target) may be reduced to less than 10mm in short axis. A partial response (PR) can be a reduction of at least 30% in the sum of diameters of the target lesions, taking the baseline sum of diameters as a reference. Progressive disease (PD) can be an increase of at least 20% in the sum of diameters of the target lesions, taking the minimum sum as a reference. In addition to a relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Stable disease (SD) is neither a sufficient reduction in quality to be a PR nor a sufficient improvement in quality to be a PD, taking the minimum sum of diameters as a reference.
[0176] In some cases, non-target lesions can be evaluated. A complete response to non-target lesions can be the disappearance and normalization of tumor marker levels. The size of all lymph nodes must be non-pathological (short axis less than 10mm). If tumor markers are initially above the upper limit of normal, they must be normalized before the patient can be considered a complete clinical response. Non-CR / non-PD is the continued presence of one or more non-target lesions and / or tumor marker levels maintained above normal limits. Progressive disease can be the appearance of one or more new lesions and / or clear progression of existing non-target lesions. Clear progression should generally not exceed the target lesion status. In some cases, the best overall response can be the best response recorded from the start of treatment to disease progression / recurrence.
[0177] In some cases, a subject treated with a treatment regimen or cell product as described herein may experience adverse events associated with the regimen or cell product. An adverse event may be any reaction, side effect or adverse event that occurs during a treatment process associated with a human drug, whether or not the event is considered to be treatment-related or clinically significant. In some cases, adverse events may include events reported by subjects, as well as clinically significant abnormal findings from physical examinations or laboratory assessments. New diseases, symptoms, signs or clinically significant laboratory abnormalities or preexisting conditions or abnormal exacerbations may be considered adverse events. All adverse events, including clinically significant abnormal findings in laboratory assessments, regardless of severity, will be tracked until they subside to grade 2 or lower, except for lymphopenia and alopecia. If it is expected that adverse events will not resolve to grade 2 or lower, the subject may stop treatment. In some cases, the treatment regimen may be administered with a toxicity reducer. A toxicity reducer may be a fever or vomiting reducer. For example, mesna may be administered to reduce toxicity, such as nausea, vomiting and diarrhea.
[0178] On the one hand, cell colonies can be tested before or with administration before infusion. It is possible to perform pre-infusion or pre-application testing to ensure that the engineered cell product is functional, sterile, and can play a role after infusion. Pre-infusion testing may include determining phenotype, cytotoxicity, memory / stemness, exhaustion, bone marrow migration, ELISA, and any combination thereof. On the one hand, pre-application testing may include performing in vitro or in vivo assays. On the one hand, the cytotoxicity level in the engineered cell colony may be determined. For example, the expression of any of the following in the cell colony can be assessed by FAC: CD3, CD4, CD8, CD45RO, CCR7, CD45RA, CD62L (L-selectin), CD27, CD28, and IL-7Rα, CD95, IL-2Rβ, CXCR3, and LFA-1. On the one hand, functional testing may also include co-culture assays, cytotoxicity assays, ELISA (e.g., quantitative interleukin-2 (IL-2) and / or IFN-γ part) or ELISPOT assays. On the one hand, the further feature of the colony provided herein is that compared with the comparable colonies undergoing ex vivo expansion for more than 2 weeks or the proliferation of comparable colonies as follows, cytotoxicity and / or bone marrow migration, greater proliferation, cytotoxicity and / or bone marrow migration are observed in the colony: (a) without activating the cell colony and (b) introducing the polynucleotides encoding CAR simultaneously with the activation part. On the one hand, the feature of the colony provided herein is also that compared with the comparable colonies undergoing ex vivo expansion for more than 2 weeks or for (a) without activating the cell colony and (b) introducing the polynucleotides encoding CAR simultaneously with the activation part, it comprises greater memory and / or dryness. In one aspect, the levels of proliferation, memory / stemness, cytotoxicity (killing ability) and / or BM migration can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or up to about 100% greater than or approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or up to about 100% greater than a comparable population that has undergone ex vivo expansion for more than 2 weeks or a comparable population that (a) has not simultaneously activated the cell population with an activating portion and (b) has introduced a polynucleotide encoding a CAR.
[0179] In some embodiments, provided herein is a point-of-care device. The point-of-care device can be a hospital, a laboratory, a clinic, a vehicle, a medical center, a recreational vehicle, a home, to name just a few exemplary facilities. The point-of-care device can include a cell infusion device. The cell infusion device can include any of the following: a bag, a pump, a syringe, a tube, a lumen, a bioreactor, an incubator, a cell counter, a centrifuge, a thermometer, a needle, a suction machine, an oxygen tank, a VAD chamber, and any combination thereof. In some embodiments, the point-of-care device includes a cell infusion device. The cell infusion device can be configured to: infuse a cell population containing engineered immune cells that have not been expanded in vitro for 2 weeks or more. On the one hand, the immune cell population is a pharmaceutical composition. In some aspects, the cell infusion device comprising an immune cell population may be further characterized in that the cell memory T cells (TCM) in the population are more abundant than the effector memory T cells (TEM). In some aspects, the cell infusion device comprises an immune cell population, wherein at least 2% of the population is a stem cell-like memory T cell (TSCM). In some embodiments, the point-of-care device includes a cell processing device configured to (a) receive a cell population comprising immune cells from a subject and (b) activate the immune cell population with an activation portion, while introducing a polynucleotide encoding at least a chimeric antigen receptor (CAR) into the immune cell. In some aspects, the CAR comprises (i) a ligand-specific ligand binding domain, (ii) a transmembrane domain, and (iii) an intracellular signaling domain. In some aspects, the cell processing device is further configured to (c) infuse the immune cell population of (b) into the subject within 2 weeks or less from the time of performing (b). In some aspects, step (c) is performed within 1 week or less from the time of performing (b). In some embodiments, the cell processing device of the point-of-care device is configured to perform steps (a) and (b) within 24 hours. In some embodiments, the cell processing device of the point-of-care device is configured to perform steps (a) and (b) within 3 hours. In some embodiments, the cell processing device of the point-of-care device is configured to perform steps (a) and (b) within 1 hour. In some embodiments, the cell processing device of the point-of-care device is configured to perform steps (a) and (b) within 30 minutes.
[0180] Example
[0181] Various aspects of the present disclosure are further illustrated by the following non-limiting examples.
[0182] Example 1: Construction of lentiviral vector
[0183] The nucleotide sequence including EF1a promoter (as shown in SEQ ID NO: 1), anti-CD19 scFv (as shown in SEQ ID NO: 3), CD28 hinge region, CD28 transmembrane region and CD28 co-stimulatory signal molecule (as shown in SEQ ID NO: 5), CD3ζ intracellular domain (as shown in SEQ ID NO: 7), and CAR (as shown in SEQ ID NO: 9) is artificially synthesized.
[0184] SEQ ID NO: 1:
[0185] gggcagagcg cacatcgccc acagtccccg agaagttggg gggaggggtcggcaattgaacgggtgccta gagaaggtgg cgcggggtaa actgggaaag tgatgtcgtgtactggctccgcctttttcc cgagggtggg ggagaaccgt atataagtgc agtagtcgcc gtgaacgttctttttcgcaacgggtttgcc gccagaacac agctgaagct tcgaggggct cgcatctctccttcacgcgcccgccgccct acctgaggcc gccatccacg ccggttgagt cgcgttctgccgcctcccgcctgtggtgcc tcctgaactg cgtccgccgt ctaggtaagt ttaaagctca ggtcgagaccgggcctttgtccggcgctcc cttggagcct acctagactc agccggctct ccacgctttg cctgaccctgcttgctcaactctacgtctt tgtttcgttt tctgttctgc gccgttacag atc
[0186] SEQ ID NO: 3:
[0187] atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagcattctcctgatcccagaca tccagatgac acagactaca tcctccctgt ctgcctctct gggagacagagtcaccatcagttgcagggc aagtcaggac attagtaaat atttaaattg gtatcagcagca aaaccagatggaactgttaaactcctgatc taccatacat caagattaca ctcaggagtc ccatcaaggt tcagtggcagtgggtctggaacagattatt ctctcaccat tagcaacctg gagcaagaag atattgccac ttacttttgccaacagggtaatacgcttc gtacacgttc c ggagggg aataacaggctccacctctggatccggcaa gcccggatct ggcgagggat ccaccaaggg cgaggtgaaactgcaggagtcaggacctg cctggtggcg ccctcacaga gcctgtccgt cacatgcactgtctcaggggtcattacc cgactatggt gtaagctgga ttcgcggc ggtctggagtggctgggagtaatatggggt agtgaaacca catactataa ttcagctctc aaatccagac tgaccatcatcaaggacaactccaagagcc aagttttctt aaaaatgaac agtctgcaaa ctgatgacac agccatttactactgtgccaaacattatta ctacctggtggtgtacgc acctcagtcaccgtctcctcagcggccgca gactacaaag acgatgacga caag
[0188] SEQ ID NO:5:
[0189] attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatggaaccattccatgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccctttgggtgctggtggttgg gggagtcctg gcttgctata gcttgctagt agcaggctcc tgcacagtga ctacatgaac atgactccccgccgcccgggcccacccgc aagcattacc agccctatgc cccaccacgc gactcgcag cctatcgctc c
[0190] SEQ ID NO:7:
[0191] agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggccagaaccagctctataacgagc tcaatctagg acgaagagag gagtacgatg tttggacaagacgtggccgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaaggcctgtagactca tacagtgaga ttgggatgaaaggcgagcgccggaggggca aggggcacga tggccttac cagggtctca gtacagccaccaaggacacctacgacgccc ttcacatgca ggccctgccc cctcgc
[0192] SEQ ID NO:9:
[0193] atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagcattcctcctgatcccagaca tccagatgac acagactaca tcctccctgt ctgcctctct gggagacagagtcaccatcagttgcagggc aagtcaggac attagtaaat atttaaattg gtatcagcag aaaccagatggaactgttaaactcctgatc taccatacat caagattaca ctcaggagtc ccatcaaggt tcagtggcagtgggtctggaacagattatt ctctcaccat tagcaacctg gagcaagaag atattgccac ttacttttgccaacagggtaatacgcttcc gtacacgttc ggagggggga ctaagttgga aataacaggctccacctctggatccggcaa gcccggatct ggcgagggat ccaccaaggg cgaggtgaaactgcaggagtcaggacctgg cctggtggcg ccctcacaga gcctgtccgt cacatgcactgtctcaggggtctcattacc cgactatggt gtaagctgga ttcgccagcc tccacgaaag ggtctggagtggctgggagtaatatggggt agtgaaacca catactataa ttcagctctc aaatccagac tgaccatcatcaaggacaactccaagagcc aagttttctt aaaaatgaac agtctgcaaa ctgatgacac agccatttactactgtgccaaacattatta ctacggtggt agctatgcta tggactactg gggtcaagga acctcagtcaccgtctcctcagcggccgca gactacaaag acgatgacga caagattgaa gttatgtatc ctcctccttacctagacaatgagaagagca atggaaccat tatccatgtg aaagggaaac acctttgtccaagtcccctatttcccggaccttctaagcc cttttgggtg ctggtggtgg ttgggggagt cctggcttgc tatagcttgctagtaacagtggcctttatt attttctggg tgaggagtaa gaggagcagg ctcctgcaca gtgactacatgaacatgactccccgccgcc ccgggcccac ccgcaagcat taccagccct atgccccacccacgcgacttcgcagcctatc gctccagagt gaagttcagc aggagcgcag acgcccccgcgtaccagcagggccagaacc agctctataa cgagctcaat ctaggacgaa gagaggagtacgatgttttggacaagagac gtggccggga ccctgagatg gggggaaagc cgagaaggaagaaccctcaggaaggcctgt acaatgaact gcagaaagat aagatggcgg aggcctacagtgagattgggatgaaaggcg agcgccggag gggcaagggg cacgatggcc tttaccagggtctcagtacagccaccaagg acacctacga cgcccttcac atgcaggccc tgccccctcg ctaa
[0194] The nucleic acid sequence encoding CAR was cloned into the lentiviral vector FUGW, and the plasmid was named GCP042.293. Plasmid GCP042 and other packaging plasmids (helper plasmids) were used to transfect T cells simultaneously. 6 293T cells were collected at 1.3×10 4 cells / cm 2 The density of inoculation was 150 cm 2 The cells were then cultured in 10% FBS DMEM medium in a culture dish and then cultured at 37°C, 5% CO2 and saturated humidity for 3 days before transfection.
[0195] 18 μg of auxiliary plasmid and 24 μg of GCP042 were added to a centrifuge tube containing 3 mL of DMEM medium, and 126 mg of PEI was then added to the tube to obtain a mixture. The mixture was allowed to stand at room temperature for 30 minutes, and then supplemented with 12 mL of DMEM containing 2% FEB to obtain a transfection medium. For transfection, after removing the culture medium, 293T cells were incubated with the transfection medium for 4 hours, and then the transfection medium was replaced with 20 mL of DMEM medium containing 2% FBS. After 72 hours, the culture medium was collected and centrifuged at 3000 g and 4 ° C for 10 min. The supernatant was then filtered with a 0.45 μm filter for further purification. The filtrate was further centrifuged at 27000 g and 4 ° C for 2 hours. The precipitate was collected and resuspended with 100 μL of pre-cooled PBS to obtain a GCL042 lentiviral suspension, and kept overnight at 4 ° C. The next day, the viral suspension was aliquoted for further use.
[0196] Example 2: Preparation of F-CART cells
[0197] To prepare F-CART cells, 100 mL of peripheral blood was collected from healthy donors. PBMCs were isolated by density gradient centrifugation at 500-600 g for 20-30 minutes. Magnetic beads combined with CD28 antibodies and CD3 antibodies (CD3 / CD28 Dynabeads, purchased from ThermoFisher) were used to sort and enrich T cells. GCL042 prepared as in Example 1 was then incubated in X-vivo15 medium at 37 ° C at 0.1 × 10 6 cells / mL to 10×10 6 T cells are transfected at a cell density between cells / mL. After transfection, the CAR-T cells of the present invention (also referred to herein as F-CART or F-CAR-T cells) can be obtained without further amplification. In this process, the cells are not activated before transfection, and these cells are also referred to as F-CART-FV1 cells in this disclosure.
[0198] Similarly, about 100 mL of peripheral blood was collected from healthy donors and PBMCs were isolated by density gradient centrifugation at 500-600 g for 20-30 minutes. Magnetic beads combined with CD28 antibodies and CD3 antibodies (CD3 / CD28 Dynabeads, purchased from ThermoFisher) were used to sort and enrich T cells. T cells were further incubated with CD3 / CD28 Dynabeads at a ratio of 0.1:1 to 5:1 (CD3 / CD28 Dynabeads: T cells) and 300 IU / mL IL2 to activate the cells. Simultaneously or subsequently, 0.1-10×10 6T cells were transfected with GCL042 at a cell density of 1 cell / mL for 4 hours and then washed with saline buffer. The F-CART cells of the present disclosure can be obtained without further amplification. In this process, the cells are activated, and these cells are also referred to as F-CART-FV2 cells in the present disclosure.
[0199] Table 1 summarizes the preparation process of F-CART-FV1 cells to F-CART-FV2 cells
[0200] Table 1 Preparation process of F-CART-FV1 and F-CART-FV2 cells
[0201]
[0202] Example 3: Lentivirus MOI and the proportion of CAR-positive cells
[0203] The proportion of CAR-positive cells using the FV1 preparation process and the FV2 preparation process was then compared. Briefly, approximately 100 mL of peripheral blood was collected from healthy donors and PBMCs were isolated by density gradient centrifugation at 500-600 g for 20-30 minutes. CD3 / CD28 Dynabeads were then used to sort and enrich T cells.
[0204] 1×10 7 The sorted T cells were divided into two groups, and F-CART-FV1 and F-CART-FV2 cells were prepared as described in Example 2. GCL042 was used to transfect T cells at a cell density of 2×10 6 cells / mL, with an MOI between 3 and 4. Specifically, the amount of virus used was calculated as: number of viruses = number of cells x MOI / virus titer. The calculated virus was then incubated with T cells for 16-24 hours to infect the T cells. After transfection, the virus was removed by centrifugation, and the cells were then collected and cultured for another 3-5 days. 0.5×10 6 -1.0×10 6 The cells were analyzed by flow cytometry for CAR positivity. The results are shown in Table 2.
[0205] Table 2 CAR positive rate of different preparation processes
[0206] preparation MOI Positive rate (%) F-CART-FV1 3.2 6.2% F-CART-FV2 3.0 33.1%
[0207] As can be seen from Table 2, the CAR positivity rate of the F-CART-FV2 preparation is higher than that of the F-CART-FV1 preparation. Subsequently, the correspondence between MOI and CAR positivity rate was studied using F-CART-FV2 cells. Figure 1 As shown. Figure 1It can be seen that when using MOIs of 0.8 and 1.6, the CAR positive rates were 31.0% and 39.8%, respectively, indicating that the positive rate was also affected by factors other than MOI at this stage; when using MOIs of 1.6 and 3.2, the CAR positive rates were 39.8% and 57.2%, respectively, indicating that with the increase in the amount of virus, the positive rate showed a nearly 1.5-fold change, and the positive rate was basically related to the amount of virus used at this stage; when using MOIs of 3.2, 6.4, and 12.8, the CAR positive rates were 57.2%, 64.6%, and 69.3%, respectively, indicating that the positive rate did not increase significantly with the increase in the amount of virus, and the virus infection had entered the platform at this stage. The results show that the preferred MOI for preparing F-CART of the present disclosure, especially F-CART-FV2, is between 1.6-6.4, so that the positive rate of F-CART can be more effectively and stably controlled.
[0208] Example 4: Preparation of C-CART cells
[0209] Control cells (also called second reference cells, C-CART or C-CAR-T cells) were prepared according to the method described in Kochenderfer, JN et al. (2013), “Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation” Blood 122(25): 4129-4139.
[0210] Briefly, approximately 100 mL of peripheral blood was collected from healthy donors and PBMCs were isolated by density gradient centrifugation at 500-600 g for 20-30 minutes. CD3 / CD28 Dynabeads were used to sort and enrich T cells. T cells were then further incubated with CD3 / CD28 Dynabeads at a ratio of 0.1:1 to 5:1 (CD3 / CD28 Dynabeads: T cells) and 300 IU / mL IL2 to activate the cells. Simultaneously or subsequently, 0.1-10 × 10 6 T cells were transfected with GCL042 at a cell density of 10 cells / mL for 4 hours and then washed with saline buffer. After activation and transfection, the modified cells were cultured for 8 days for expansion to obtain control cells (also called second reference cells, C-CART or C-CAR-T cells).
[0211] Example 5: Positive rate of F-CART cells to C-CART cells
[0212] The presence and absence of CD19 + In the case of tumor cell stimulation, CAR-positive cells (CAR-positive cells) were cultured in vitro in F-CART (such as F-CART-FV2 cells) and C-CART cells after recovery from cryopreservation. + ) ratio. The results are as follows Figure 2 As shown. Figure 2 It can be seen that for the recovered F-CART cells, the CAR+ ratio decreased with the extension of culture time, and after the addition of tumor antigens, the CAR+ ratio increased again ( Figure 2 The solid line in the middle represents the group without tumor antigen addition, and the dotted line represents the group with tumor antigen addition), indicating that CAR+ cells can be enriched by tumor antigen stimulation and the polynucleotide encoding CAR is stably integrated into the T cell genome. Figure 2 It also showed that before tumor antigen stimulation, at the starting point, the CAR+ ratio in F-CART cells was much higher than that in C-CART cells, and from day 16, the CAR+ ratio in C-CART cells decreased significantly, but the CAR+ ratio in F-CART still showed a slight increase. After tumor antigen stimulation, both F-CART and C-CART cells showed a significantly increased CAR+ ratio.
[0213] Example 6: Lymphocyte Subpopulation Analysis
[0214] Lymphocyte subsets in the starting material (corresponding T cells without virus transfection) and F-CART cells (such as F-CART-FV2 cells) are analyzed by conventional flow cytometry (see Garcia RL et al., Analysis of proliferative grade using anti-PCNA / cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. The American journal of pathology, 1989, 134(4): 733).
[0215] Flow cytometry was performed using 2-3 × 10 6 The expression of markers including CD3, CD4, CD8, CD45RO and CD62L was analyzed in the starting T cells and F-CART cells. The results are shown in Table 3 and Figure 3 shown.
[0216] Table 3 Lymphocyte subsets
[0217] <![CDATA[CD3 + ]]> <![CDATA[CD4 + / CD8 - ]]> <![CDATA[CD8 + / CD4 - ]]> TEM TCM <![CDATA[T N ]]> Starting Materials 74.5% 38.1% 45.2% 23.0% 21.5% 32.7% F-CART 99.9% 43.2% 45.4% 45.9% 23.5% 15.3%
[0218] In Table 3, TEM represents CD45RO + / CD62L- effector T cells; TCM stands for CD45RO + / CD62L + Central memory T cells; T N CD45RO - / CD62L + Initial (or naive) T cells have great differentiation potential and can differentiate into cell subsets, such as TEM and TCM.
[0219] The results showed that CD3 + The proportion of T cells is much higher than that of the starting material, indicating effective T cell sorting and enrichment. + T and CD8 + The proportion of T cells was basically the same as that of the starting material. Compared with the starting material, the proportion of lymphocyte subsets in F-CART changed, among which the proportion of TCM and TEM in F-CART increased, while T N This may be due to the fact that after T cell activation, the original T N Differentiation of the population. These results show that the F-CART preparation process of the present application can be used to prepare activated T cells with differentiation potential.
[0220] Example 7: In vitro expansion of CAR-T cells
[0221] F-CART cells (such as F-CART-FV2 cells) and C-CART cells were tested for cell viability and viable cell count on days 0, 2, 5, 8, 11, and 13 to compare the in vitro proliferation of F-CART (such as F-CART-FV2) and C-CART preparations.
[0222] In brief, X-vivo15 medium containing 300IU / mL IL-2 was preheated in a 37°C water bath. F-CART cells (such as F-CART-FV2 cells) and C-CART cells were thawed in a 37°C water bath for 2-3 minutes, then transferred to the preheated medium, mixed evenly, and the total volume of the cell suspension was measured. The cell viability and cell density in 300 μL of F-CART and C-CART cell suspensions were calculated using an NC-200 counter, and the number of cells was calculated based on the volume. The two groups of cells were then centrifuged at 250-300g for 8-10 minutes. The supernatant was removed and the cells were resuspended to 0.5×10 6 cells / mL to 1.0×10 6The cells were plated at a density of 10 cells / mL and cultured at 37°C with 5% CO2. Cell viability and viable cell counts were calculated on days 0, 2, 5, 8, 11, and 13 to compare the proliferation of F-CART cells to C-CART cells. During this process, the cell density was maintained at 0.5×10 6 cells / mL and 1.0×10 6 cells / mL.
[0223] The proliferation of the two groups under tumor antigen stimulation was further compared. In brief, primary tumor cells expressing CD19 (from B-ALL tumor patients) were co-cultured with F-CART cells and C-CART cells from day 0. Cell viability and viable cell count were calculated on days 2, 5, 8, 11, and 13, during which the cell density was maintained at 0.5 × 10 6 cells / mL and 1.0×10 6 The results are shown in Table 4. Figure 4A and Figure 4B shown.
[0224] Table 4 CAR-T cell proliferation fold
[0225]
[0226] The results showed that the proliferation ability of F-CART cells was significantly stronger than that of C-CART cells, regardless of the presence or absence of tumor cell stimulation, indicating that F-CART cells have superior expansion ability.
[0227] Example 8: In vitro tumor killing efficacy of CAR-T
[0228] In order to compare the in vitro tumor killing efficacy of F-CART (such as F-CART-FV2) and C-CART preparations, F-CART cells (such as F-CART-FV2 cells) and C-CART cells were thawed and cultured in X-vivo15 medium containing 10% (v / v) AB serum and 300 IU / mL IL-2, and the tumor killing effect was detected on the second day.
[0229] In brief, X-vivo15 medium containing 10% (v / v) AB serum and 300IU / mL IL-2 was preheated in a 37°C water bath. The prepared F-CART cells (such as F-CART-FV2 cells) and C-CART cells were thawed in a 37°C water bath for 2-3 minutes, then transferred to the preheated medium, mixed evenly, and the total volume of the cell suspension was measured. The cell viability and cell density in 300 μL of F-CART and C-CART cell suspensions were calculated using an NC-200 counter, and the cell number was calculated based on the volume. The two groups of cells were then centrifuged at 250-300g for 8-10min. The supernatant was removed and the cells were resuspended to 0.5×10 with an appropriate amount of X-vivo15 medium containing 10% (v / v) AB serum and 300IU / mL IL-2. 6 cells / mL-1.0×10 6 The cells were seeded at a density of 10 cells / mL in plates and cultured at 37°C under 5% CO2.
[0230] On the second day, 0.5 × 10 6 -1.0×10 6 The CAR+ ratio was analyzed for each cell. As target cells, HELA-CD19, HELA and HEK293T cells at P2-P10 were washed with 10 mL of DPBS, digested with 5-10 mL of 0.25% trypsin at 37°C for 1-3 min, and then neutralized with 5-10 mL of complete medium (containing 10% FBS) and repeatedly pipetted to form a single cell suspension. Subsequently, the three groups of target cells were centrifuged at 300 g for 5 min. The supernatant was removed and the cells were resuspended in RPMI 1640 complete medium containing 10% FBS. The number of cells was counted, and the cell viability of the three groups was ≥85%. The cell density was then adjusted to 1×10 5 cells / mL.
[0231] The assay procedure was established according to the instructions of xCELLLigence. In particular, each group of target cells was added to an E-plateview 96-well plate, left in an incubator for 30 min, and then the cells were checked for attachment. When the cell index (Cell-Index) of HELA-CD19 cells detected by xCELLLIgence was ≥ 2, the required number of CAR+ cells were collected according to the CAR+ ratio analyzed above and centrifuged at 300g for 5 min. The supernatant was removed and the cells were resuspended in RPMI 1640 complete medium to the appropriate density. The E-plate View 96 plate was removed from the xCELLIgence assay and the supernatant was discarded. According to the desired ratio of CAR-T cells to target cells, CAR-T cells were added to each well of the plate. The E-plate view 96 plate was then subjected to cell killing assay for 24-48 hours.
[0232] Collect and plot data as shown in Table 5 and Figure 5 As shown, the half-killing time of target cells was calculated as the time point with the maximum cell index (CImax) minus the time point with half the maximum cell index (CImax / 2).
[0233] Figure 5 Among them, 1 is HELA-CD19, 2 is NT+HELA-CD19 (5:1), 3 is C-CART+HELA-CD19 (1:1), 4 is F-CART+HELA-CD19 (1:1), 5 is C-CART+HELA-CD19 (5:1), and 6 is F-CART+HELA-CD19 (5:1). A is the starting point, the time is 7.90 hours, and the cell index is 1.02; B is F-CART+HELA-CD19 (5:1), the time is 8.91 hours, and the cell index is 0.51; C is C-CART+HELA-CD19 (5:1), the time is 15.23 hours, and the cell index is 0.51; D is F-CART+HELA-CD19 (1:1), the time is 16.77 hours, and the cell index is 0.51; E is C-CART+HELA-CD19 (1:1), the time is 51.23 hours, and the cell index is 0.52.
[0234] Table 5 Overview of half-kill time
[0235] Half kill time (h) CART+HELA-CD19(1:1) CART+HELA-CD19(5:1) F-CART 8.87h 1.01h C-CART 43.33h 7.33h
[0236] The results showed that in the two models with effector cell: target cell ratio of 5:1 and 1:1, the half-killing time of F-CART was shorter than that of C-CART, indicating that the killing effect of F-CART on tumor cells was significantly stronger than that of C-CART. Similar results were also observed using HELA cells and HEK293T cells.
[0237] Example 9: CAR-T response to tumor antigen stimulation
[0238] Compare cytokines released by F-CART (such as F-CART-FV2) and C-CART preparations to evaluate the response to tumor antigen stimulation, where F-CART cells (such as F-CART-FV2 cells) and C-CART cells undergo cytokine detection on day 2, using untransfected T cells (starting material) described in Example 2 as a control.
[0239] In brief, the culture medium is preheated in a 37°C water bath. F-CART cells (such as F-CART-FV2 cells) and C-CART cells are thawed in a 37°C water bath for 2-3 minutes, then transferred to the preheated culture medium, mixed evenly, and the total volume of the cell suspension is measured. The cell viability and cell density in 300 μL of F-CART and C-CART cell suspensions were calculated using an NC-200 counter, and the number of cells was calculated based on the volume. The cells were then centrifuged at 250-300g for 8-10 minutes. The supernatant was removed and the cells were resuspended to 0.5×10 6 cells / mL to 1.0×10 6 The cells were inoculated into plates at a density of 10 cells / mL and cultured at 37°C, 5% CO2. On the second day, the cells were aspirated and mixed thoroughly, and then 0.3×10 cells / mL were added to each group. 6 -1.0×10 6 Cells for CAR + Ratio analysis. According to CAR + The cells were collected and centrifuged at 300 g for 5 min, and then the supernatant was removed and the cells were resuspended to 1 × 10 6 The density of cells / mL.
[0240] Molt4 cells (without tumor antigen stimulation) and Raji cells (with tumor antigen stimulation) were used as negative targets and positive targets, respectively. First, the cell number and viability of 0.3-0.5 mL of target cell suspension were calculated. Then the two groups of target cells were further centrifuged at 300 g for 5 min. The supernatant was removed and the cells were resuspended to 1×10 in RPMI 1640 complete medium. 6 The density of cells / mL.
[0241] Subsequently, 100 μL of effector cells (control T cells, F-CART cells, and C-CART cells) and target cells (Molt4 cells or Raji cells) were added to each well of a 96-well plate at a ratio of 1:1 and incubated at 37°C, 5% CO2 for 18-24 hours. After incubation, the cells were centrifuged at 300 g for 5 min. 100-150 μL of supernatant was collected and transferred to a new 96-well plate, and the release of cytokines (including GM-CSF, IL-2, TNF-α, and IFN-γ) was detected by ELISA, as shown in Figure 2. Figure 6A-6D shown.
[0242] from Figure 6A-6D It can be seen that there is no significant difference in the level of GM-CSF released between F-CART and C-CART. IL-2 is a factor released by activated T cells, and the level of IL-2 released by F-CART is significantly higher than that of C-CART, indicating that F-CART has a strong activation effect under tumor antigen stimulation. Both TNF-α and IFN-γ levels indicate the direct killing effect of T cells on target cells, and the levels of these two factors in F-CART are significantly higher than those in C-CART, indicating that the killing activity of F-CART is better than that of C-CART.
[0243] Example 10: In vivo tumor killing efficacy
[0244] Using CD19 + Raji B malignant cell line was used to establish CDX model (homologous transplant tumor model) in immunodeficient mice (NDG mice). Briefly, Raji-Luc cells were suspended in PBS to 5 × 10 5 The density of cells / 0.2 mL was used and 0.2 mL of cells were injected into each B-NDG (B-NSG) mouse via the tail vein. From day 0 of injection, the mice were imaged to observe the tumor growth. When the average signal of the mouse image reached 5×10 6 During P / S, mice with moderate signals were selected and randomly divided into different groups, with 3 mice in each group. On the same day, mice were injected with F-CART cells (such as F-CART-FV2 cells), C-CART cells, untransfected T cells (starting material), and blank cells with only cell cryopreservation solution via tail vein injection. After injection, tumor growth of each animal was observed twice a week by imaging, and the results were as follows Fig. 7A and 7B As shown in the results, F-CART showed a significantly stronger inhibitory effect on mouse tumors and eventually eliminated the tumors. Figure 7B As shown, using 5×10 5At the (5E5) dose, C-CART showed a certain tumor suppression effect but could not eliminate the tumor, while F-CART completely eliminated the tumor, providing a strong anti-tumor efficacy.
[0245] Example 11: In vivo toxicity
[0246] 2×10 6 The weight of the mice was measured before and after administration of the F-CART cells (such as F-CART-FV2 cells) of Example 10, C-CART cells, untransfected T cells (starting material) and blank at a dose of (2E6). The changes in the weight of the animals before and after administration were compared, as shown in Figure 8 As shown. Figure 8 As can be seen in the figure, the weight change (%) represents the percentage of the weight after administration to the original weight, which is calculated as weight change (%) = weight after administration / original weight × 100%.
[0247] The results showed that compared with the blank group and the starting material group, the body weight of animals in the F-CART group and the C-CART group did not change significantly, while the body weight of animals in the F-CART group seemed to be more stable, indicating the non-obvious toxicity of the preparation.
[0248] Example 12: Dose-dependent tumor inhibition in vivo
[0249] The height (2×10 6 cells / 0.2mL), medium (5×10 5 cells / 0.2 mL) and low (5×10 4 F-CART cells (such as F-CART-FV2 cells) at a dose of 10 cells / 0.2 mL and blank cells were administered to mice as established in Example 10 to observe changes in tumor size. The results are shown in Fig. 9 As shown. Fig. 9 It can be seen that the inhibition of tumors by F-CART cells is dose-dependent, and the size of the tumor decreases with the increase of the administered dose.
[0250] Example 13: In vivo proliferation of CAR-T cells
[0251] The height (2×10 6 cells / 0.2mL), medium (5×10 5 cells / 0.2 mL) and low (5×10 4F-CART cells (such as F-CART-FV2 cells) at a dose of 10 cells / 0.2 mL and blank cells were administered to mice as established in Example 10, and then peripheral blood of the mice was collected to analyze the expansion of CAR-T cells by flow cytometry (see Garcia RL et al., Analysis of proliferative grade using anti-PCNA / cyclin monoclonalantibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. The American journal of pathology, 1989, 134 (4): 733). The results are as follows Fig.10 shown.
[0252] from Fig.10 It can be seen that F-CART cells show rapid expansion 28 days after administration, especially between days 14 and 21. The expansion capacity of F-CART cells is dose-dependent and increases with the increase in the administered dose.
[0253] Example 14: Subpopulations of F-CART cells versus C-CART cells
[0254] T cell status and exhaustion were evaluated to compare the subpopulations of F-CART (such as F-CART-FV2) and C-CART preparations. Subpopulations of F-CART cells (such as F-CART-FV2 cells) and C-CART cells were analyzed by flow cytometry (see Garcia RL et al., Analysis of proliferative grade using anti-PCNA / cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flowcytometric analysis. The American journal of pathology, 1989, 134 (4): 733).
[0255] Briefly, cells were collected from three healthy donors, and F-CART cells and C-CART cells were prepared as described in Examples 2 and 4. Then 1×10 6The cells were co-cultured with irradiated K562-CD19 cells at a ratio of 1:1 for 10 days. During the culture process, irradiated K562-CD19 cells were supplemented every 3 days to maintain a 1:1 ratio. On days 6 and 10, the expression of PD1 and LAG3 on the surface of F-CART and C-CART cells was analyzed by flow cytometry. The results are shown in Fig.11A and Fig. 11B As shown. Fig.11A and Fig. 11B It can be seen that PD1 in the F-CART group + LAG3 + The proportion of cells was significantly lower than that of C-CART on both days 6 and 10, indicating that there were fewer inhibited or exhausted cells in the F-CART group.
[0256] Similarly, cells were collected from three healthy donors, and F-CART cells and C-CART cells were prepared as described in Examples 2 and 4. Then, 1×10 6 The cells were co-cultured with irradiated K562-CD19 cells at a ratio of 1:1 for 10 days. During the culture process, irradiated K562-CD19 cells were supplemented every 3 days to maintain a 1:1 ratio. The expression of CD62L and CD45RO on the surface of F-CART and C-CART cells was then analyzed by flow cytometry to evaluate the differentiation status of the cells. The results are shown in Tables 6 and Fig.12 shown.
[0257] Table 6 Subpopulations of F-CART vs. C-CART
[0258] F-CART (mean ± SD) C-CART (mean ± SD) TSCM 6.42±3.64* 0.39±0.13 TCM 73.47±2.85* 58.03±8.34 TEM 18.8±1.77** 41.06±8.47 TEFF 1.28±0.26* 0.48±0.16
[0259] *P<0.05, **P<0.01
[0260] From the results, it can be seen that the proportion of TSCM and TCM cells in the F-CART group was higher than that in the C-CART group, and the proportion of TEM cells was lower than that in the C-CART group, indicating that F-CART cells were less differentiated, younger in state, and had stronger proliferation and differentiation potential.
[0261] Example 15: Safety and clinical efficacy of F-CART cell preparations
[0262] F-CART cells were administered to human patient XF001 to study the safety and efficacy of the preparation. Patient XF001, female, 39 years old, 150cm tall, 70kg in weight, was diagnosed with chronic myeloid leukemia (CML) for 15 years. Four months before F-CART treatment, the patient was found and diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) and central nervous system leukemia. The patient also had a drug-resistant mutation T315I / V299L in BCR-ABL. Various chemotherapy treatments were ineffective, and the patient also developed resistance to tyrosine kinase inhibitors and did not respond to conventional chemotherapy.
[0263] Leukocytes were collected from the patient, and F-CART cells containing CD19-CAR were prepared from the patient according to the method of Example 2. The interval from apheresis to cell infusion was only 10 days, and the preparation process of F-CART cells was only 24 hours. The patient first underwent 3 days of FC chemotherapy pretreatment (1-3 days, daily administration of fludarabine 50 mg and cyclophosphamide 300 mg), and then 4.2x10 6 The number of cells (about 6x10 4 The patients were infused with F-CART preparations (cells / kg body weight).
[0264] like Fig. 13B As shown in the figure, the patient's body temperature was normal on the 8th day, and symptoms such as fever and infection appeared from the 10th to the 13th day after the infusion of F-CART cells. The symptoms were judged to be primary cytokine release syndrome (primary CRS). The patient was then treated with antipyretic treatment and meropenem was used to treat the infection. On the 16th day, the patient's body temperature returned to normal (as shown in the figure). Fig. 13B shown).
[0265] like Fig.13A As shown, 1-7 days after F-CART infusion, flow cytometry results showed that very little CD19 appeared in peripheral blood + B cells, and PCR did not detect the number of copies of the nucleic acid molecule encoding CAR (CAR copy number). 8-28 days after F-CART infusion, CD19 was not detected in peripheral blood + B cells. On the 13th day after F-CART infusion, the CAR copy number reached a peak (4670.2 copies / μg DNA), and on the 28th day, the copy number dropped back to 15.4 copies / μg DNA. On the 56th day, the copy number decreased to 0. The results of flow cytometry analysis of CAR-T (CAR + The changes in cell number were consistent with the results of CAR copy number.
[0266] On the 18th day after F-CART infusion, analysis of samples obtained from bone puncture showed that protozoan lymphocytes accounted for 0.5% with normal morphology; granulocyte proliferation was active; minimal residual disease (MRD) was evaluated as CML, indicating that the patient's B-ALL MRD was cleared. Therefore, the patient was diagnosed with chronic phase CML (CP-CML). The patient received his son's HLA7 / 12 half-compatible hematopoietic stem cell transplantation (HSCT) 40 days after F-CART infusion and showed leukocyte reconstruction. He was discharged 20 days after transplantation. Changes in patients' immune response-related factors (such as IL-6 and C-reactive protein CRP) are shown in Figure 2. Fig. 13C and Fig.13D shown.
[0267] From the above results, it can be found that after administering low doses of F-CART cells to patients, the MRD of B-ALL was successfully eliminated without causing severe CRS and neurotoxicity.
[0268] Based on rapid preparation, the infusion of the F-CART of the present application is at least 7-10 days faster than conventional CD19 CAR-T (C-CART), indicating the advantage of F-CART in treatment time. In addition, compared with conventional CD19 CAR-T (C-CART), when using F-CART preparations, the CAR in the patient + The ratio and CAR copy number peaks occurred at later time points.
[0269] Example 16: Safety and clinical efficacy of F-CART cell preparations
[0270] F-CART cells were administered to human patient F01 to study the safety and efficacy of the preparation. After enrollment, PBMCs were isolated from the patient, and F-CART cells containing CD19-CAR from the patient were prepared according to the method described in Example 2. The patient first received 3 days of chemotherapy pretreatment (fludarabine 50 mg × 3 days + cyclophosphamide 0.4 g × 3 days + cytarabine 0.5 g × 4 days), and then the prepared F-CART cells were injected at a rate of approximately 1.07 x 10 5 The patient is infused with a dose of 10 cells / kg body weight.
[0271] like Fig.14A As shown, on the 10th day after infusion of F-CART, the patient developed fever, and the body temperature was as high as 39.4°C. The fever was relieved after treatment. No symptoms of hypoxia or hypotension, CRS manifestations, or neurotoxicity were found. The patient did not receive tocilizumab or any other hormonal drugs. CRS was rated as grade one. In addition, changes in cytokines including CRP, IL-6, IL-10, INF-γ, and sCD25 in the patient's peripheral blood were also measured, as shown in Figure 1. Fig. 14CAs shown. Compared with the baseline, the secretion of IL-6 increased on day 21 after F-CART infusion. Other cytokines did not show significant changes.
[0272] like Fig. 14B As shown, significant proliferation of F-CART cells was observed in peripheral blood (PB) from day 7 to day 14 after infusion. On day 7 after infusion, the CAR copy number (qPCR) and F-CART cell number (FACS) in peripheral blood were 195,297 copies / μg DNA and 27.5 cells / μl, respectively; on day 10 after infusion, the CAR copy number (qPCR) and F-CART cell number (FACS) in peripheral blood were 106822 copies / μg DNA and 20 cells / μl, respectively; on day 14 after infusion, the CAR copy number (qPCR) and F-CART cell number (FACS) in peripheral blood were 162464 copies / μg DNA and 26.5 cells / μl, respectively. Proliferation decreased significantly on day 21, and F-CART cells could still be detected on day 28 after infusion. On days 14 and 28 after infusion, the number of CAR copies in the bone marrow (BM) was detected to be 26429 copies / μg DNA and 68135.6 copies / μg DNA, respectively, and qPCR did not detect CAR amplification. In addition, on days 14 and 28 after infusion of F-CART cells, no abnormal B cells were detected in the patient's peripheral blood, and no abnormal cells or tumors were found in the bone marrow samples by flow cytometry.
[0273] It can be seen that administering small doses of F-CART cells to patients is safe and effective in killing tumor cells in vivo.
[0274] Example 17: Clinical efficacy of F-CART cell preparations
[0275] The F-CART cell preparations were administered to human patients DF06, GF001, XF002, TF003, TF002, DF04, DF01, XF001, and TF001, who were diagnosed with relapsed or refractory B-ALL, respectively.
[0276] Leukocytes were collected from the patients, and F-CART cells containing CD19-CAR were prepared from each patient according to the method described in Example 2. The interval from apheresis to cell infusion was only 10 days, and the preparation process of F-CART cells was only 24 hours. During the treatment, the prepared F-CART cells were inoculated at a rate of about 10 4 Up to 10 7 (about 10 3 cells / kg body weight to about 10 6 The dose of 10 cells / kg body weight was infused into each patient. Fig.15 shown.
[0277] During treatment, patient TF002 withdrew from the study on day 10 after F-CART infusion. Five patients (TF001, XF001, DF01, DF04, and XF002) achieved complete remission (CR), of which four (XF001, DF01, DF04, and XF002) achieved minimal residual disease (MRD - ). These results demonstrate the effectiveness of F-CART cell preparations in tumor treatment.
[0278] In addition, 8 of 9 patients developed CRS (cytokine release syndrome) (except TF002 patients), and only 2 patients (TF001 and XF002) developed grade 3 or higher CRS, as well as grade 1 neurotoxicity (NT). CRS in 8 patients occurred between days 3 and 10 after infusion. These results indicate that F-CART cell preparations are relatively safe.
[0279] Example 18: Phenotypic Analysis of F-CART vs. C-CART
[0280] The lymphocyte subsets of C-CART and F-CART cells were analyzed by conventional flow cytometry. 2-3×10 6 The expression of markers CD3, CD4, CD8, CD45RO and CD62L was analyzed by flow cytometry. The results are shown in Table 7 and Fig.16A , Fig. 16B and Fig. 16C shown.
[0281] Table 7 C-CART vs. F-CART
[0282]
[0283]
[0284] In Table 7, TEM represents CD45RO + / CD62L - TCM stands for effector T cells with CD45RO + / CD62L + Central memory T cells; T N CD45RO - / CD62L + Initial (or naive) T cells have great differentiation potential and can differentiate into cell subsets, such as TEM and TCM.
[0285] The results showed that the ratio of TSCM and TCM was more abundant in the FasT CAR-T population. More CD45RO+ / CD62L+(TCM) was observed in FasT CAR-T cells than CD45RO+ / CD62L-(TEM) (4-fold increase). In addition, more CD45RO- / CD62L+(TSCM) was observed in F-CART than in C-CART (31-fold increase). These results indicate that the F-CART preparation process of the present application can be used to prepare activated T cells with differentiation potential and a "young" phenotype with a non-exhausted phenotype.
[0286] Example 19: In vitro expansion, phenotype and cytotoxicity of F-CAR-T cells against C-CAR-T cells
[0287] Fold expansion in F-CART cells and C-CART cells was quantified on days 8, 12, and 18 to compare the in vitro proliferation of the two methods.
[0288] Subpopulations of C-CART and F-CART cells were also analyzed by conventional flow cytometry. 2-3×10 6 The expression of markers CD3, CD4, CD8, PD-1 and LAG3 in the starting C-CART cells and F-CART cells was analyzed by flow cytometry.
[0289] The cytotoxicity of F-CART and C-CART was compared using a real-time cell analyzer (RTCA) assay. RTCA is a technique that uses real-time cell monitoring to detect migration, cytotoxicity, and adhesion / proliferation of cells during direct and indirect co-culture. In brief, a CD19 + C-CART cultured with tumor cells, using CD19 + F-CART in tumor cell culture, using CD19 + Co-culture of non-transduced cells and tumor cells (Hela-CD19) cultured with tumor cells. Background measurements were taken from the wells by adding 50 μL of the same culture medium to the E-16 plate. Subsequently, the RTCA software package 1.2 was used to calibrate the plate. The cells were plated in fresh culture medium at a density of 20,000 per well to a final volume of 200 μl. Before starting the software schedule, the cells were incubated in the RTCA scaffold at 37 ° C and 5% CO2 for 4 min. The impedance signal was recorded every 5 min for the first 25 scans (2 h), and every 10 min before the end of the experiment (40 hours). After 20 h of the impedance reading, 140 μL of culture medium was removed from each well and replaced with an appropriate volume of conditioned medium (CM).
[0290] Cytokine secretion of IL-2 and IFNγ was assessed using culture medium from the RTCA assay. Briefly, 100 uL of culture medium was collected from the co-culture assay and assessed by ELISA.
[0291] The results are as follows Fig.17A , Fig. 17B , Fig. 17C , Fig.17D and Fig.18 As shown. The results showed that the percentage of PD1+LAG3+CAR-T cells was significantly reduced compared with conventionally manufactured CAR-T. The results also showed that F-CART exhibited CD19-specific killing, tumor-specific cytokine secretion, and similar killing ability compared with C-CART.
[0292] Example 21: In vitro analysis of F-CART on C-CART subject samples
[0293] CART cells were prepared using the F-CART method and the conventional method for subjects in Table 8.
[0294] Table 8: Summary of patient samples
[0295]
[0296] Cell expansion
[0297] Leukocytes were collected from the patients, and F-CART and C-CART cells from each subject expressing CD19-CAR were prepared according to the method described in Example 2. The interval from apheresis to cell infusion was only 10 days, and the preparation process of F-CART cells was only 24 hours.
[0298] Comparison of the expansion of F-CART and C-CART under tumor antigen stimulation. Briefly, primary tumor cells expressing CD19 (from B-ALL tumor patients) were co-cultured with F-CART cells and C-CART cells from day 0. Cell viability and viable cell counts were calculated on days 9, 13, and 17. During this process, the cell density was maintained at 0.5×10 6 cells / mL and 1.0×10 6 The results are as follows Fig.19A The results showed that FasT CAR-T (F-CART) had significantly better proliferation ability than conventionally manufactured CAR-T (C-CART).
[0299] Phenotype
[0300] Lymphocyte subsets of C-CART and F-CART cells from subject GC007F were analyzed by conventional flow cytometry. 2-3×106 The expression of markers CD3, CD4, CD8, CD45RO and CD62L was analyzed by flow cytometry in the starting C-CART cells and F-CART cells. Fig.19B , Fig.19C , Fig.19D and as shown in Table 9. The results showed that TCM was more abundant in the FasT CAR-T population compared with C-CART.
[0301] Table 9: Cellular phenotype of GC007F
[0302]
[0303] In addition, flow cytometry was used to determine cell depletion. Lymphocyte subsets from C-CART and F-CART cells of subject GC007F were analyzed by conventional flow cytometry. The expression of markers CD3, CD8, PD-1, and LAG3 were analyzed in CAR-positive cells by flow cytometry. The results are shown in Fig.19E The results showed that the percentage of PD1+LAG3+CAR-T cells was significantly lower than that of conventionally manufactured CAR-T.
[0304] Cytotoxicity RTCA and ELISA
[0305] The cytotoxicity of GC007F F-CART and C-CART in the subjects was compared using the real-time cell analyzer (RTCA) assay previously described in Example 17, using a 1:1 effector to target ratio. Fig. 20A shown.
[0306] The cytokine secretion of IL-2 and IFNγ was assessed using the culture medium from the RTCA assay. Briefly, 100 uL of culture medium was collected from the co-culture assay and assessed by ELISA. Fig. 20B The results also showed that F-CART exhibited CD19-specific killing, tumor-specific cytokine secretion, and similar killing ability compared with C-CART.
[0307] Cytotoxicity luciferase assay
[0308] NALM-6 or Raji tumor cells expressing luciferase were cultured at 3×10 5The concentration of cells / ml was placed in triplicate in a 96-well round-bottom plate, D-firefly luciferin potassium salt (75 μg / ml; Caliper Hopkinton, MA) was applied, and measured with a photometer. This was done to establish a BLI baseline reading before any cell death occurred and to ensure that the target cells were evenly distributed in the wells. Subsequently, effector F-CART or C-CART cells were added at a ratio of 5: 1, 1: 1, and 0.2: 1 effector to target (E: T) and incubated at 37 ° C for 2 or 4 hours. BLI was then measured for 10 seconds as relative light units (RLU) using a photometer (Packard Fusion Universal Microplate Analyzer, Model A153600). Cells were treated with 1% Nonidet P-40 (NP40) or water as a measure of maximum lethality. Target cells incubated in the absence of effector cells were used to measure spontaneous death RLU. Cells were imaged at 2 hours or 4 hours. Triplicate wells were averaged and percent lysis was calculated from the data using the following equation: % specific lysis = 100 x (spontaneous death RLU - test RLU) / (spontaneous death RLU - maximum killing RLU).
[0309] The results are shown in Fig. 20C It is shown that the in vitro cytotoxicity between F-CART and C-CART is comparable, so the manufacturing method of simultaneous transduction and activation does not significantly affect the cytotoxicity of engineered cells while reducing manufacturing time. Table 10 below shows a summary of various in vitro and in vivo findings of comparative studies between F-CART and C-CART.
[0310] Table 10: Summary of F-CART vs. C-CART
[0311] Performance characteristics F-CART C-CART proliferation ++++ + Memory / Dry +++ + Exhaustion + +++ Killing ability (in vitro) +++ +++ Killing ability (in vivo) +++ + BM Migration +++ +
[0312] Example 22: In vivo analysis of F-CART vs. C-CART in a mouse leukemia model
[0313] NOG mice (NOD.Cg-Prkdcscid Il2rgtm1Sug / JicTac) were transplanted with Raji-Luc cells. Briefly, Raji-Luc cells were suspended in PBS to 5 × 10 5 The density of cells / 0.2 mL was used and 0.2 mL of cells were injected into each mouse through the tail vein. From day 0 of injection, the mice were imaged to observe the tumor growth. When the average signal of the mouse image reached 5×10 6At P / S, mice with moderate signals were selected and randomly divided into different groups, with 3 mice in each group. On the same day, F-CART cells, C-CART cells, untransfected T cells, and blanks with only cell cryopreservation solution were injected into the tail vein of mice. After injection, tumor growth of each animal was observed by bioluminescence imaging twice a week.
[0314] The results are as follows Fig.21A As shown in the results, it can be seen that F-CART showed a significantly stronger tumor reduction effect and eventually eliminated the tumor.
[0315] Example 23: In vivo analysis of the infiltration and chemotaxis of F-CART versus C-CART in a mouse leukemia model
[0316] NOG mice (NOD.Cg-Prkdcscid Il2rgtm1Sug / JicTac) were transplanted with NALM-6-Luc cells. Briefly, NALM-6 cells were suspended in PBS to 5 × 10 5 The density of cells / 0.2mL was used, and 0.2mL of cells were injected into each mouse by tail vein injection. Seven days after tumor cell injection, mice were injected with F-CART cells, C-CART cells, untransfected T cells, and blanks with cell cryopreservation solution alone. After treatment, the infiltration of cells into the bone marrow was evaluated on day 10 by isolating bone marrow from the femurs of mice and evaluating the presence of CAR-positive cells in the samples. The treatment schematic is depicted in Fig.22A The results are shown in Fig. 22B and Fig. 22C The results showed that 10 days after CAR-T infusion, there was significantly more F-CART infiltration in the bone marrow compared with C-CART-treated mice.
[0317] Flow cytometry was also used to analyze subpopulations of C-CART and F-CART cells. The expression of markers CD3, CD4, CD8, and CXCR4 was analyzed by flow cytometry. The results are shown in Fig.22D , Fig.22E and Fig.22F The results showed that the expression of CXCR4 was higher in F-CART-treated mice.
[0318] Chemotaxis was studied using a 5 μm pore size transwell plate (Costar, Cambridge, MA). 5Cells were distributed in the upper chamber and chemokines or medium alone were added to the lower chamber. Mouse SDF-1α and human SDF-1α were tested at concentrations of 0 ng / ml, 10 ng / ml, 25 ng / ml and 100 ng / ml. The plates were incubated at 37°C for 2 hours. Migrated cells were collected and counted using CFSE and the migration index was calculated as follows: (n° migrated cells / n° distributed cells) x 100. The migration index obtained with medium alone was subtracted from each value. The results are shown in Figure 22G and Fig.22H The results showed that more CFSE-labeled F...
Claims
1. A method for producing a population of engineered immune cells expressing a chimeric antigen receptor (CAR) and / or an engineered T cell receptor (TCR), comprising: (a) contacting an immune cell population obtained from a subject with an activating moiety to obtain a contacted immune cell population; (b) introducing a polynucleotide encoding the CAR or TCR into the contacted immune cell population described in (a), thereby generating an engineered immune cell population expressing the CAR or TCR, and (c) harvesting a population of engineered immune cells expressing the CAR or TCR for infusion into the subject; wherein the total duration of both (a) and (b) does not exceed 36 hours, and wherein, except for (a) to (c), the method does not comprise ex vivo expansion.
2. The method of claim 1, wherein the total duration of (a) to (c) does not exceed 36 hours.
3. The method of claim 1, wherein said harvesting comprises cryopreserving said engineered immune cell population.
4. The method of claim 1, wherein the activated portion is removed after step (b).
5. The method of claim 1, wherein the introducing in (b) and the contacting in (a) are performed on the same day.
6. The method of claim 5, wherein the introducing in (b) is performed within about 4 hours or less after the contacting in (a).
7. The method of claim 1, wherein in (b), the activation moiety and the polynucleotide are contacted together with the immune cell population for no more than 24 hours.
8. The method of claim 1, wherein the immune cell population is activated after (a).
9. The method of claim 1, wherein the activation moiety associates with the immune cell population during the introducing in (b).
10. The method according to any one of claims 1-9, wherein the activation moiety comprises an anti-CD3 antibody and / or an anti-CD28 antibody.
11. The method of claim 10, wherein the activation moiety is conjugated to a bead, a plate and / or a matrix.
12. The method according to any one of claims 1-9, wherein the introducing in (b) comprises transducing the contacted immune cell population with a viral vector and / or a transposon vector.
13. The method according to claim 12, wherein the viral vector is a retroviral vector, a lentiviral vector and / or an adeno-associated viral vector.
14. The method according to any one of claims 1-9, 11 and 13, wherein the immune cell population is about 10 4 cells / mL to about 10 8 The cells were seeded at a density of 10 cells / mL.
15. The method of claim 12, wherein the viral vector is plated at a mean infectiousness (MOI) of about 0.1 to about 10.
16. The method of any one of claims 1-9, 11, 13 and 15, further comprising contacting a cytokine with the immune cell population.
17. The method of claim 16, wherein the cytokines comprise IL2, IL7, IL15 and / or IL21.
18. The method of any one of claims 1-9, 11, 13, 15 and 17, wherein the engineered immune cell population is not cultured in the presence of human serum.
19. The method of any one of claims 1-9, 11, 13, 15 and 17, wherein the engineered immune cell population is characterized in that central memory T cells (TCM) are more abundant than effector memory T cells (TEM) in the population.
20. An engineered immune cell population produced by the method of any one of claims 1-19.
21. A point-of-care device comprising a cell infusion device configured to infuse the engineered immune cell population of claim 20.
22. Use of the engineered immune cell population according to claim 20 for preparing a medicament for treating cancer in a subject in need thereof.
